# **University of Alabama at Birmingham**

Report on Federal Awards In Accordance With the Uniform Guidance For the Year Ended September 30, 2019

EIN: 63-6005396

## University of Alabama at Birmingham Report on Federal Awards in Accordance With the Uniform Guidance Index

For the Year Ended September 30, 2019

	Page(s)
Part I Federal Award Programs	
Report of Independent Auditors on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance With Government Auditing Standards	1–2
Report of Independent Auditors on Compliance With Requirements That Could Have a Direct and Material Effect on Each Major Program and On Internal Control Over Compliance in Accordance With the Uniform Guidance	3–5
Schedule of Expenditures of Federal Awards	6–22
Notes to Schedule of Expenditures of Federal Awards	23–24
Part II Schedule of Findings and Questioned Costs	
Schedule of Findings and Questioned Costs Year Ended September 30, 2019	25
Part III Summary Schedule of Prior Audit Findings	
Summary Schedule of Prior Audit Findings	26
Part IV 2019 Financial Report	

Part I Federal Award Programs



## Report of Independent Auditors on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with Government Auditing Standards

To the Board of Trustees of The University of Alabama:

We have audited, in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in Government Auditing Standards issued by the Comptroller General of the United States, the financial statements of the business-type activities and the discretely presented component unit of The University of Alabama at Birmingham ("UAB"), a campus of the University of Alabama System, which is a component unit of the State of Alabama, which comprise the statements of net position as of September 30, 2019, and the related statements of revenues, expenses, and changes in net position and of cash flows (where applicable) for the year then ended, and the related notes to the financial statements, and have issued our report thereon dated January 20, 2020. Our report includes an emphasis of matter paragraph regarding the presentation of the financial statements as discussed in Note 1 to the financial statements. Our report includes a reference to other auditors who audited the financial statements of Southern Research Institute, as described in our report on UAB's financial statements. This report does not include the results of the other auditors' testing of internal control over financial reporting or compliance and other matters that are reported on separately by those auditors. The financial statements of Triton Health Systems, L.L.C., UAB Athletics Foundation and UAB Research Foundation were not audited in accordance with Government Auditing Standards and accordingly, this report does not include reporting on internal control over financial reporting or instances of reportable noncompliance associated with these component units.

#### Internal Control Over Financial Reporting

In planning and performing our audit of the financial statements, we considered UAB's internal control over financial reporting ("internal control") to determine the audit procedures that are appropriate in the circumstances for the purpose of expressing our opinions on the financial statements, but not for the purpose of expressing an opinion on the effectiveness of UAB's internal control. Accordingly, we do not express an opinion on the effectiveness of UAB's internal control.

A *deficiency in internal control* exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, misstatements on a timely basis. A *material weakness* is a deficiency, or a combination of deficiencies, in internal control such that there is a reasonable possibility that a material misstatement of the entity's financial statements will not be prevented, or detected and corrected on a timely basis. A *significant deficiency* is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.



Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during our audit we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses may exist that have not been identified.

#### **Compliance and Other Matters**

As part of obtaining reasonable assurance about whether UAB's financial statements are free from material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts and grant agreements, noncompliance with which could have a direct and material effect on the determination of financial statement amounts. However, providing an opinion on compliance with those provisions was not an objective of our audit, and accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.

#### Purpose of this Report

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the entity's internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the entity's internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

Birmingham, Alabama January 20, 2020

Pricewaterhouse Coopers LLP



Report of Independent Auditors on Compliance with Requirements That Could Have a Direct and Material Effect on Each Major Program and on Internal Control Over Compliance in Accordance with the Uniform Guidance

To the Board of Trustees of the University of Alabama:

#### Report on Compliance for Each Major Federal Program

We have audited the University of Alabama at Birmingham's ("UAB"), a campus of The University of Alabama System, which is a component unit of the State of Alabama, compliance with the types of compliance requirements described in the *OMB Compliance Supplement* that could have a direct and material effect on each of UAB's major federal programs for the year ended September 30, 2019. UAB's major federal programs are identified in the summary of auditor's results section of the accompanying schedule of findings and questioned costs.

UAB's basic financial statements include the operations of Southern Research Institute ("SRI"), UAB's discretely presented component unit, which expended \$47,548,107 in federal awards during its year ended December 28, 2018 which is not included in UAB's schedule of expenditures of federal awards for the year ended September 30, 2019. Our audit, described below, did not include the operations of SRI because SRI engaged other auditors to perform an audit in accordance with the Uniform Guidance.

#### Management's Responsibility

Management is responsible for compliance with federal statutes, regulations and the terms and conditions of its federal awards applicable to its federal programs.

#### Auditors' Responsibility

Our responsibility is to express an opinion on compliance for each of UAB's major federal programs based on our audit of the types of compliance requirements referred to above. We conducted our audit of compliance in accordance with auditing standards generally accepted in the United States of America; the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States; and the audit requirements of Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance). Those standards and the Uniform Guidance require that we plan and perform the audit to obtain reasonable assurance about whether noncompliance with the types of compliance requirements referred to above that could have a direct and material effect on a major federal program occurred. An audit includes examining, on a test basis, evidence about UAB's compliance with those requirements and performing such other procedures as we considered necessary in the circumstances.



We believe that our audit provides a reasonable basis for our opinion on compliance for each major federal program. However, our audit does not provide a legal determination of UAB's compliance.

#### Opinion on Each Major Federal Program

In our opinion, The University of Alabama at Birmingham complied, in all material respects, with the types of compliance requirements referred to above that could have a direct and material effect on each of its major federal programs for the year ended September 30, 2019.

#### Other Matter

As indicated in Part I to the accompanying Schedule of Findings and Questioned Costs, we have audited the Student Financial Assistance cluster as a major program. Also, as indicated in the first paragraph of this report, we performed our audit of compliance using the compliance requirements contained in the OMB Compliance Supplement, including those contained in Part V 5.3, Compliance Requirement N, Special Tests and Provisions, Section 10 "Gramm-Leach-Bliley Act-Student Information Security." This section includes three suggested audit procedures with respect to verification that the institution (1) designated an individual to coordinate the information security program, (2) performed a risk assessment that addresses the three required areas in 16 CFR 314.4(b), and (3) documented a safeguard for each risk identified. Our procedures in relation to these three items were limited to inquiry of and obtaining written representation from management and obtaining and reading management's documentation related to these three items. Our procedures did not include an analysis of the adequacy or completeness of the risk assessment performed or the safeguards for each risk identified by management.

#### Report on Internal Control Over Compliance

Management of UAB is responsible for establishing and maintaining effective internal control over compliance with the types of compliance requirements referred to above. In planning and performing our audit of compliance, we considered UAB's internal control over compliance with the types of requirements that could have a direct and material effect on each major federal program to determine the auditing procedures that are appropriate in the circumstances for the purpose of expressing an opinion on compliance for each major federal program and to test and report on internal control over compliance in accordance with the Uniform Guidance, but not for the purpose of expressing an opinion on the effectiveness of internal control over compliance. Accordingly, we do not express an opinion on the effectiveness of UAB's internal control over compliance.

A deficiency in internal control over compliance exists when the design or operation of a control over compliance does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, noncompliance with a type of compliance requirement of a federal program on a timely basis. A material weakness in internal control over compliance is a deficiency, or combination of deficiencies, in internal control over compliance, such that there is a reasonable possibility that material noncompliance with a type of compliance requirement of a federal program will not be prevented, or detected and corrected, on a timely basis. A significant deficiency in internal control over compliance is a deficiency, or a combination of deficiencies, in internal control over compliance with a type of compliance requirement of a federal program that is less severe than a material weakness in internal control over compliance, yet important enough to merit attention by those charged with governance.



Our consideration of internal control over compliance was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control over compliance that might be material weaknesses or significant deficiencies. We did not identify any deficiencies in internal control over compliance that we consider to be material weaknesses. However, material weaknesses may exist that have not been identified.

The purpose of this report on internal control over compliance is solely to describe the scope of our testing of internal control over compliance and the results of that testing based on the requirements of the Uniform Guidance. Accordingly, this report is not suitable for any other purpose.

#### Report on Schedule of Expenditures of Federal Awards Required by the Uniform Guidance

We have audited the financial statements of the business-type activities and the discretely presented component unit of UAB as of and for the year ended September 30, 2019, and the related notes to the financial statements, which collectively comprise UAB's basic financial statements. We issued our report thereon dated January 20, 2020, which contained unmodified opinions on those financial statements. Our audit was conducted for the purpose of forming opinions on the financial statements that collectively comprise the basic financial statements. The accompanying schedule of expenditures of federal awards is presented for purposes of additional analysis as required by the Uniform Guidance and is not a required part of the basic financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the basic financial statements. The information has been subjected to the auditing procedures applied in the audit of the financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the basic financial statements or to the basic financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, the schedule of expenditures of federal awards is fairly stated, in all material respects, in relation to the basic financial statements as a whole.

Birmingham, Alabama

Pricewaterhouse Coopers LLP

June 24, 2020, except for our report on the Schedule of Expenditures of Federal Awards, as to which the date is January 20, 2020

Federal Program	CFDA Number	Direct	Pass-through	Pass-Through Grantor	Contract/Award or Pass-Through Num	Total Expenditures	Passed to Subrecipients
Research and Development							
Department of Agriculture			•				•
Agriculture and Food Research Initiative (AFRI)	10.310	\$ 84,019 84,019	\$ -	•		\$ 84,019	\$ -
Total Department of Agriculture		84,019		:		84,019	<del></del>
Department of Commerce Cluster Grants	11.020	98,523	-			98,523	
Unallied Science Program	11.472	-	1,451	AUBURN UNIVERSITY	ACQ-210-039-2019-AU	1,451	
Measurement and Engineering Research and Standards	11.609	-	26,001	TROY STATE UNIVERSITY	70NANB18H289	26,001	
Unknown	11.RD		25,824	UNIVERSITY OF MARYLAND	120416	25,824	
Total Department of Commerce		98,523	53,276	•		151,799	
Department of Defense Basic and Applied Scientific Research	12.300		564 746	WRIGHT STATE UNIVERSITY	N00014-16-1-3159	564,746	
Basic and Applied Scientific Research	12.300	129.083	504,740	WRIGHT STATE UNIVERSITY	N00014-16-1-3159	129,083	
Military Medical Research and Development	12.420	8,553,331	-			8,553,331	3,115,351
Military Medical Research and Development	12.420	-	578,606		W81XWH-17-0619 W81XWH-17-2-0052	578,606	
Military Medical Research and Development Military Medical Research and Development	12.420 12.420	-	62,922 46,284	THE MIND RESEARCH NETWORK REGENTS OF THE UNIVERSITY OF COLORADO	W81XWH-17-2-0052 W81XWH-17-0597	62,922 46,284	
Military Medical Research and Development	12.420	-	3,556	DIGNITY HEALTH DBA ST. JOSEPH'S HOSPTIAL & MEDICAL	W81XWH-14-2-0191	3,556	
Military Medical Research and Development	12.420	-	1,278	GREENVILLE HOSP SYS	W81XWH-08-1-0473	1,278	
Military Medical Research and Development Military Medical Research and Development	12.420 12.420	-	334 328	DUKE UNIVERSITY UNIVERSITY OF SOUTHERN CALIFORNIA	W81XWH-14-1-0473 W81XWH-13-MRPRA-MRFA	334 328	
Military Medical Research and Development	12.420	-	(16)		W81XWH-17-1-0597	(16)	
Basic Scientific Research	12.431	-	76,011	UNIVERSITY OF TENNESSEE( KNOXVILLE)	W911NF-15-1-0614	76,011	
Basic Scientific Research	12.431	-	43,241	THE UNIVERSITY OF MONTANA	W911NF-15-2-0020	43,241	
Basic, Applied, and Advanced Research in Science and Engineering	12.630	84,618	_			84,618	
Uniformed Services University Medical Research Projects	12.750	133,503	-			133,503	30,686
Air Force Defense Research Sciences Program	12.800	154,922				154,922	
Research and Technology Development Contract #W911QY-15-C-0134	12.910 12.RD	1,912,149	7,624	UNIVERSITY OF CENTRAL FLORIDA	W31P4Q-15-1-0008	7,624 1,912,149	1,385,778
Contract #FA9101-18-D-0004	12.RD 12.RD	944,802				944.802	1,305,776
Contract	12.RD	-	233,996		SP4701-17-D-1161	233,996	
Contract	12.RD	-	203,408	EMORY UNIVERSITY	HDTRA1-15-C-0075	203,408	
Contract Contract	12.RD 12.RD	-	141,455 138,904	ALION SCIENCE AND TECHNOLOGY CORPORATION ADVANCED TECHNOLOGY INTERNATIONAL	FA8075-14-D-0014 SP4701-17-D-1134	141,455 138,904	
Contract	12.RD	-	122,163		GS04T-09-DBC-0017	122,163	
Contract #FA4417-16-P-R026	12.RD	120,940	-			120,940	
Contract Contract	12.RD	-	118,711	ADVANCED TECHNOLOGY INTERNATIONAL	SP4701-15-C7003	118,711	
Contract	12.RD 12.RD	-	85,080 77.885	TDA THE GENEVA FOUNDATION	W81XWH-17-C-0141 HU0001172TS04 (N17-A06)	85,080 77,885	
Contract	12.RD	-	75,250	ADVANCED TECHNOLOGY INTERNATIONAL	2016-517	75,250	
Contract	12.RD	-	62,397	ADVANCED TECHNOLOGY INTERNATIONAL	2017-523	62,397	
Contract Contract	12.RD 12.RD	-	13,100 6,538	CHILDREN'S HOSPITAL BOSTON BERTEC CORPORATION	W81XWH-17-1-0532 W81XWH-18-C-0029	13,100 6,538	
Total Department of Defense	12.RD	12,033,348	2,663,801	BERTEC CORPORATION	W61XWH-16-C-0029	14,697,149	4,531,815
Department of Interior		12,000,040	2,000,001	•		14,037,143	4,001,010
Marine Turtle Conservation Fund	15.645	4.884	-			4.884	
Total Department of Interior		4,884	-	•		4,884	_
Department of Justice				•			
National Institute of Justice Research, Evaluation, and Development							
Project Grants	16.560	208,133				208,133	98,906
Edward Byrne Memorial Justice Assistance Grant Program Comprehensive Opioid Abuse Site-Based Program	16.738 16.838	-	28,093 271.080	CITY OF BIRMINGHAM JEFFERSON COUNTY COMMISSION	PROJECT SAFE NEIGHBORHOODS 2018 2018-AR-BX-K013	28,093 271,080	
Total Department of Justice	10.030	208,133	299,173	- JETT ERSON COUNTT COMMISSION	2010-AK-DA-K013	507,306	98,906
Department of Transportation		200,100	255,175	•		307,300	30,300
Highway Research and Development Program	20,200	_	107.828	NATL ACADEMY OF SCIENCES	DTFH61-13-H-00024	107.828	
Highway Training and Education	20.215	18,034	-			18,034	
National Highway Traffic Safety Administration (NHTSA)	20.011		444 ====	NATIONAL CAPETY COUNCIL	DThii 100451 100470	444.500	00.400
Discretionary Safety Grants University Transportation Centers Program	20.614 20.701	-	114,598 178,997		DTNH2215H00473 69A3551747104	114,598 178,997	22,426
University Transportation Centers Program	20.701	-	2,098		UF-EIES-1200009 TASK 1	2,098	
University Transportation Centers Program	20.701	-		UNIVERSITY OF FLORIDA	UF-EIES-1200009 TASK 16	421	
Contract #DTNH2217D00066 Opt 1	20.RD	295,926	-			295,926	
Contract #DTNH2217D00066 Contract	20.RD 20.RD	43,668	( <u>4</u> 127)	VIRGINIA TECH	DTMC7514D00011L-7006	43,668 (4.127)	
Unknown	20.RD			ALABAMA DEPT OF TRANSPORTATION	K-15-1884	181,120	
Total Department of Transportation		357,628	580,935	•		938,563	22,426
•				<del>-</del>			

Federal Program	CFDA Number	Direct	Pass-through	Pass-Through Grantor	Contract/Award or Pass-Through Num	Total Expenditures	Passed to Subrecipients
National Aeronautics and Space Administration							
Exploration	43.003	-	31,859	GEORGIA INSTITUTE OF TECHNOLOGY	NNX16AT06G	31,859	
Exploration	43.003	3,892	-			3,892	
Space Operations	43.007	96,269	-			96,269	
Contract #NNJ15HA80B	43.RD	8,154,498	-			8,154,498	
Contract	43.RD	-	20,956		80NSSC18C0169	20,956	
Contract	43.RD	-	10,496		80NSSC18P1984	10,496	
Contract	43.RD		2,481	NATIONAL INSTITUTE OF AEROSPACE ASSOCIATES INC	4600006339	2,481	
Total National Aeronautics and Space Administration		8,254,659	65,792	-		8,320,451	<u> </u>
National Foundation on the Arts and the Humanities							
Promotion of the Humanities_Fellowships and Stipends	45.160	56	-	_		56	
Total National Foundation on the Arts and the Humanities		56	-	=		56	<u> </u>
National Science Foundation							
Engineering Grants	47.041	432,648	-			432,648	
Engineering Grants	47.041		20,297	GEORGIA INSTITUTE OF TECHNOLOGY	1643289	20,297	
Mathematical and Physical Sciences	47.049	998,746	-			998,746	
Geosciences	47.050	676,303	-			676,303	
Computer and Information Science and Engineering	47.070 47.070	248,178	37	UNIVERSITY OF ALABAMA IN TUSCALOOSA	CNS-1335263	248,178 37	
Computer and Information Science and Engineering Biological Sciences	47.070	1,294,920	37	UNIVERSITY OF ALABAMA IN TUSCALOUSA	CNS-1335263	1,294,920	24,503
Social, Behavioral, and Economic Sciences	47.074	77,937	-			77,937	28,250
Education and Human Resources	47.076	1,357,517				1,357,517	20,230
Education and Human Resources	47.076	1,337,317	121,406	UNIVERSITY OF ALABAMA IN TUSCALOOSA	1619659	121,406	
Education and Human Resources	47.076		42.329	UNIVERSITY OF ALABAMA IN TUSCALOOSA	DGE-1723250	42,329	
Education and Human Resources	47.076	_	11,128		1617-184	11,128	
International Science and Engineering (OISE)	47.079	251,097				251,097	
Office of Integrative Activities	47.083		518,325	UNIVERSITY OF ALABAMA IN HUNTSVILLE	OIA-1655280	518,325	
Office of Integrative Activities	47.083	-	500,229	CLEMSON UNIVERSITY	OIA-1632881	500,229	
Office of Integrative Activities	47.083	-	367,202	MEDICAL UNIVERSITY OF SOUTH CAROLINA	OIA-1539034	367,202	
Office of Integrative Activities	47.083	-	296,853	LOUISIANA STATE UNIVERSITY	OIA-1632891	296,853	
Office of Integrative Activities	47.083	-	121,636	UNIVERSITY OF SOUTHERN MISSISSIPPI	OIA-1632825	121,636	
Office of Integrative Activities	47.083	98,717	-	_		98,717	
Total National Science Foundation		5,436,063	1,999,442	_		7,435,505	52,753
Department of Veterans Affairs							
Contract - Intergovernmental Personnel Agreements	64.RD	3,199,375	-			3,199,375	
Contract #VA247-17-C-0209	64.RD	212,121	-			212,121	
Contract #FFS-36C24E18C0024	64.RD	55,610	-			55,610	
Contract #36C24718C0197	64.RD	46,302	-			46,302	
Contract #36C24718C0188	64.RD	26,429	-			26,429	
Contract #36C24718C0003 OPTION 1	64.RD	24,254	-			24,254	
Contract #1101BX001756-01A2	64.RD	6,559	-			6,559	
Contract #36C24718P2511 Contract #VA247-17-P-2119	64.RD 64.RD	3,000 576	-			3,000 576	
Total Department of Veterans Affairs	04.ND	3,574,226				3,574,226	
•		3,574,220		=		3,574,226	<u>-</u>
Department of Energy Office of Science Financial Assistance Program	81.049	723,029				723,029	78,010
	81.049	68,860	-			68,860	13.796
Fossil Energy Research and Development Fossil Energy Research and Development	81.089	68,860	47,563	SOUTHERN STATES ENERGY BOARD	DE-FE0029465	47,563	13,790
Fossil Energy Research and Development	81.089		1.945		DE-FE0024296	1,945	
Stewardship Science Grant Program	81.112	168,573	1,545	MONTH OF THE OWNER	52.20024230	168,573	
Stewardship Science Grant Program	81.112	.00,070	(39,640)	CARNEGIE INSTITUTE OF WASHINGTON	DE-NA002006	(39,640)	
Contract	81.RD	-	35,795		DE-AC52-07NA27644	35,795	
Contract	81.RD	-	15,289		DE-AC05-00OR22725	15,289	
Total Department of Energy		960,462	60,952			1,021,414	91,806
Department of Education				-			
National Institute on Disability and Rehabilitation Research	84.133	_	3,163	UNIVERSITY OF ILLINOIS AT CHICAGO	2016-00319-01-05-7931	3,163	
Education Research, Development and Dissemination	84.305	302.529	5,105	ZZ Z. Z.Z.MOIO/II ONIO/IO		302.529	
Total Department of Education	01.000	302,529	3,163	-		305.692	
. San Separation of Eddodion		302,329	3,103	-		303,092	

Federal Program	CFDA Number	Direct	Pass-through	Pass-Through Grantor	Contract/Award or Pass-Through Num	Total Expenditures	Passed to Subrecipients
Department of Health and Human Services							
Laboratory Training, Evaluation, and Quality Assurance Programs	93.064	343	-			343	
Global AIDS	93.067	-	198,652	CENTRE FOR INFECTIOUS DISEASE RESEARCH IN ZAMBIA	1NU2GGH001920-01-S01	198,652	
Chronic Diseases: Research, Control, and Prevention Birth Defects and Developmental Disabilities - Prevention and Surveillance	93.068 93.073	693,520	24.725	ALABAMA DEPT OF PUBLIC HEALTH	C90116057-6NU50DD000002	693,520 24,725	43,206
Family Smoking Prevention and Tobacco Control Act Regulatory Research	93.073	258,000	24,725	ALABAMA DEPT OF PUBLIC HEALTH	C90116057-6NU50DD000002	24,725 258,000	20.749
Blood Disorder Program: Prevention, Surveillance, and Research	93.080	200,000	39,353	HEMOPHILIA OF GEORGIA INC	6NU27DD001155-04-02	39,353	20,7 10
Blood Disorder Program: Prevention, Surveillance, and Research	93.080	-	2,385	HEMOPHILIA OF GEORGIA INC	1NU27DD00115501-00	2,385	
Food and Drug Administration_Research	93.103	155,911	-	CHILDRENG LICORITAL MEDICAL CENTER CHICANATA CHI	10015000000	155,911	6,312
Food and Drug Administration_Research Environmental Health	93.103 93.113	8,081,656	15,099	CHILDRENS HOSPITAL MEDICAL CENTER CINCINNATI OH	1R01FD005092	15,099 8,081,656	1,265,726
Environmental Health	93.113	-	78,137	VIRGINIA TECH	7R01ES023029-02	78,137	1,200,720
Environmental Health	93.113	-	6,809	WAYNE STATE UNIVERSITY	1R01ES022606	6,809	
Environmental Health	93.113	-	6,257	AUBURN UNIVERSITY	1R21ES024850-01A1	6,257	
Oral Diseases and Disorders Research	93.121	12,208,793	40.747	LININ/EDOLTY OF DOOL FOTED	4D04DE00704F 04	12,208,793	6,642,298
Oral Diseases and Disorders Research Oral Diseases and Disorders Research	93.121 93.121	-	19,717 6,753	UNIVERSITY OF ROCHESTER LOUISIANA STATE UNIVERSITY	1R01DE027245-01 5R01DE019452-08	19,717 6,753	
Oral Diseases and Disorders Research	93.121	-	5.184	UNIVERSITY OF CONNECTICUT HEALTH CENTER	1R34DE027410-01	5.184	
Oral Diseases and Disorders Research	93.121	-	757	INDIANA UNIVERSITY	1R03DE025646-01A1	757	
Oral Diseases and Disorders Research	93.121	-	(660)	LOUISIANA STATE UNIVERSITY	5R01DE019452-07	(660)	
Centers for Research and Demonstration for Health Promotion and Disease Prevention	93.135	746,548	_			746,548	31.623
Centers for Research and Demonstration for Health Promotion and Disease Prevention	93.135	-	11,993	WEST VIRGINIA UNIVERSITY	5U48DP005004-03	11,993	
Injury Prevention and Control Research and State and Community Based Programs	93.136	-	46,773	MINNESOTA HEALTHSOLUTIONS CORPORATION	2R44CE002753-02	46,773	
NIEHS Hazardous Waste Worker Health and Safety Training	93.142	264,153				264,153	78,284
AIDS Education and Training Centers Human Genome Research	93.145 93.172	-	163,159	VANDERBILT UNIVERSITY MEDICAL CENTER HUDSON ALPHA INSTITUTE FOR BIOTECHNOLOGY	HRSA-15-032/5U1OH30535-03-00 5U01HG007301-06	163,159 587,419	
Human Genome Research	93.172	566,393	567,419	HUDSON ALPHA INSTITUTE FOR BIOTECHNOLOGY	5001HG007301-06	566,393	153,707
Human Genome Research	93.172	-	143,638	HARVARD MEDICAL - SCHEPHENS EYE RESEARCH	2U01HG007530-05	143.638	100,101
Human Genome Research	93.172	-	2,062	HUDSON ALPHA INSTITUTE FOR BIOTECHNOLOGY	2U01HG007301-05	2,062	
Research Related to Deafness and Communication Disorders	93.173	1,133,400	-			1,133,400	138,599
Research Related to Deafness and Communication Disorders	93.173	-	23,521	BAEBIES INC	R44DC016576	23,521	
Research and Training in Complementary and Alternative Medicine National Research Service Awards. Health Services Research Training	93.213 93.225	108,676 (122)	-			108,676 (122)	
Research on Healthcare Costs, Quality and Outcomes	93.226	1,558,507	-			1,558,507	
Research on Healthcare Costs, Quality and Outcomes	93.226	-	34,679		1R01HS025703-01A1	34,679	
Research on Healthcare Costs, Quality and Outcomes	93.226	-	3,259	UNIVERSITY OF ALABAMA IN TUSCALOOSA	1R21HS026571-01	3,259	
National Center on Sleep Disorders Research	93.233	633,715	-	VALUE CONTROL TO A STATE OF THE CONTROL OF THE CONT		633,715	116,603
National Center on Sleep Disorders Research Mental Health Research Grants	93.233 93.242	7,973,829	6,342	VANDERBILT UNIVERSITY MEDICAL CENTER	5R03HL135453-02	6,342 7,973,829	1,011,954
Mental Health Research Grants	93.242	1,513,025	389,424	UNIVERSITY OF PITTSBURGH	1R01MH115754-01A1	389,424	1,011,934
Mental Health Research Grants	93.242	-	149,445		1R01MH112386-01A1	149,445	
Mental Health Research Grants	93.242	-	83,286	MERIDIAN BIOTECH, LLC	1R41MH119793-01A1	83,286	
Mental Health Research Grants	93.242	-	43,030	VANDERBILT UNIVERSITY MEDICAL CENTER	5R01MH113438-02	43,030	
Mental Health Research Grants Mental Health Research Grants	93.242 93.242	-	22,988 18,066	THE MCLEAN HOSPITAL CORP UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	1R56MH111471-01A1 1R01MH111889-01	22,988 18.066	
Mental Health Research Grants  Mental Health Research Grants	93.242	-	18,066	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL UNIVERSITY OF CALIFORNIA IN SAN DIEGO	1RF1MH1171889-01 1RF1MH117155-01	17,786	
Mental Health Research Grants	93.242	_	14,376		7R01MH110681-03	14,376	
Mental Health Research Grants	93.242	-	12,551	VANDERBILT UNIVERSITY MEDICAL CENTER	1R01MH113438-01A1	12,551	
Mental Health Research Grants	93.242	-	11,981	UNIVERSITY OF PITTSBURGH	1R01MH103313-01A1	11,981	
Mental Health Research Grants Mental Health Research Grants	93.242	-	11,335 9.925		1U01MH115495-01	11,335	
Mental Health Research Grants	93.242 93.242		9,925 7.493	CENTRE FOR INFECTIOUS DISEASE RESEARCH IN ZAMBIA UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	5U01MH115495-02 5U01MH110925-03S1	9,925 7,493	
Mental Health Research Grants	93.242	_	6,517		5R01MH112385-01	6,517	
Mental Health Research Grants	93.242	-	4,627	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	5U01MH110925-02	4,627	
Mental Health Research Grants	93.242	-		UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	5U01MH110925	4,474	
Mental Health Research Grants	93.242	-	3,300		7K23MH104073-04	3,300	
Mental Health Research Grants Mental Health Research Grants	93.242 93.242	-	(17)	UNIVERSITY OF CALIFORNIA IN SAN FRANCISCO THE REGENTS OF THE UNIVERSITY OF CALFORNIA	5R01MH102198-03 R01MH095683	(17)	
Occupational Safety and Health Program	93.242	1.356.986	(353)	THE REGERTS OF THE UNIVERSITY OF CALFORNIA	170 HWI 1033003	1,356,986	424.232
Health Systems Strengthening and HIV/AIDS Prevention, Care and Treatment under the	55.E5E	.,550,550				.,000,000	.27,202
President's Emergency Plan for AIDS Relief	93.266	-	23,730	CENTRE FOR INFECTIOUS DISEASE RESEARCH IN ZAMBIA	5001GH000526-02	23,730	
Alcohol Research Programs	93.273	973,546	47.005	IOUNG HODIVING HAILVED CITY	D2444027200	973,546	401,708
Alcohol Research Programs Alcohol Research Programs	93.273 93.273	-	47,335 19,955		R34AA027200 1U01AA026209-01	47,335 19,955	
Alcohol Research Programs	93.273	-	17,743		5U01AA020793-08	17,743	
Alcohol Research Programs	93.273	-		UNIVERSITY OF WASHINGTON	5U01AA020793-07	3,440	

Federal Program	CFDA Number	Direct	Pass-through	Pass-Through Grantor	Contract/Award or Pass-Through Num	Total Expenditures	Passed to Subrecipients
Drug Abuse and Addiction Research Programs	93.279	2,090,700	-			2,090,700	95,145
Drug Abuse and Addiction Research Programs	93.279	-	177,445		1R15DA045564-01	177,445	
Drug Abuse and Addiction Research Programs	93.279	-	84,563	UNIVERSITY OF TEXAS AT DALLAS	1R34DA040954-01A1	84,563	
Drug Abuse and Addiction Research Programs	93.279	-	44,001	UNIVERSITY OF WASHINGTON	3UG1DA013714-17S2	44,001	
Drug Abuse and Addiction Research Programs	93.279	-	34,333		1UG3DA047003	34,333	
Drug Abuse and Addiction Research Programs Drug Abuse and Addiction Research Programs	93.279 93.279	-		YALE UNIV YALE UNIV	1UG3DA047003-01 5P30DA018343-14	18,573 10,005	
Drug Abuse and Addiction Research Programs	93.279	-	10,005	TALE UNIV	5F30DA016343-14	10,005	
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	88,928	-			88,928	
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	-	23,498	WAKE FOREST UNIVERSITY SCHOOL OF MEDICINE	R01EB020125	23,498	
Minority Health and Health Disparities Research	93.307	4,633,891				4,633,891	1,029,303
Minority Health and Health Disparities Research	93.307	-	594,131		1U54MD008602	594,131	54,223
Minority Health and Health Disparities Research Minority Health and Health Disparities Research	93.307 93.307	-	48,907 25,637	DREXEL UNIVERSITY COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK	7R01MD013558-03 5U01MD011279-03	48,907 25,637	
Minority Health and Health Disparities Research	93.307		10.967	WAKE FOREST UNIVERSITY SCHOOL OF MEDICINE	5R01MD011279-03 5R01MD009055-04	10.967	
Minority Health and Health Disparities Research	93.307	_	7.462		1R13MD012439-01A1	7.462	
Minority Health and Health Disparities Research	93.307	-	521		5R01MD009118-02	521	
Trans-NIH Research Support	93.310	9,192,610	-			9,192,610	3,398,149
Trans-NIH Research Support	93.310	-		INDIANA UNIVERSITY	7R01AG043972-06	226,700	
Trans-NIH Research Support	93.310	-		MEDICAL UNIVERSITY OF SOUTH CAROLINA	5UG3OD023316-02	91,874	
Trans-NIH Research Support	93.310	-	41,372		5U54GM119023	41,372	
Trans-NIH Research Support	93.310	-	24,614 3,757		3R01DK111622-02S1	24,614	
Trans-NIH Research Support Trans-NIH Research Support	93.310 93.310	-		HARVARD COLLEGE MEDICAL UNIVERSITY OF SOUTH CAROLINA	5U01HG007530-04 1UG30D023316-01	3,757 (14,469)	
Rare Disorders: Research, Surveillance, Health Promotion, and Education	93.315	69.982	(14,469)	MEDICAL UNIVERSITY OF SOUTH CAROLINA	10G30D023316-01	69.982	
National Center for Advancing Translational Sciences	93.350	10,733,237	-			10,733,237	2,296,619
National Center for Advancing Translational Sciences	93.350	-	280,616	UNIVERSITY OF MASSACHUSETTS WORCESTER	5U01TR001812-03	280,616	2,200,010
National Center for Advancing Translational Sciences	93.350	-	175,665		5U01TR001806-03	175,665	
National Center for Advancing Translational Sciences	93.350	-	41,962		5U01TR001812-04	41,962	
National Center for Advancing Translational Sciences	93.350	-	27,114	UNIVERSITY OF PITTSBURGH	5UL1TR001857-03	27,114	
National Center for Advancing Translational Sciences	93.350	-	23,603	THE REGENTS OF THE UNIVERSITY OF CALFORNIA	3UL1TR001414-04S1	23,603	
National Center for Advancing Translational Sciences	93.350	-	10,639	UNIVERSITY OF PITTSBURGH	5UL1TR001857-04	10,639	
National Center for Advancing Translational Sciences National Center for Advancing Translational Sciences	93.350 93.350	-	(26) (94)	UNIVERSITY OF PITTSBURGH NORTHWESTERN UNIVERSITY	5UL1TR001857-02 1U01TR001806-01	(26) (94)	
National Center for Advancing Translational Sciences  National Center for Advancing Translational Sciences	93.350	-		BLONDIN BIO SCIENCE LLC	1R43TR001283-01	(20,115)	
Research Infrastructure Programs	93.351	168,879	(20,113)	BEOINDIN BIO SCIENCE EEC	1143114001203-01	168,879	
21st Century Cures Act - Beau Biden Cancer Moonshot	93.353	192,910	-			192,910	50,343
Nursing Research	93.361	1,256,398	-			1,256,398	
Nursing Research	93.361	-	159,675		1R01NR018391-01	159,675	
Nursing Research	93.361	-	32,467	RHODE ISLAND MEMORIAL HOSPITAL	5R01NR014782-03	32,467	
Nursing Research	93.361	-	4,631	DANA-FARBER CANCER INSTITUTE	5R01NR016720-03	4,631	
Nursing Research Cancer Cause and Prevention Research	93.361 93.393	5,671,960	3,553	DANA-FARBER CANCER INSTITUTE	5R01NR016720-02	3,553 5,671,960	459,913
Cancer Cause and Prevention Research	93.393	5,671,960	81,353	DARTMOUTH COLLEGE	1R01CA225792-01A1	81,353	459,915
Cancer Cause and Prevention Research	93.393		80,670	DARTMOUTH COLLEGE	6R01CA229197-02	80,670	
Cancer Cause and Prevention Research	93.393	_	45,589	UNIVERSITY OF MASSACHUSETTS WORCESTER	5R01CA218008-02	45,589	
Cancer Cause and Prevention Research	93.393	-	44,868	UNIVERSITY OF KANSAS MEDICAL CENTER	1R01CA226838-01A1	44,868	
Cancer Cause and Prevention Research	93.393	-	39,360	BOSTON UNIVERSITY MEDICAL CAMPUS	1R01CA224432-01A1	39,360	
Cancer Cause and Prevention Research	93.393	-	22,332	UNIVERSITY OF NORTH CAROLINA AT CHARLOTTE	5U01CA235507-02	22,332	
Cancer Cause and Prevention Research	93.393	-	16,942	BAYLOR COLLEGE OF MEDICINE	5R01CA194473-04	16,942	
Cancer Cause and Prevention Research	93.393	-	7,885	FRED HUTCHINSON CANCER RESEARCH CENTER	5R01CA211996-02	7,885	
Cancer Cause and Prevention Research Cancer Cause and Prevention Research	93.393 93.393	-	3,960 16	FRED HUTCHINSON CANCER RESEARCH CENTER BAYLOR COLLEGE OF MEDICINE	5R01CA211996-03 1R01CA149973-01	3,960 16	
Cancer Detection and Diagnosis Research	93.394	3,012,766	10	BATLOR COLLEGE OF MEDICINE	TRUTCA 149973-01	3,012,766	281.457
Cancer Detection and Diagnosis Research	93.394	-	171,313	UNIVERSITY OF OKLAHOMA	1R01CA193378-01	171,313	201,101
Cancer Detection and Diagnosis Research	93.394	-	49,922		U01CA214114	49,922	
Cancer Detection and Diagnosis Research	93.394	-	33,299	MASSACHUSETTS GENERAL HOSPITAL	5U01CA152990-08	33,299	
Cancer Detection and Diagnosis Research	93.394	-	30,389	MASSACHUSETTS GENERAL HOSPITAL	5U01CA152990-09	30,389	
Cancer Detection and Diagnosis Research	93.394	-	17,166		U24CA196067	17,166	
Cancer Detection and Diagnosis Research	93.394	-	16,871	UNIVERSITY OF MASSACHUSETTS WORCESTER	1R01CA194787-01A1	16,871	
Cancer Detection and Diagnosis Research Cancer Detection and Diagnosis Research	93.394 93.394	-	15,037 796	UNIVERSITY OF BRITISH COLUMBIA NRG ONCOLOGY INC	1R01CA221918-01A1 1U10CA180860-1	15,037 796	
Cancer Detection and Diagnosis Research  Cancer Detection and Diagnosis Research	93.394 93.394	-	/96 (13)		1U10CA180860-1 5U24CA196067-03	796 (13)	
Cancer Treatment Research	93.395	3,759,706	(13)	5.1.55255 . 1110	332 YOA 130001-03	3,759,706	609,096
Cancer Treatment Research	93.395	-	118,750	CHILDREN'S HOSPITAL OF PHILADELPHIA	U10CA098543	118,750	000,000
Cancer Treatment Research	93.395	-		CHILDREN'S HOSPITAL OF PHILADELPHIA	5U10CA180886-04	89,998	

Federal Program	CFDA Number	Direct	Pass-through	Pass-Through Grantor	Contract/Award or Pass-Through Num	Total Expenditures	Passed to Subrecipients
Cancer Treatment Research	93.395	_	52.319	JOHNS HOPKINS UNIVERSITY	UM1 CA137443	52,319	
Cancer Treatment Research	93.395	-	50.214	CHILDREN'S HOSPITAL OF PHILADELPHIA	UG1CA189955	50,214	
Cancer Treatment Research	93.395	-	43,181	CHILDREN'S HOSPITAL OF PHILADELPHIA	U10CA180886	43,181	
Cancer Treatment Research	93.395	-	35,502	BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE	5R01CA196854-03	35,502	
Cancer Treatment Research	93.395	-	31,596	JOHNS HOPKINS UNIVERSITY	U01CA137443	31,596	
Cancer Treatment Research	93.395	-	26,851	OREGON HEALTH & SCIENCES UNIVERSITY	5UG1CA189974-05	26,851	
Cancer Treatment Research Cancer Treatment Research	93.395 93.395	-	18,805 15,165	MAYO CLINIC ROCHESTER CHILDREN'S HOSPITAL OF PHILADELPHIA	5UG1CA189823-03 UM1CA097452	18,805 15,165	6,500
Cancer Treatment Research	93.395		14,252	ST. JUDE CHILDREN'S RESEARCH HOSPITAL	5U24CA055727-24	14.252	
Cancer Treatment Research	93.395	_	13.796	CHILDREN'S HOSPITAL OF PHILADELPHIA	1UG1CA189955-01	13,796	
Cancer Treatment Research	93.395	-	13,739	CHILDREN'S HOSPITAL OF PHILADELPHIA	5UG1CA189955-02	13,739	
Cancer Treatment Research	93.395	-	11,562	UNIVERSITY OF SOUTH ALABAMA	3R01CA175772-03S1	11,562	
Cancer Treatment Research	93.395	-	10,652	TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER	7R01CA219187-02	10,652	
Cancer Treatment Research	93.395	-	9,275	CHILDREN'S HOSPITAL OF PHILADELPHIA	1U10CA180886-01	9,275	
Cancer Treatment Research	93.395	-	8,706	CHILDREN'S HOSPITAL OF PHILADELPHIA	1R01CA196854	8,706	
Cancer Treatment Research	93.395 93.395	-	7,500 6,663	CHILDREN'S HOSPITAL OF PHILADELPHIA NRG ONCOLOGY INC	U10CA180886-05 5U10CA180868-05	7,500 6,663	
Cancer Treatment Research Cancer Treatment Research	93.395		3.198	JOHNS HOPKINS UNIVERSITY	5UM1CA137443	3,198	
Cancer Treatment Research	93.395	-	3,158	NRG ONCOLOGY INC	U10CA180868	3,158	
Cancer Treatment Research	93.395	-	2.156	NRG ONCOLOGY INC	2U10CA180868-06	2.156	
Cancer Treatment Research	93.395	-	2,084	JOHNS HOPKINS UNIVERSITY	UM1CA137443	2,084	
Cancer Treatment Research	93.395	-	743	CHILDREN'S HOSPITAL OF PHILADELPHIA	1U10CA180886	743	
Cancer Treatment Research	93.395	-	(91)	SEATTLE CHILDREN'S HOSPITAL	1R01CA175216-01A1	(91)	
Cancer Treatment Research	93.395	-	(373)		5U10CA180886-03	(373)	
Cancer Treatment Research Cancer Biology Research	93.395 93.396	3,487,854	(4,268)	JOHNS HOPKINS UNIVERSITY	U01CA137443-01	(4,268) 3,487,854	373,850
Cancer Biology Research	93.396	3,407,034	170.858	CORNELL UNIVERSITY	5R01CA201402-04	170.858	373,030
Cancer Biology Research	93.396	-	52.232	CEDARS-SINAI MEDICAL CENTER	5P01CA098912	52,232	
Cancer Biology Research	93.396	-	10,875	CEDARS-SINAI MEDICAL CENTER	5P01CA098912-14	10,875	
Cancer Biology Research	93.396	-	8,235	H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE	1R21CA216227-01	8,235	
Cancer Biology Research	93.396	-	735	UNIVERSITY OF SOUTH CAROLINA RESEARCH FOUNDATION	5U01CA158428-05	735	
Cancer Centers Support Grants	93.397	6,569,811		IOUNG HORIZING HANGEROUTY		6,569,811	158,905
Cancer Centers Support Grants Cancer Centers Support Grants	93.397 93.397	-	579,487 521,299	JOHNS HOPKINS UNIVERSITY BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE	5P50CA098252-15 2P50CA107399-11A1	579,487 521,299	46,295
Cancer Centers Support Grants  Cancer Centers Support Grants	93.397		131.796	INDIANA UNIVERSITY	5U54CA196519-04	131,796	40,293
Cancer Centers Support Grants	93.397	_	3,903	INDIANA UNIVERSITY	5U54CA196519-03	3,903	
Cancer Centers Support Grants	93.397	-	2,446	INDIANA UNIVERSITY	5U54CA196519-02	2,446	
Cancer Research Manpower	93.398	1,077,762	-			1,077,762	
Networking2Save: CDCs National Network Approach to Preventing and Controlling Tobacco-							
related Cancers in Special Populations	93.431		10,091	NATIONAL AFRICAN AMERICAN TOBACCO PREVENTION NETWO	NU58DP006488-01-00	10,091	
ACL National Institute on Disability, Independent Living, and Rehabilitation Research	93.433	3,214,195	8.842	LININ/EDOLTY OF ILLINIOIS AT OLIOAGO	00075000 00 00	3,214,195	506,440
ACL National Institute on Disability, Independent Living, and Rehabilitation Research ACL National Institute on Disability, Independent Living, and Rehabilitation Research	93.433 93.433	-	8,842 145	UNIVERSITY OF ILLINOIS AT CHICAGO AMERICAN INSTITUTES FOR RESEARCH	90RT5020-03-00 90DP0082	8,842 145	
Foster Care Title IV-E	93.658		64,479	UNIVERSITY OF ALABAMA IN TUSCALOOSA	C90161203	64,479	
Foster Care_Title IV-E	93.658	-	(221)		C60161203	(221)	
Preventing Heart Attacks and Strokes in High Need Areas	93.816	-	125,719		5NU58DP006265	125,719	
Cardiovascular Diseases Research	93.837	29,572,004	-			29,572,004	6,726,072
Cardiovascular Diseases Research	93.837	-	580,909		5P01HL06999-15	580,909	
Cardiovascular Diseases Research Cardiovascular Diseases Research	93.837	-	485,070	CORNELL UNIVERSITY	2R01HL080477	485,070	
Cardiovascular Diseases Research  Cardiovascular Diseases Research	93.837 93.837	-	394,846 286.763	WAKE FOREST UNIVERSITY SCHOOL OF MEDICINE VANDERBILT UNIVERSITY MEDICAL CENTER	2P01HL051952-21A1 1P01HL128203-01A1	394,846 286,763	
Cardiovascular Diseases Research	93.837		204,803	INDIANA UNIVERSITY	1R01HL145528-01	204,803	
Cardiovascular Diseases Research	93.837		175,805		1R01HL13519901A1	175,805	
Cardiovascular Diseases Research	93.837	-	163,472	LOMA LINDA UNIVERSITY	1R01HL142291-01	163,472	
Cardiovascular Diseases Research	93.837	-	121,490		1R01HL144773-01	121,490	
Cardiovascular Diseases Research	93.837	-	115,778	SEATTLE BIOMEDICAL RESEARCH INSTITUTE	1R01HL146130-01	115,778	
Cardiovascular Diseases Research	93.837	-	96,250	BOSTON UNIVERSITY MEDICAL CAMPUS	1U01HL146382-01	96,250	
Cardiovascular Diseases Research	93.837	-	91,117	MAYO CLINIC ROCHESTER	5R01HL131535-03	91,117	
Cardiovascular Diseases Research Cardiovascular Diseases Research	93.837 93.837	-	89,519 75,741	UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION	7R01HL091357-06 7R01HL055673-19	89,519 75,741	
Cardiovascular Diseases Research  Cardiovascular Diseases Research	93.837	-	75,741 55.876	MEDICAL COLLEGE OF WISCONSIN	1R01HL140493-01A1	75,741 55.876	
Cardiovascular Diseases Research	93.837	_	50,732		2R44HL132172-03	50,732	
Cardiovascular Diseases Research	93.837	-	49,502		5U01HL101422	49,502	
Cardiovascular Diseases Research	93.837	-	43,150	DUKE UNIVERSITY	5R01HL133618-03	43,150	
Cardiovascular Diseases Research	93.837	-	38,436	BRIGHAM & WOMENS HOSPITAL	5U01HL123336-04	38,436	
Cardiovascular Diseases Research	93.837	-	34,289	OHIO STATE UNIVERSITY RESEARCH FOUNDATION	5R01HL128857-03	34,289	

Federal Program	CFDA Number	Direct	Pass-through	Pass-Through Grantor	Contract/Award or Pass-Through Num	Total Expenditures	Passed to Subrecipients
Cardiovascular Diseases Research	93.837	_	29.151	OHIO STATE UNIVERSITY RESEARCH FOUNDATION	5R01HL128857-04	29,151	
Cardiovascular Diseases Research	93.837	-	28,247	UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC	1R01HL125877-01A1	28,247	
Cardiovascular Diseases Research	93.837	-	26,827	INDIANA UNIVERSITY	7R25HL124208-05	26,827	
Cardiovascular Diseases Research	93.837	-	24,819		5R01HL126524-03	24,819	
Cardiovascular Diseases Research	93.837	-	17,609	UNIVERSITY OF WASHINGTON	1R01HL36868-01A1	17,609	
Cardiovascular Diseases Research	93.837	-	17,285	EMORY UNIVERSITY KAISER FOUNDATION RESEARCH INSTITUTE	5R01HL129511-03	17,285	
Cardiovascular Diseases Research Cardiovascular Diseases Research	93.837 93.837	-	16,933 16,416		1R01HL122658 5R01HL126524-04	16,933 16,416	
Cardiovascular Diseases Research	93.837		15,693	REGENTS OF THE UNIVERSITY OF MINNESOTA	5R01HL136679-02	15,693	
Cardiovascular Diseases Research	93.837	-	15,590	KAISER FOUNDATION RESEARCH INSTITUTE	1R01HL122658-01A1	15,590	
Cardiovascular Diseases Research	93.837	-	15,292	UNIVERSITY OF MARYLAND	1U24HL134763-01	15,292	
Cardiovascular Diseases Research	93.837	-	15,096	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	1R01HL142825-01A1	15,096	
Cardiovascular Diseases Research	93.837	-	13,377	TULANE UNIVERSITY	5R01HL127092-02	13,377	
Cardiovascular Diseases Research Cardiovascular Diseases Research	93.837 93.837	-	10,299 9,182	HARVARD MEDICAL - SCHEPHENS EYE RESEARCH UNIVERSITY OF NEBRASKA AT OMAHA	1R01HL136685-001 4UM1HL112958-03	10,299 9,182	
Cardiovascular Diseases Research	93.837		8,699	BRIGHAM & WOMENS HOSPITAL	5R01HL132021-02	8,699	
Cardiovascular Diseases Research	93.837	-	8,696	OREGON HEALTH & SCIENCES UNIVERSITY	1R01HL136373-01A1	8,696	
Cardiovascular Diseases Research	93.837	-	8,473	COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK	1R01HL139837-01	8,473	
Cardiovascular Diseases Research	93.837	-	7,747	MASSACHUSETTS GENERAL HOSPITAL	1U01HL123336-01	7,747	
Cardiovascular Diseases Research	93.837	-	7,693	UNIVERSITY OF MINNESOTA	1R21HL135300-01	7,693	
Cardiovascular Diseases Research	93.837	-	5,938	MASSACHUSETTS GENERAL HOSPITAL	5U01HL123336-06	5,938	
Cardiovascular Diseases Research Cardiovascular Diseases Research	93.837 93.837	-	5,293 5,067	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL NORTHWESTERN UNIVERSITY	1R01HL143885-01A1 2R01HL107577-05A1	5,293 5.067	
Cardiovascular Diseases Research	93.837		2,458	BRIGHAM & WOMENS HOSPITAL	5U01HL130163-02	2,458	
Cardiovascular Diseases Research	93.837	-	2,271	THE GEORGE WASHINGTON UNIVERSITY	U24HL140168	2,271	
Cardiovascular Diseases Research	93.837	-	1,726	UNIVERSITY OF MICHIGAN	U01HL094345	1,726	
Cardiovascular Diseases Research	93.837	-	1,421	HUDSON ALPHA INSTITUTE FOR BIOTECHNOLOGY	5R01HL069321-12	1,421	
Cardiovascular Diseases Research	93.837	-	1,048	NEW ENGLAND RESEARCH INSTITUTES INC	U01HL107407	1,048	
Cardiovascular Diseases Research Cardiovascular Diseases Research	93.837 93.837	-	1,037 908	BRIGHAM & WOMENS HOSPITAL	5R01HL117713-03 7R01HL104135-05	1,037 908	
Cardiovascular Diseases Research	93.837	-	908	UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION NEW YORK UNIVERSITY MEDICAL SCHOOL	U01HL105907	908	
Cardiovascular Diseases Research	93.837	-	24		5P01HL06999-12	24	
Cardiovascular Diseases Research	93.837	-	(1,270)		UM1HL119089	(1,270)	
Cardiovascular Diseases Research	93.837	-	(2,854)	UNIVERSITY OF WASHINGTON	3U01HL120393-04S1	(2,854)	
Cardiovascular Diseases Research	93.837	-	(4,151)		5P01HL06999-14	(4,151)	
Cardiovascular Diseases Research	93.837	-	(6,739)		1UM1HL119073-02	(6,739)	
Cardiovascular Diseases Research Lung Diseases Research	93.837 93.838	10.371.030	(26,587)	UNIVERSITY OF WASHINGTON	5U01HL077863-10	(26,587) 10.371.030	985.581
Lung Diseases Research	93.838	10,371,030	196.418	UNIVERSITY OF CALIFORNIA IN SAN FRANCISCO	5U01HL137880-02	196,418	900,001
Lung Diseases Research	93.838	-	168.019		1R01HL136414	168,019	
Lung Diseases Research	93.838	-	132,494	NATIONAL JEWISH MEDICAL AND RESEARCH CENTER	2R01HL089897	132,494	
Lung Diseases Research	93.838	-	77,139	THE GEORGE WASHINGTON UNIVERSITY	R01HL098354	77,139	
Lung Diseases Research	93.838	-	71,506	UNIVERSITY OF SOUTH ALABAMA	1R01HL140182-01A1	71,506	
Lung Diseases Research Lung Diseases Research	93.838	-	53,672		5U01HL137880-03	53,672	
Lung Diseases Research	93.838 93.838	-	44,303 42.896	COPD FOUNDATION NORTHWESTERN UNIVERSITY	5U01HL128954-04 5R01HL122477	44,303 42.896	
Lung Diseases Research	93.838	-	38,866	JOHNS HOPKINS UNIVERSITY	K23HL123594-03S1	38,866	
Lung Diseases Research	93.838	-	37,660	YALE UNIV	1U01HL145567-01	37,660	
Lung Diseases Research	93.838	-	28,132	COPD FOUNDATION	5U01HL128954-03	28,132	
Lung Diseases Research	93.838	-	27,680	EMORY UNIVERSITY	1R01HL136414-01A1	27,680	
Lung Diseases Research	93.838 93.838	-	24,534 22.050		1R01HL141473-01	24,534	
Lung Diseases Research Lung Diseases Research	93.838		22,050	NORTHWESTERN UNIVERSITY UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	5R01HL122477-05 1U24HL141762-01	22,050 20.507	
Lung Diseases Research	93.838	_	17,660	THE GEORGE WASHINGTON UNIVERSITY	2R01HL098354-04	17,660	
Lung Diseases Research	93.838	-	10,876	SANFORD RESEARCH	1R01HL135112-01A1	10,876	
Lung Diseases Research	93.838	-	8,500	UNIVERSITY OF PITTSBURGH	5U01HL1289454-04	8,500	
Lung Diseases Research	93.838	-	7,592	COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK	2R01HL103676-05	7,592	
Lung Diseases Research	93.838	-	3,669	EMORY UNIVERSITY	1R01HL139876-01	3,669	
Lung Diseases Research	93.838	-	3,028 1,197	THE GEORGE WASHINGTON UNIVERSITY	5R01HL098354	3,028	
Lung Diseases Research Lung Diseases Research	93.838 93.838	-	1,197 1,187	UNIVERSITY OF PITTSBURGH COPD FOUNDATION	5U01HL128954-03 5U01HL128954-05	1,197 1,187	
Blood Diseases and Resources Research	93.839	847,387	1,107	30. 5. 33.15.110N	300 II IE 120334-03	847,387	48.546
Blood Diseases and Resources Research	93.839	,	317,104	INDIANA UNIVERSITY	5R24HL123767-04 REVISED	317,104	,0
Blood Diseases and Resources Research	93.839	-	189,688	BETH ISRAEL DEACONESS MEDICAL CENTER	1P01HL131477-01A1	189,688	
Blood Diseases and Resources Research	93.839	-	44,871	MEDICAL UNIVERSITY SOUTH CAROLINA FOUNDATION	5U01HL133990-03	44,871	
Blood Diseases and Resources Research	93.839	-	24,572	UNIVERSITY OF WASHINGTON	1R01HL126538	24,572	

Endoral Brauran	CFDA	Direct	Dage through	Dans Through Country	Contract/Award or Pass-Through	Total Expenditures	Passed to
Federal Program	Number	Direct	Pass-through	Pass-Through Grantor	Num	Expenditures	Subrecipients
Blood Diseases and Resources Research	93.839	_	22,452	MEDICAL UNIVERSITY OF SOUTH CAROLINA	1R01HL133896-01A1	22,452	
Blood Diseases and Resources Research	93.839	-	10,949		1U01HL130048-01A1	10,949	
Blood Diseases and Resources Research	93.839	-	8,891	UNIVERSITY OF WASHINGTON	1U01HL116383-01	8,891	
Blood Diseases and Resources Research	93.839	-	5,855	AUGUSTA UNIVERSITY	5U01HL117684-05	5,855	
Blood Diseases and Resources Research	93.839		1,424	WASHINGTON UNIVERSITY IN ST LOUIS	1R21HL28863-01A1	1,424	
Arthritis, Musculoskeletal and Skin Diseases Research Arthritis, Musculoskeletal and Skin Diseases Research	93.846 93.846	6,781,408	66.305	THE HOSPITAL FOR SICK CHILDREN	5R21AR074006-02	6,781,408 66.305	1,260,122
Arthritis, Musculoskeletal and Skin Diseases Research	93.846		29.131		1U01AR068043-01A1	29.131	
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	_	23,653		UH2AR067681	23,653	
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	_	9,449		1R01AR072615-01A1	9,449	
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	-	7,523	EMORY UNIVERSITY	5R01AR048266-14	7,523	
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	-	698	UNIVERSITY OF MINNESOTA	5R01AR055267	698	
Arthritis, Musculoskeletal and Skin Diseases Research	93.846		(743)	CHILDREN'S HOSPITAL OF PHILADELPHIA	1U19AR069525-01-REVISED	(743)	
Diabetes, Digestive, and Kidney Diseases Extramural Research Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	23,728,177	470.007	THE OFORGE MACHINIOTON LINIVERGITY	01104701000040	23,728,177	1,919,422
Diabetes, Digestive, and Kidney Diseases Extramural Research  Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847 93.847	-	291,262	THE GEORGE WASHINGTON UNIVERSITY COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK	2U01DK298246 5R01DK082753-08	470,607 291,262	33,440
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847		277.561	ENDOMIMETICS, LLC	5R44DK109789-03	277,561	33,440
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	188,729		5R01DK103608-03	188,729	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	108,429	MOUNT SINAI SCHOOL OF MEDICINE	5U54DK083909	108,429	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	105,319		7R01DK104347-03	105,319	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-		UNIVERSITY OF MIAMI	1R01DK116875-01A1	98,012	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	66,020		1R01DK114888-01	66,020	
Diabetes, Digestive, and Kidney Diseases Extramural Research Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847 93.847	-	62,974 54,979	INDIANA UNIVERSITY COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK	1R01DK116603-01A1 1R01DK105124-01	62,974 54,979	
Diabetes, Digestive, and Kidney Diseases Extramural Research  Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847		52,732		1DP3DK108245-01	52,732	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	_	52,732		1R01DK104845-01	52,792	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	51,228	KAISER FOUNDATION RESEARCH INSTITUTE	1R01DK106201-03	51,228	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	50,687	TUFTS MEDICAL CENTER INC.	5U01DK102730-03	50,687	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	48,495		2U01DK066143-16	48,495	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	44,270		5R01DK113111-03	44,270	
Diabetes, Digestive, and Kidney Diseases Extramural Research Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847 93.847	-	42,544		5R01DK111966-03 1R01DK111966	42,544 41.010	
Diabetes, Digestive, and Kidney Diseases Extramural Research  Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847 93.847	-	41,010 38,560	UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER	1R01DK111966 5U01DK058369-18	41,010 38,560	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847		28,931	OREGON HEALTH & SCIENCES UNIVERSITY	7R01DK112358-02	28,931	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	_	28,126		5P50DK096418-07	28,126	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	25,179		5UM1DK100867-06 REVISED	25,179	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	23,658	VANDERBILT UNIVERSITY MEDICAL CENTER	5R01DK084246-08	23,658	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	16,438		5UM1DK100866	16,438	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	14,085		5U01DK082315-10	14,085	
Diabetes, Digestive, and Kidney Diseases Extramural Research Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847 93.847	-	13,497 9,994		1R01DK121007-01 7UM1DK072493-12	13,497 9,994	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847		7.948		5UM1DK072493-12 5UM1DK100867-06	7.948	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	_	4.073	UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER	2U01DK058369-16	4.073	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	3,638	THE GEORGE WASHINGTON UNIVERSITY	R01DK104845	3,638	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	2,055	KAISER FOUNDATION RESEARCH INSTITUTE	1R01DK106201-01	2,055	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	1,931	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	4UM1DK100867-04	1,931	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	1,149	CHIVE NOTE OF THE STATE OF THE	5K23DK087919-04	1,149	
Diabetes, Digestive, and Kidney Diseases Extramural Research Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847 93.847	-	1,062 731	UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER EMORY UNIVERSITY	5U01DK058369-17 5R01DK087694-09	1,062 731	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847		421	COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK	1R21DK109690-01	421	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	228		PA-12-091	228	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	49	REGENTS OF THE UNIVERSITY OF COLORADO	5UM1DK072493-14	49	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-		JOHNS HOPKINS UNIVERSITY	U01DK062431	(117)	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-		SEATTLE CHILDREN'S HOSPITAL	5R01DK103608-02	(474)	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-		THE GEORGE WASHINGTON UNIVERSITY THE RESEARCH INSTITUTE AT NATIONWIDE CHILDRENS HOS	2U01DK298246-06 5UM1DK100866-05 REVISED	(659)	
Diabetes, Digestive, and Kidney Diseases Extramural Research Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847 93.847	-		THE RESEARCH INSTITUTE AT NATIONWIDE CHILDRENS HOS THE CHILDREN'S MERCY HOSPITAL	U01DK066143	(12,682) (15,386)	
Diabetes, Digestive, and Kidney Diseases Extramural Research  Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	(15,386)		2U01DK066143 2U01DK066143-11	(20,978)	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847			THE CHILDREN'S MERCY HOSPITAL  THE CHILDREN'S MERCY HOSPITAL	5U01DK066143-11	(25,619)	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	19,269,484	(20,010)	- "		19,269,484	2,377,303
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853			MASSACHUSETTS GENERAL HOSPITAL	5P01NS087997	273,638	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	187,196		1R01NS102624-01	187,196	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	98,911		5U01NS080168-04	98,911	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853 93.853	-	89,474 82.105		5R01NS087913 5R01NS097443-03	89,474 82,105	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	8∠,105	CORNELL UNIVERSITY	3RUTN5U9/443-U3	82,105	

Federal Program	CFDA Number	Direct	Pass-through	Pass-Through Grantor	Contract/Award or Pass-Through	Total Expenditures	Passed to Subrecipients
reactal Frogram	Number	Direct	rass-tillough	rass-illiough Giantoi	Num	Experiultures	Subrecipients
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	81,249	COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK	5R01NS097876-03	81,249	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	72,221	CHILDREN'S HOSPITAL BOSTON	3U01NS082320-05S1	72,221	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	71,234	UNIVERSITY OF MICHIGAN	1R01NS092706-01A1	71,234	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	59,715		5R01NS097876-02	59,715	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	56,095	CHILDREN'S HOSPITAL BOSTON	5U54NS092090	56,095	
Extramural Research Programs in the Neurosciences and Neurological Disorders Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853 93.853		53,402 52,334	MAYO CLINIC JACKSONVILLE MASSACHUSETTS GENERAL HOSPITAL	5U01NS080168-06 1U01NS093663-01A1	53,402 52,334	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	43,676		1R01NS099209-01	43.676	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	43.487	SOUTHERN RESEARCH INSTITUTE	5R01NS101958-02-03	43,487	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	42,647	OREGON HEALTH & SCIENCES UNIVERSITY	1U01NS095926-01	42,647	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	27,145		2U01NS038455-16A1	27,145	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	24,880	MASSACHUSETTS GENERAL HOSPITAL	1U01NS090259-01A1	24,880	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	24,472		5U01NS082320-04	24,472	
Extramural Research Programs in the Neurosciences and Neurological Disorders Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853 93.853	-	19,412 18.827	UNIVERSITY OF MIAMI NORTHWESTERN UNIVERSITY	1R01NS084288-01A1 1R01NS093843-01A1	19,412 18.827	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	14.926	UNIVERSITY OF SOUTHERN CALIFORNIA	5U54NS092089-03	14,926	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	14,558	SOUTHERN RESEARCH INSTITUTE	5R01NS101958-04	14,558	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	13,921	CHILDREN'S NATIONAL MEDICAL CENTER	7U01NS081041-05	13,921	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	13,555	VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSIT	R01NS05062	13,555	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	12,085	UNIVERSITY OF CINCINNATI	1U01NS095869-01A1	12,085	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	10,793	CHILDREN'S HOSPITAL BOSTON	5U01NS082320-05	10,793	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	9,485	MASSACHUSETTS GENERAL HOSPITAL	1U10NS077420	9,485	
Extramural Research Programs in the Neurosciences and Neurological Disorders Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853 93.853	-	8,110 7,973	STANFORD UNIVERSITY THE METHODIST HOSPITAL RESEARCH INST	1R01NS103037-01A1 1U01NS104326-01	8,110 7,973	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	6.818	UNIVERSITY OF TEXAS AT DALLAS	2R01NS065926-05A1	6.818	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	_	6.622	AUGUSTA UNIVERSITY	7R01NS090083-04	6,622	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	6,366	CHILDRENS HOSPITAL MEDICAL CENTER CINCINNATI OH	5R01NS096053-03	6,366	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	5,328	MAYO CLINIC JACKSONVILLE	5U01NS080168-02	5,328	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	4,376		U01NS093663	4,376	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	3,558	UNIVERSITY OF CINCINNATI	1U01NS100699-01A1	3,558	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	3,456	UNIVERSITY OF CINCINNATI	1U01NS099043-01A1	3,456	
Extramural Research Programs in the Neurosciences and Neurological Disorders  Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853 93.853	-	3,220 2,437	UNIVERSITY OF CINCINNATI CHILDRENS HOSPITAL MEDICAL CENTER CINCINNATI OH	1U01NS102353-01A1 1R01NS096053-01A1	3,220 2,437	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853		1.323	NORTHWESTERN UNIVERSITY	5U01NS080818-03	1.323	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	206	MAYO CLINIC JACKSONVILLE	5R01NS097876-02	206	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	(879)	AUGUSTA UNIVERSITY	1R01NS090083-01A1	(879)	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	(1,719)	COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK	1R01NS097876-01A1	(1,719)	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853		(8,400)	CLEVELAND CLINIC FOUNDATION	5R01NS087913-02	(8,400)	
Allergy, Immunology and Transplantation Research	93.855	44,828,369	-	FAMILY HEALTH INTERNATIONAL	11111111000010	44,828,369	17,040,779
Allergy, Immunology and Transplantation Research Allergy, Immunology and Transplantation Research	93.855 93.855	-	399,644		UM1AI068619 5R01AI064060-12	399,644 321,142	
Allergy, Immunology and Transplantation Research	93.855		315,409	EMORY UNIVERSITY	5R01Al064060-12 5R01Al064060-13	315,409	
Allergy, Immunology and Transplantation Research	93.855	- :	260.925	BRIGHAM & WOMENS HOSPITAL	5UM1Al068636-12	260,925	
Allergy, Immunology and Transplantation Research	93.855	-	243,963	EMORY UNIVERSITY	1P01Al125180	243,963	
Allergy, Immunology and Transplantation Research	93.855	-	233,683	BIODTECH INC	2R44AI114445-02A1	233,683	
Allergy, Immunology and Transplantation Research	93.855	-	225,684	UNIVERSITY OF MARYLAND	1R01AI125561-01	225,684	
Allergy, Immunology and Transplantation Research	93.855	-	207,389		1R01Al126322-02	207,389	
Allergy, Immunology and Transplantation Research	93.855 93.855	-		UNIVERSITY OF KANSAS EMORY UNIVERSITY	1R01Al125093-01 1P01Al125180-01	173,892	
Allergy, Immunology and Transplantation Research Allergy, Immunology and Transplantation Research	93.855	-	155,422		7UM1AI106701-06	166,013 155,422	
Allergy, Immunology and Transplantation Research	93.855		154,714		5U01Al113362	154,714	
Allergy, Immunology and Transplantation Research	93.855	-	152,270	FRED HUTCHINSON CANCER RESEARCH CENTER	5UM1AI068614-13	152,270	
Allergy, Immunology and Transplantation Research	93.855	-	151,175		UM1AI068633	151,175	
Allergy, Immunology and Transplantation Research	93.855	-	145,239	FRED HUTCHINSON CANCER RESEARCH CENTER	5UM1AI068614-11	145,239	
Allergy, Immunology and Transplantation Research	93.855	-	141,341	JOHNS HOPKINS UNIVERSITY	UM1AI068632	141,341	
Allergy, Immunology and Transplantation Research	93.855	-	141,015		5UM1AI068614-12	141,015	
Allergy, Immunology and Transplantation Research	93.855 93.855	-	129,208 126,194	UNIVERSITY OF TEXAS MEDICAL BRANCH UNIVERSITY OF CALIFORNIA LOS ANGELES	1R01Al127744 UM1Al06716	129,208 126,194	
Allergy, Immunology and Transplantation Research Allergy, Immunology and Transplantation Research	93.855 93.855	-	126,194 113,121		5U19AI113173-05	126,194 113,121	
Allergy, Immunology and Transplantation Research	93.855	-	106.192	UNIVERSITY OF WASHINGTON UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	5U19AI113173-05 5U19AI109965-05	106,192	
Allergy, Immunology and Transplantation Research	93.855	_	95,961	UNIVERSITY OF VIRGINIA	1R01Al129678-01	95,961	
Allergy, Immunology and Transplantation Research	93.855	-	94,763	UNIVERSITY OF CALIFORNIA LOS ANGELES	7UM1AI068636-13	94,763	
Allergy, Immunology and Transplantation Research	93.855	-	91,211	BRIGHAM & WOMENS HOSPITAL	5UM1AI106701-05	91,211	
Allergy, Immunology and Transplantation Research	93.855	-	86,685	BRIGHAM & WOMENS HOSPITAL	2UM1AI068636-08	86,685	
Allergy, Immunology and Transplantation Research	93.855	-	81,806	OREGON HEALTH & SCIENCES UNIVERSITY	R01Al133712-02	81,806	

	CFDA				Contract/Award or Pass-Through	Total	Passed to
Federal Program	Number	Direct	Pass-through	Pass-Through Grantor	Num	Expenditures	Subrecipients
Allergy, Immunology and Transplantation Research	93.855		80.882	MOUNT SINAL SCHOOL OF MEDICINE	5U01Al063594	80,882	
Allergy, Immunology and Transplantation Research	93.855		80,111	VANDERBILT UNIVERSITY MEDICAL CENTER	1U01AI132004-01	80.111	
Allergy, Immunology and Transplantation Research	93.855	_	62.834	JOHNS HOPKINS UNIVERSITY	2U01AI069918-13 REVISED	62,834	
Allergy, Immunology and Transplantation Research	93.855	_	60,512	UNIVERSITY OF SOUTHERN CALIFORNIA	1R21AI130927-01A1	60,512	
Allergy, Immunology and Transplantation Research	93.855	_	50,241	UNIVERSITY OF CALIFORNIA LOS ANGELES	7UM1AI106716	50,241	
Allergy, Immunology and Transplantation Research	93.855	-	49,274	UNIVERSITY OF CALIFORNIA IN SAN FRANCISCO	1UM1AI110498-02	49,274	
Allergy, Immunology and Transplantation Research	93.855	-	47,323	MAGEE-WOMEN'S RESEARCH INSTIUTUE & FOUNDATION	5UM1AI068633-13 REVISED	47,323	
Allergy, Immunology and Transplantation Research	93.855	-	44,988	UNIVERSITY OF CALIFORNIA IN SAN FRANCISCO	5U01AI118594-04	44,988	
Allergy, Immunology and Transplantation Research	93.855	-	43,454	MAGEE-WOMEN'S RESEARCH INSTIUTUE & FOUNDATION	5UM1AI068633-13	43,454	
Allergy, Immunology and Transplantation Research	93.855	-	36,176	MAGEE-WOMEN'S RESEARCH INSTIUTUE & FOUNDATION	5UM1AI068633-12 REVISED	36,176	
Allergy, Immunology and Transplantation Research	93.855	-	35,870	NORTHWESTERN UNIVERSITY	1P01Al131346-01	35,870	
Allergy, Immunology and Transplantation Research	93.855	-	35,400	UNIVERSITY OF SOUTHERN CALIFORNIA	1R01Al135122-01A1	35,400	
Allergy, Immunology and Transplantation Research	93.855	-	32,684	UNIVERSITY OF CALIFORNIA IN DAVIS	1R01Al143554-01	32,684	
Allergy, Immunology and Transplantation Research	93.855	-	30,861	BRIGHAM & WOMENS HOSPITAL	5UM1AI068636	30,861	
Allergy, Immunology and Transplantation Research	93.855	-	29,259	UNIVERSITY OF MARYLAND	2U19AI110820-06	29,259	
Allergy, Immunology and Transplantation Research	93.855	-	28,836	UNIVERSITY OF MARYLAND	1R01Al125841-01	28,836	
Allergy, Immunology and Transplantation Research	93.855	-	28,032 27,454	UNIVERSITY OF ROCHESTER	1U01Al131344-01	28,032	
Allergy, Immunology and Transplantation Research	93.855 93.855	-	27,454 25,201	UNIVERSITY OF ROCHESTER BRIGHAM & WOMENS HOSPITAL	5R01AI129518-02 5UM1AI068636-11	27,454 25,201	
Allergy, Immunology and Transplantation Research Allergy, Immunology and Transplantation Research	93.855	-		UNIVERSITY OF CALIFORNIA LOS ANGELES	7UM1AI068636-13 REVISED	23,925	
Allergy, Immunology and Transplantation Research	93.855	-	23,925 23,536	BROWN UNIVERSITY	1R56Al120830-01A1	23,536	
Allergy, Immunology and Transplantation Research	93.855	-	20,068	HARVARD COLLEGE	1R01Al145547-01	20,068	
Allergy, Immunology and Transplantation Research	93.855		18.822	UNIVERSITY OF KANSAS	1R01Al138970-01	18,822	
Allergy, Immunology and Transplantation Research	93.855		16,699	UNIVERSITY OF CALIFORNIA LOS ANGELES	1R01Al137680-01A1	16,699	
Allergy, Immunology and Transplantation Research	93.855		16,519		UM1 AI068619	16,519	
Allergy, Immunology and Transplantation Research	93.855		16.042	DUKE UNIVERSITY	5UM1AI00645-05	16.042	
Allergy, Immunology and Transplantation Research	93.855	_	15.498	UNIVERSITY OF ROCHESTER	5R01Al17787-03	15,498	
Allergy, Immunology and Transplantation Research	93.855	_	14,860	ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA U	5U19AI103461-06	14,860	
Allergy, Immunology and Transplantation Research	93.855	-	14,339	VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSIT	R01Al34972-01A1	14,339	
Allergy, Immunology and Transplantation Research	93.855	-	13,205	JOHNS HOPKINS UNIVERSITY	5U01AI069918-14	13,205	
Allergy, Immunology and Transplantation Research	93.855	-	13,085	UNIVERSITY OF TEXAS HEALTH CENTER AT SAN ANTONIO	1R01Al141877-01A1	13,085	
Allergy, Immunology and Transplantation Research	93.855	-	10,733	UNIVERSITY OF CALIFORNIA LOS ANGELES	5UM1AI068636	10,733	
Allergy, Immunology and Transplantation Research	93.855	-	9,465	JOHNS HOPKINS UNIVERSITY	5UM1AI068632-13	9,465	
Allergy, Immunology and Transplantation Research	93.855	-	8,958	UNIVERSITY OF CALIFORNIA LOS ANGELES	UM1AI068636-13	8,958	
Allergy, Immunology and Transplantation Research	93.855	-	7,703	UNIVERSITY OF CALIFORNIA IN SAN FRANCISCO	5U01AI118594-05	7,703	
Allergy, Immunology and Transplantation Research	93.855	-	4,945	DUKE UNIVERSITY	5UM1AI104681-08	4,945	
Allergy, Immunology and Transplantation Research	93.855	-	4,725	UNIVERSITY OF CALIFORNIA IN SAN FRANCISCO	5U54AI082973-10	4,725	
Allergy, Immunology and Transplantation Research	93.855	-	4,585	BENAROYA RESEARCH INSITUTE AT VIRGINIA MASON	5UM1AI109565-025	4,585	
Allergy, Immunology and Transplantation Research	93.855	-	4,529	THERAPEUTICS SYSTEMS RESEARCH LAB	2R44AI00401-03	4,529	
Allergy, Immunology and Transplantation Research	93.855	-	4,507	IIII EOIBA	2R44Al141044-02	4,507	
Allergy, Immunology and Transplantation Research	93.855	-	3,927	MAGEE-WOMEN'S RESEARCH INSTIUTUE & FOUNDATION BRIGHAM & WOMENS HOSPITAL	5UM1Al068633-12	3,927 3.711	
Allergy, Immunology and Transplantation Research Allergy, Immunology and Transplantation Research	93.855 93.855	-	3,711 3,256	JOHNS HOPKINS UNIVERSITY	5R01AI12001-03 1U01AI134591-01&02	3,711	
Allergy, Immunology and Transplantation Research Allergy, Immunology and Transplantation Research	93.855	-	2,337	DUKE UNIVERSITY	5UM1AI104681-06	2,337	
Allergy, Immunology and Transplantation Research	93.855		2,087	ACTUATED MEDICAL INC	2R44Al080335-04	2,087	
Allergy, Immunology and Transplantation Research	93.855		1.973	MEDICAL UNIVERSITY OF SOUTH CAROLINA	5R01Al128864-02	1,973	
Allergy, Immunology and Transplantation Research	93.855	_	1,549	JOHNS HOPKINS UNIVERSITY	5UM1AI068632-11	1,549	
Allergy, Immunology and Transplantation Research	93.855	_	1.161	JOHNS HOPKINS UNIVERSITY	5UM1AI068632-10	1,161	
Allergy, Immunology and Transplantation Research	93.855	-	919	DUKE CLINICAL RESEARCH INSTITUTE	5UM1AI04681-05	919	
Allergy, Immunology and Transplantation Research	93.855	-	417	MOUNT SINAI SCHOOL OF MEDICINE	5U01AI063594-14	417	
Allergy, Immunology and Transplantation Research	93.855	-	267	JOHNS HOPKINS UNIVERSITY	2U01AI069918-11	267	
Allergy, Immunology and Transplantation Research	93.855	-	(29)	ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA U	5R01-Al097096-05	(29)	
Allergy, Immunology and Transplantation Research	93.855	-	(49)	FRED HUTCHINSON CANCER RESEARCH CENTER	5UM1AI068614-10	(49)	
Allergy, Immunology and Transplantation Research	93.855	-	(59)	IMMUNO-MYCOLOGICS INC	2R44AI096945	(59)	
Allergy, Immunology and Transplantation Research	93.855	-	(444)	UNIVERSITY OF WASHINGTON	5U19AI113173-03	(444)	
Allergy, Immunology and Transplantation Research	93.855	-	(1,219)		U54AI082973-08	(1,219)	
Allergy, Immunology and Transplantation Research	93.855	-		CHILDREN'S HOSPITAL BOSTON	1R01Al1084011-04	(2,087)	
Allergy, Immunology and Transplantation Research	93.855	-	(12,360)	UNIVERSITY OF CALIFORNIA IN DAVIS	4R01Al049342-10A1	(12,360)	
Biomedical Research and Research Training	93.859	7,151,615	-			7,151,615	126,263
Biomedical Research and Research Training	93.859	-	121,339	JOHNS HOPKINS UNIVERSITY	1R01GM121404-01A1	121,339	
Biomedical Research and Research Training	93.859	-	9,888	ST. JUDE CHILDREN'S RESEARCH HOSPITAL	5R01GM118578-03	9,888	
Biomedical Research and Research Training	93.859	-	2,275	ST. JUDE CHILDREN'S RESEARCH HOSPITAL	1R01GM118578-01A1	2,275	
Biomedical Research and Research Training Biomedical Research and Research Training	93.859	-	2,001	WASHINGTON UNIVERSITY IN ST LOUIS	5R01GM113838-03	2,001	
	93.859 93.859	-	(7,079)	UNIVERSITY OF MISSISSIPPI MEDICAL CENTER UNIVERSITY OF PITTSBURGH	1R01GM103799 5R01GM101197-03	(7,079) (9,227)	
Biomedical Research and Research Training	33.009	-	(9,227)	UNIVERSITE OF FILLSBURGH	2K01GM101187-02	(9,227)	

	CFDA				Contract/Award or Pass-Through	Total	Passed to
Federal Program	Number	Direct	Pass-through	Pass-Through Grantor	Num	Expenditures	Subrecipients
Child Health and Human Development Extramural Research	93.865	9,945,794				9,945,794	2,238,970
Child Health and Human Development Extramural Research	93.865	5,545,754	772.840	THE GEORGE WASHINGTON UNIVERSITY	U10HD036801	772,840	52,665
Child Health and Human Development Extramural Research	93.865	_	600.075	RTI INTERNATIONAL	U10HD34216	600.075	02,000
Child Health and Human Development Extramural Research	93.865	_	426,591	HARVARD COLLEGE	5U01HD052102-14	426,591	
Child Health and Human Development Extramural Research	93.865	_	285,767	UNIVERSITY OF CALIFORNIA IN SAN FRANCISCO	1R01HD089918-01	285,767	
Child Health and Human Development Extramural Research	93.865	-	267,754	RTI INTERNATIONAL	2U24HD069031	267,754	
Child Health and Human Development Extramural Research	93.865	-	263,236	UNIVERSITY OF CAPE TOWN	5R01HD083026-04	263,236	
Child Health and Human Development Extramural Research	93.865	-	203,940	INDIANA UNIVERSITY	5R01HD86007-02	203,940	
Child Health and Human Development Extramural Research	93.865	-	190,221	WASHINGTON UNIVERSITY IN ST LOUIS	1U01HD077384-02	190,221	
Child Health and Human Development Extramural Research	93.865	-	111,919	SHARP HEALTHCARE FOUNDATION	5R01HD088646-02	111,919	
Child Health and Human Development Extramural Research	93.865	-	91,424	SHARP HEALTHCARE FOUNDATION	5R01HD088646-03	91,424	
Child Health and Human Development Extramural Research	93.865	-	76,474	HARVARD COLLEGE	5U01HD052102-15	76,474	
Child Health and Human Development Extramural Research Child Health and Human Development Extramural Research	93.865 93.865	-	62,283 61,428	BAEBIES INC REGENTS OF THE UNIVERSITY OF COLORADO	1R44HD095225-02 5R01HD080477-05	62,283 61,428	
Child Health and Human Development Extramural Research	93.865	-	61,426	WASHINGTON UNIVERSITY IN ST LOUIS	1R01HD086323-02	61,426	
Child Health and Human Development Extramural Research	93.865		30.139	FLORIDA STATE UNIVERSITY	7U19HD089875-03	30,139	
Child Health and Human Development Extramural Research	93.865	_	27.703	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	1R01HD086139-01A1	27,703	
Child Health and Human Development Extramural Research	93.865	_	22,408	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	5U24HD089880-02	22,408	
Child Health and Human Development Extramural Research	93.865	-	18,580	BENTEN TECHNOLOGIES	2R44HD072823-02	18,580	
Child Health and Human Development Extramural Research	93.865	-	13,178	THE RESEARCH INSTITUTE AT NATIONWIDE CHILDRENS HOS	5R01HD088033-03	13,178	
Child Health and Human Development Extramural Research	93.865	-	11,953	NEW YORK PRESBYTERIAN HOSPITAL-WEILL CORNELL MEDIC	3P01HD067244-08S1	11,953	
Child Health and Human Development Extramural Research	93.865	-	11,129	BAEBIES INC	1R44HD095225-01	11,129	
Child Health and Human Development Extramural Research	93.865	-	9,011	FROM THE FUTURE, LLC	1R43HD093522-01	9,011	
Child Health and Human Development Extramural Research	93.865	-	6,343		5U19HD089875-05	6,343	
Child Health and Human Development Extramural Research	93.865	-	2,839	UNIVERSITY OF KWAZULU-NATAL	1R21HD083011-01	2,839	
Child Health and Human Development Extramural Research	93.865	-	2,256	UNIVERSITY OF MARYLAND	2R01HD067126-06A1	2,256	
Child Health and Human Development Extramural Research	93.865	-	1,879 1,541	UNIVERSITY OF CALIFORNIA LOS ANGELES	1R01HD092471-01	1,879	
Child Health and Human Development Extramural Research Child Health and Human Development Extramural Research	93.865 93.865	-	1,541	THE RESEARCH INSTITUTE AT NATIONWIDE CHILDRENS HOS SHARP HEALTHCARE FOUNDATION	1R01HD088033-01A1 1R01HD088646-01A1	1,541 480	
Child Health and Human Development Extramural Research	93.865		(116)		5U01HD052102-13	(116)	
Child Health and Human Development Extramural Research	93.865		(598)		5R01HD080477-04	(598)	
Aging Research	93.866	10.578.957	(555)	RECEIVED OF THE CHIVEROFF OF COECHADO	310111D000477-04	10,578,957	620,791
Aging Research	93.866	-	443,490	UNIVERSITY OF FLORIDA	2R37AG033906-11	443,490	020,701
Aging Research	93.866	-	256,313	JOHNS HOPKINS UNIVERSITY	1RF1AG050609-01A1	256,313	
Aging Research	93.866	-	141,455	UNIVERSITY OF MICHIGAN	1RF1AG057540-01	141,455	
Aging Research	93.866	-	137,348	UNIVERSITY OF WASHINGTON	1R01AG056486-01	137,348	
Aging Research	93.866	-	120,004	UNIVERSITY OF SOUTHERN CALIFORNIA	U19AG02-4904	120,004	
Aging Research	93.866	-	107,694	INDIANA UNIVERSITY	1R01AG057703-01	107,694	
Aging Research	93.866	-	97,101	UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION	1R01AG046920-01A1	97,101	
Aging Research	93.866	-	82,435	UNIVERSITY OF SOUTHERN CALIFORNIA	1U24AG057437-01	82,435	
Aging Research	93.866	-	73,513	WAKE FOREST UNIVERSITY SCHOOL OF MEDICINE	1R01AG058571-01	73,513	
Aging Research Aging Research	93.866 93.866	-	71,900 51,213	DREXEL UNIVERSITY UNIVERSITY OF CALIFORNIA IN SAN FRANCISCO	1R01AG049970 1R01AG059009	71,900 51,213	
Aging Research	93.866		38.943	WAKE FOREST UNIVERSITY SCHOOL OF MEDICINE	1R01AG055606-01	38,943	13,013
Aging Research	93.866		36,921	INDIANA UNIVERSITY	1RF1AG0556111-01	36,921	13,013
Aging Research	93.866	_	36.057	NORTHWESTERN UNIVERSITY	1R01AG047416-01A1	36,057	
Aging Research	93.866	_	32.829	UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION	4R37AG004542-27	32.829	
Aging Research	93.866	-	31,743	UNIVERSITY OF WASHINGTON	1R56AG057262-01	31,743	
Aging Research	93.866	-	31,007	WAKE FOREST UNIVERSITY SCHOOL OF MEDICINE	5U01AG029824-07	31,007	
Aging Research	93.866	-	25,216	THE JACKSON LAORATORY	5R01AG052608-03	25,216	
Aging Research	93.866	-	23,916	THE REGENTS OF THE UNIVERSITY OF CALFORNIA	7R01AG056360-02	23,916	
Aging Research	93.866	-	16,932	WAKE FOREST UNIVERSITY SCHOOL OF MEDICINE	R24AG044325	16,932	
Aging Research	93.866	-	13,823	MINNEAPOLIS MEDICAL RESEARCH FOUNDATION	U01AG029824-07S2	13,823	
Aging Research	93.866 93.866	-	13,241 12.362		1R03AG056446-01	13,241	
Aging Research Aging Research	93.866	-	8.375	COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK PENNSYLVANIA STATE UNIVERSITY (THE)	1R01AG057709 1U012AG062370	12,362 8.375	
Aging Research	93.866	-	8,375 7.891	UNIVERSITY OF WISCONSIN IN MADISON	5R01AG040178-07	8,375 7.891	
Aging Research	93.866	-	7,091	REGENTS OF THE UNIVERSITY OF COLORADO	1R01AG054366-01A1	7,091	
Aging Research	93.866		5.944	UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER	5R01AG047290-03	5,944	
Aging Research	93.866	_	3,523	THE JACKSON LAORATORY	5R01AG052608-04	3,523	
Aging Research	93.866	-	2,566	BRIGHAM & WOMENS HOSPITAL	1R01AG054366-01A1	2,566	
Aging Research	93.866	-	2,293	NORTHERN CALIFORNIA INST FOR RESEARCH AND EDU	1R01AG063887-01	2,293	
Aging Research	93.866	-	223	UNIVERSITY OF CALIFORNIA LOS ANGELES	5R01AG054366-03	223	
Aging Research	93.866	-	(4,720)	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	5K23AG038548-02	(4,720)	
Vision Research	93.867	12,622,301	-			12,622,301	2,223,177

Federal Program	CFDA Number	Direct	Pass-through	Pass-Through Grantor	Contract/Award or Pass-Through Num	Total Expenditures	Passed to Subrecipients
Vision Research	93.867	_	292.649	UNIVERSITY OF CALIFORNIA - BERKELEY	R01EY023591	292,649	
Vision Research	93.867		270,754	VANDERBILT UNIVERSITY MEDICAL CENTER	1U24EY029893-01	270.754	
Vision Research	93.867	_	193,260	MOUNT SINAI SCHOOL OF MEDICINE	R01EY015220	193,260	
Vision Research	93.867	_	174,209	UNIVERSITY OF MISSISSIPPI MEDICAL CENTER	2R01EY014263-09	174,209	
Vision Research	93.867	_	78,809	UNIVERSITY OF FLORIDA	1R01EY028968-01A1	78,809	
Vision Research	93.867	_	69,176	JAEB CENTER FOR HEALTH RESEARCH INC	MTS1	69.176	
Vision Research	93.867	-	66,159	UNIVERSITY OF FLORIDA	R01EY024280	66,159	
Vision Research	93.867	-	62,551	OKLAHOMA MEDICAL RESEARCH FOUNDATION	1R01EY024944-01A1	62,551	
Vision Research	93.867	-	52,682	MICHIGAN STATE UNIVERSITY	5R01EY016077-10	52,682	
Vision Research	93.867	-	43,496	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	5R01EY026220-03	43,496	
Vision Research	93.867	-	43,105		2R01EY022091-05A1	43,105	
Vision Research	93.867	-	38,720	UNIVERSITY OF TEXAS HEALTH SCIENCE CTR AT HOUSTON	2R01EY022362-04A1	38,720	
Vision Research	93.867	-	31,182	JAEB CENTER FOR HEALTH RESEARCH INC	5U10EY011751-20	31,182	
Vision Research	93.867	-	18,922	UNIVERSITY OF ILLINOIS AT CHICAGO	5R01EY024966-04	18,922	
Vision Research	93.867	-	14,235		1R01EY030192-01	14,235	
Vision Research	93.867	-	5,206	NEW YORK UNIVERSITY MEDICAL SCHOOL	1U10EY026869-01	5,206	
Vision Research	93.867	-	886	SALUS UNIVERSITY	5U10EY022599-04	886	
Vision Research Vision Research	93.867 93.867	-	397 (44)	OREGON HEALTH & SCIENCES UNIVERSITY SALUS UNIVERSITY	1R21EY027079-01 1U10EY022599-03	397 (44)	
HIV Emergency Relief Project Grants	93.914	-	74.784	BOSTON UNIVERSITY MEDICAL CAMPUS	5U69HA30462-02-00	74,784	
HIV Emergency Relief Project Grants	93.914	-	6.299	THE FENWAY INSTITUTE, FENWAY HEALTH	U69HA31067	6,299	
International Research and Research Training	93.989	227,665	0,299	THE PENWAT INSTITUTE, PENWAT HEALTH	009HA31007	227.665	87.326
International Research and Research Training	93.989	227,003	45,204	UNIVERSIDAD PERUANA CAYETANO HEREDIA	5D43TW009763-05	45,204	07,320
Contract	93.RD		2,261,234	THE SOCIETY OF THORACIC SURGEONS	HHSN268201100025C	2,261,234	
Contract #HHSN268201800005I TO 01 BASE	93.RD	1,517,303	2,201,204	THE GOODETT OF THORAGIO GORGEONG	11110142002011000230	1,517,303	394,029
Contract #HHSN272201600018C	93.RD	729.375				729.375	445,192
Contract #HHSN261201500036I	93.RD	635.477	_			635,477	324.843
Contract #HHSN272201300012I/HHSN27200014	93.RD	634,073	_			634,073	463,305
Contract	93.RD		588,321	VANDERBILT UNIVERSITY MEDICAL CENTER	HHSN272201300023I	588,321	,
Contract #HHSN272201300012I	93.RD	541,638	-			541,638	410,872
Contract #HHSN272201300012I/HHSN27200013	93.RD	533,334	-			533,334	495,517
Contract #HHSN272201600017C	93.RD	429,452	-			429,452	94,504
Contract #HHSN268201800007I TO 01 BASE	93.RD	396,359	-			396,359	
Contract #HHSN272201100035C-Option 2	93.RD	392,868	-			392,868	156,308
Contract #HHSN272201300012I-TO12 Opt 2	93.RD	392,348	-			392,348	153,056
Contract #75D30118C02902	93.RD	386,500	-			386,500	23,850
Contract #HHSN261201500036I TO9	93.RD	352,117	-			352,117	295,340
Contract #HHSN261201500036I TO 07	93.RD	346,327	-			346,327	
Contract #HHSN272201100037C	93.RD	339,682	-			339,682	88,992
Contract #HHSN27201300012I/HHSN27200011	93.RD	337,564	-			337,564	101,487
Contract #HHSN275201300014C Contract #HHSN272201100038C	93.RD 93.RD	332,168 323.329	-			332,168 323.329	445 400
Contract #HHSN272201100036C	93.RD 93.RD	303,764	-			303,764	115,190
Contract #HHSN2722011000161 Contract #HHSN268201800005I TO 01 Opt 1	93.RD 93.RD	303,764	-			303,764	32,484
Contract #HHSN2612015000051 TO 10	93.RD 93.RD	295,672	-			295,672	152,958
Contract #HHSN272201100036C	93.RD	287,218	_			287,218	41,127
Contract #HHSN272201100034C	93.RD	281,679				281,679	35.636
Contract #HHSN261201500036I TO 11	93.RD	254,233	_			254,233	129,519
Contract #HHSN261201500036I TO8	93.RD	208,103	-			208,103	,0
Contract #HHSN268200900047C OPT5	93.RD	207,189	-			207,189	
Contract #HHSN272201300012I/HHSN27200010	93.RD	206,916	-			206,916	206,916
Contract #200-2017-96217	93.RD	187,288	-			187,288	60,000
Contract #75D30118C02929	93.RD	147,489	-			147,489	
Contract #HHSN272201300012I/HHSN27200012	93.RD	110,062	-			110,062	50,962
Contract	93.RD	-	102,796	MEDICAL UNIVERSITY OF SOUTH CAROLINA	1UG30D023316-01	102,796	
Contract #HHSN272201300012I/HHSN27200007	93.RD	100,163	-			100,163	60,750
Contract	93.RD	-	91,404	LEIDOS BIOMEDICAL RESEARCH, INC	HHSN261200800001E	91,404	
Contract #HHSN268201800007I TO 01 Opt 1	93.RD	88,727	-			88,727	
Contract #HHSN271201500088C	93.RD	79,079	-			79,079	== 0.1
Contract #HHSN272201300012I/HHSN27200011	93.RD	74,937	-	LININ/EDOLTY OF DOOLIEGTED	111001070004000000	74,937	55,917
Contract	93.RD	-	56,115		HHSN272201200005C	56,115	
Contract	93.RD	45.700	48,971	UNIVERSITY OF WISCONSIN IN MADISON	HHSN261201200033I	48,971	
Contract #75N93019D00016 Contract	93.RD 93.RD	45,762	40.004	UNIVERSITY OF ROCHESTER	HHSN27220140000SC	45,762 40,924	
Contract	93.RD 93.RD	-	40,924		HHSN273201600003I	40,924 40,168	
OUT MADE	33.112		70,100	3301.12 & 331.2111110 0101EM01110		70,100	

CFDA	Contract/Award or Pass-Through	Total	Passed to
Federal Program Number Direct Pass-through	Pass-Through Grantor Num	Expenditures	Subrecipients
Contract 93.RD - 35.518 ATOX BIO, LTD	HHSO1002014000013C	35,518	
Contract 93.RD - 28,253 DUKE UNIVERSITY	HHSN272200900023C	28,253	
Contract 93.RD 27,196 NORTHWESTERN UNIVER Contract #HHSN272201300012I/HHSN27200015 93.RD 24,065	SITY HHSN261201200035I	27,196	40.007
Contract #HHSN272201300012I/HHSN27200015 93.RD 24,065 - Contract 93.RD - 22.295 DELPHI GENOMICS, LLC	HHSN261201700014C	24,065 22,295	10,967
Contract 93.RD - 22.202 RAND CORPORATION	HHSM-500-2017-00083G	22,202	
Contract 93.RD - 19,169 SUMMIT OXFORD LIMITED	HHSO100201700014C	19,169	
Contract #HHSN272201100035C 93.RD 18,128 -		18,128	18,128
Contract         93.RD         -         17,565         UNIVERSITY OF HAWAII           Contract         93.RD         -         17,245         MAYO CLINIC ROCHESTEI	R01CA0208851 R HHSN261201200042I	17,565 17,245	
53.RD   -   17,249   WATO CLINIC ROCHESTE	HHSND2002013M53890B	15,229	
Contract 93.RD - 14,721 NORTHWESTERN UNIVER		14,721	
Contract 93.RD - 12,994 EASTERN COOPERATIVE		12,994	
Contract 93.RD - 10,089 UNIVERSITY OF PENNSYL		10,089	
Contract         93.RD         - 10,000         EASTERN COOPERATIVE           Contract         93.RD         - 9,263         GHILDREN'S HOSPITAL OF		10,000 9,263	
Sand		8,846	
Contract 93.RD - 6,139 UNIVERSITY OF MICHIGAN	N HHSN268201100026C	6,139	
	DICAL CENTER CINCINNATI OH HHSN272201300016I	4,249	
Contract 93.RD - 3,352 RAND CORPORATION	HHSM-500-2014-00399G	3,352	
Contract         93.RD         -         3,143         ABT ASSOCIATES INC           Contract         93.RD         -         2,624         FRED HUTCHINSON CANC	HHSD20002013M53890B/75D30118F030 ER RESEARCH CENTER 5UM1AI068614-13	3,143 2,624	
2,04   RED   - 2,05   JOHNS HOPKINS UNIVERSE   - 2,550   JOHNS UNIVERSE   - 2,550   - 2,550   JOHNS UNIVERSE   - 2,550   JOHNS UNIVERSE   - 2,550   - 2,550   JOHNS UNIVERSE   - 2,550   JOHNS UNIVERSE   - 2,550		2,550	
Contract #75N91019D00019/75N91019F00129 93.RD 2,538 -		2,538	
Contract 93.RD - 1,806 WASHINGTON UNIVERSIT		1,806	
Contract 93.RD - 1,540 WESTAT CORPORATION	HHSN275201800001I	1,540	
Contract         93.RD         -         1,448         CONRAD, EASTERN VIRGI           Contract         93.RD         -         894         UNIVERSITY OF MISSISSIS		1,448 894	
Contract #HHSN271201700015C 93.RD 131 -	THISN2000 T0000 T01	131	
Contract 93.RD - (66) AMERICAN COLLEGE OF F	RADIOLOGY ACRIN-6685	(66)	
Contract 93.RD - (697) ABT ASSOCIATES INC	HHSD20002013M53890B/200-2013-F-5754	(697)	
Contract         93.RD         - (1,214)         CONRAD, EASTERN VIRGI           Contract #16IPA0001611537-1         93.RD         (1,302)         -	NIA MEDICAL SCHOOL 200-2016-91451	(1,214) (1,302)	
Contract #16IPA0001611537-1         93.RD         (1,302)           Contract         93.RD         (4,324)         CHILDRENS HOSPITAL ME	EDICAL CENTER CINCINNATI OH HHSN2722013000161	(1,302)	
Contract 93.RD - (17.631) DUKE UNIVERSITY	HHSN-275201000031	(17,631)	
Contract 93.RD - (31,004) DUKE UNIVERSITY	HHSN-2752010000031	(31,004)	
Unknown 93.RD - 77,637 EASTERN COOPERATIVE		77,637	
Unknown         93.RD         - 75,273         UNIVERSITY OF ROCHEST           Unknown         93.RD         - 36,062         MINNESOTA HEALTHSOLL		75,273 36,062	
	S DISEASE RESEARCH IN ZAMBIA MO85-5001GH000526-02	24,274	
Unknown         93.RD         -         22,895         JOHNS HOPKINS UNIVERS		22,895	
Unknown 93.RD - 18,280 OREGON HEALTH & SCIEN		18,280	
Unknown 93.RD - 4,374 UNIVERSITY OF MARYLAN		4,374	
Unknown         93.RD         -         2,487         DUKE UNIVERSITY           Unknown         93.RD         -         1,971         AMERICAN COLLEGE OF F	U10CA76001 RADIOLOGY ACRIN-6698	2,487 1,971	
Unknown 93.RD - 1,553 AMERICAN COLLEGE OF F		1,553	
Unknown 93.RD - 489 MAYO CLINIC ROCHESTEI		489	
Unknown 93.RD 427 MINNESOTA HEALTHSOLU	JTIONS CORPORATION R43HD097762	427	
Total Department of Health and Human Services 279,703,622 33,181,779	-	312,885,401	59,872,558
Department of Homeland Security			
Contract #70RSAT18CB0000042 97.RD <u>677,378</u>	-	677,378	
Total Department of Homeland Security 677,378 -	-	677,378	
U. S. Agency for International Development			
USAID Foreign Assistance for Programs Overseas 98.001 - 124,361 INTL AIDS VACCINE INITIA USAID Foreign Assistance for Programs Overseas 98.001 - 43.026 NATI ACADEMY OF SCIEN		124,361	
USAID Foreign Assistance for Programs Overseas 98.001 - 43,026 NATL ACADEMY OF SCIEN USAID Foreign Assistance for Programs Overseas 98.001 - 3,702 EMORY UNIVERSITY	ICES AID-263-A-15-00002 AID-OAA-A-16-00032	43,026 3,702	
Total U. S. Agency for International Development - 171.089	ND-0AA-A-10-00032	171.089	
Total Research and Development 311,695,530 39,079,402		350,774,932	64,670,264
	-	330,114,932	04,070,204
Student Financial Assistance Department of Education			
Pederal Supplemental Education Opportunity Grant 84.007 763,878 -		763,878	
Federal Work-Study Program 84.033 914,553 -		914,553	
Federal Perkins Loan - Outstanding loans at fiscal year beginning 84.038 11,530,979 -		11,530,979	
Federal Pell Grant 84.063 24,498,054 -		24,498,054	
Direct Student Loans 84.268 167,141,359 - Teacher Education Assistance for College and Higher Education Grants (TEACH) 84.379 37,967 -		167,141,359 37,967	
Total Department of Education - Total Department of Education Glaris (TEACH) 04-379 37,907 - 204,886,790 - 204,886	•	204.886.790	

Federal Program	CFDA Number	Direct	Pass-through	Pass-Through Grantor	Contract/Award or Pass-Through Num	Total Expenditures	Passed to Subrecipients
Department of Health and Human Services							
Nurse Faculty Loan Program - Outstanding loans at fiscal year beginning	93.264	2,312,338	-			2,312,338	
Nurse Faculty Loan Program - New loans issued during fiscal year	93.264	706,868	-			706,868	
Health Professions Student Loans - Outstanding loans at fiscal year beginning Health Professions Student Loans - New loans issued during fiscal year	93.342 93.342	1,665,762 46,418	-			1,665,762 46,418	
Nurse Faculty Loan Program ARRA - Outstanding loans at fiscal year beginning	93.408	87,638	-			87,638	
Total Department of Health and Human Services		4.819.024				4.819.024	
Total Student Financial Assistance		209,705,814				209,705,814	
G.E.A.R. Programs		200,700,011				200,100,011	-
Department of Education							
Gaining Early Awareness and Readiness for Undergraduate Programs	84.334	3,957,908				3,957,908	1,191,845
Total Department of Education		3,957,908				3,957,908	1,191,845
Total G.E.A.R. Programs		3,957,908				3,957,908	1,191,845
Head Start							
Department of Health and Human Services							
Head Start	93.600	983,535 983,535				983,535 983,535	92,390 92,390
Total Department of Health and Human Services		,					
Total Head Start		983,535				983,535	92,390
Ryan White Part D							
Department of Health and Human Services Coordinated Services and Access to Research for Women, Infants, Children, and Youth	93.153	866,867				866,867	75,000
Total Department of Health and Human Services	93.133	866,867				866,867	75,000
Total Ryan White Part D		866,867				866,867	75,000
Other Programs							
Department of Agriculture							
Child and Adult Care Food Program Child and Adult Care Food Program	10.558	-	42,578	ALABAMA DEPT OF HUMAN RESOURCES ALABAMA DEPT OF EDUCATION	ADS-0000 ADS-0000	42,578	
Distance Learning and Telemedicine Loans and Grants	10.558 10.855	404,905	34,204	ALABAMA DEPT OF EDUCATION	ADS-0000	34,204 404.905	
Contract	10.U00	-	11,048	ALABAMA DEPT OF EDUCATION	226.10	11,048	
Total Department of Agriculture		404,905	87,830			492,735	
Department of Defense							
Contract - Navy Medicine/Dentristry/Optometry	12.U01	778,805	-			778,805	
Contract - Air Force Unknown	12.U02	163,021	-			163,021	
Contract - Army Health Profession Students Contract - Go Army	12.U03	91,498	-			91,498	
Contract - Go Army Contract - Air Force Reserve	12.U04 12.U05	61,750 49,778	-			61,750 49,778	
Contract - Army Corp of Engineers	12.U06	19,729	_			19,729	
Contract - Coast Guard Unknown	12.U07	9,000	-			9,000	
Contract - Navy Unknown	12.U08	5,004				5,004	
Total Department of Defense		1,178,584				1,178,584	-
Department of Justice							
Drug Court Discretionary Grant Program	16.585	-			201-DC-BX-0025	123,031	
Drug Court Discretionary Grant Program	16.585		20,215	JEFFERSON COUNTY COMMISSION	2015-DC-BX-0082	20,215	
Total Department of Justice			143,246			143,246	
Department of Labor	47.000	4 000 000				4 000 000	075 070
H-1B Job Training Grants  Total Department of Labor	17.268	1,082,838				1,082,838	675,978 675,978
•		1,082,838				1,082,838	6/5,9/8
Department of Transportation - Highway Planning and Construction Cluster	20.205		39,722	ALABAMA DEPT OF TRANSPORTATION	14-0255	20.722	
Highway Planning and Construction Highway Planning and Construction	20.205		39,722 16,171	ALABAMA DEPT OF TRANSPORTATION ALABAMA DEPT OF TRANSPORTATION	07-04278	39,722 16,171	
Highway Planning and Construction	20.205	-	1,059	ALABAMA DEPT OF TRANSPORTATION	930-935	1,059	4,699
Highway Planning and Construction	20.205		(98)	ALABAMA DEPT OF TRANSPORTATION	930-921	(98)	
Total Department of Transportation - Highway Planning and Construction Cluster			56,854			56,854	4,699
Department of Transportation							
Unknown	20.U09		150,393	ALABAMA DEPT OF TRANSPORTATION	DBE/SS	150,393	
Total Department of Transportation			150,393			150,393	-
Appalachian Regional Commission							·
Appalachian Research, Technical Assistance, and Demonstration Projects	23.011	(107,660)				(107,660)	
Total Appalachian Regional Commission		(107,660)				(107,660)	
National Aeronautics and Space Administration							·
Education	43.008	-	90,357	UNIVERSITY OF ALABAMA IN HUNTSVILLE	NNX15AJ18H	90,357	
Education	43.008	-		LAWSON STATE COMMUNITY COLLEGE	4200595413	9,664	
Education  Total National Association and Space Administration	43.008		(489)	UNIVERSITY OF ALABAMA IN HUNTSVILLE	NNX14AQ99A	(489)	
Total National Aeronautics and Space Administration			99,532			99,532	

Federal Program	CFDA Number	Direct	Pass-through	Pass-Through Grantor	Contract/Award or Pass-Through Num	Total Expenditures	Passed to Subrecipients
National Foundation on the Arts and the Humanities							
Promotion of the Humanities_Federal/State Partnership Unknown	45.129 45.U10	-	1,000 5,800	ALABAMA HUMANITIES FOUNDATION ALABAMA COUNCIL ON THE ARTS	1218-2420MN 2019-23576	1,000 5,800	
Unknown	45.U11	-	5,800	ALABAMA COUNCIL ON THE ARTS	2019-23594	5,800	
Unknown	45.U12		5,800		2019-23498	5,800	
Total National Foundation on the Arts and the Humanities			18,400			18,400	
Department of Veterans Affairs	041140	2 200	_			0.000	
Contract #VA247-18-AP6986 Contract #VA247-17-Q-0939 36C24718C0003	64.U13 64.U14	3,000 2.037	-			3,000 2.037	
Total Department of Veterans Affairs		5,037		•		5,037	
Department of Education - TRIO Cluster							
TRIO_Student Support Services	84.042	664,601	-			664,601	
TRIO_Upward Bound TRIO_McNair Post-Baccalaureate Achievement	84.047 84.217	698,862 236,216	-			698,862 236,216	
Total Department of Education - TRIO Cluster	04.217	1,599,679				1,599,679	
Department of Education		1,055,075				1,399,079	
Graduate Assistance in Areas of National Need	84.200	220,896	-			220,896	
Special Education - Personnel Development to Improve Services and Results for Children with							
Disabilities Research in Special Education	84.325 84.324	403,369 88,034	-			403,369 88,034	
Child Care Access Means Parents in School	84.335	108,622				108,622	
English Language Acquisition State Grants	84.365	1,164,268	-			1,164,268	
Improving Teacher Quality State Grants	84.367 84.411	-	325,690	ALABAMA DEPT OF EDUCATION NATIONAL WRITING PROJECT	PL 107-110 U411A160004	325,690	
Investing in Innovation (i3) Fund Student Support and Academic Enrichment Program	84.411	-	329 29,130	ALABAMA DEPT OF EDUCATION	1H79SM080971-01	329 29,130	
Unknown	84.U15		11,005	ALABAMA DEPT OF CHILDREN'S AFFAIRS	17FC2506016011	11,005	
Total Department of Education		1,985,189	366,154			2,351,343	
Consumer Product Safety Commission							
Contract #61320618N0009	87.U16	77,751				77,751	
Total Consumer Product Safety Commission		77,751		•		77,751	
Department of Health and Human Services - Aging Cluster Nutrition Services Incentive Program	93.053	42.427	_			42.427	2.933
Total Department of Health and Human Services - Aging Cluster	00.000	42,427	_			42,427	2,933
Department of Health and Human Services - Medicaid Cluster							
Medical Assistance Program	93.778		33,606	UNIVERSITY OF FLORIDA	MED180	33,606	
Total Department of Health and Human Services - Medicaid Cluster			33,606			33,606	
Department of Health and Human Services Training in General, Pediatric, and Public Health Dentistry	00.050	044.074				044.074	04.054
CFDA 93.059 Total	93.059	244,874 244,874				244,874	81,951 81,951
Hospital Preparedness Program (HPP) and Public Health Emergency Preparedness (PHEP)							
Aligned Cooperative Agreements	93.074	-	(22,115)	ALABAMA DEPT OF PUBLIC HEALTH	C70115129	(22,115)	
Hospital Preparedness Program (HPP) and Public Health Emergency Preparedness (PHEP) Aligned Cooperative Agreements	93.074	_	(25 135)	ALABAMA DEPT OF PUBLIC HEALTH	C70115130	(25,135)	
CFDA 93.074 Total	00.07 1		(47,250)		0.01.0.00	(47,250)	
Healthy Marriage Promotion and Responsible Fatherhood Grants	93.086			COLORADO SEMINARY/ UNIVERSITY OF DENVER	90FM0062-01-01	10.319	
Healthy Marriage Promotion and Responsible Fatherhood Grants	93.086		6,307	COLORADO SEMINARY/ UNIVERSITY OF DENVER	GS-10F-0050L	6,307	
CFDA 93.086 Total			16,626			16,626	
Enhance Safety of Children Affected by Substance Abuse	93.087	614,670	_			614,670	
CFDA 93.087 Total	00.007	614,670				614,670	
Area Health Education Centers Point of Service Maintenance and Enhancement Awards	93.107	1,325,972				1,325,972	1,078,386
CFDA 93.107 Total		1,325,972				1,325,972	1,078,386
Maternal and Child Health Federal Consolidated Programs  Maternal and Child Health Federal Consolidated Programs	93.110 93.110	2,104,398	48,882	ALABAMA DEPT OF MENTAL HEALTH	1U4CMC32312-01-00	2,104,398	20,000
Maternal and Child Health Federal Consolidated Programs  Maternal and Child Health Federal Consolidated Programs	93.110	-	48,882 17,991	WYOMING DEPARTMENT OF HEALTH	H18MC00058	48,882 17,991	
Maternal and Child Health Federal Consolidated Programs	93.110		9,809		6UK2MC31458-02-01	9,809	
CFDA 93.110 Total		2,104,398	76,682			2,181,080	20,000
Project Grants and Cooperative Agreements for Tuberculosis Control Programs	93.116	-	103,940		C90116105-5NU52PS004653-05-00	103,940	
Project Grants and Cooperative Agreements for Tuberculosis Control Programs	93.116		33,837	ALABAMA DEPT OF PUBLIC HEALTH	C80113116-U62PS004653-03-03	33,837	
CFDA 93.116 Total			137,777	•		137,777	
Nurse Anesthetist Traineeships	93.124	22,457				22,457	
CFDA 93.124 Total		22,457				22,457	<del></del>

Federal Program	CFDA Number	Direct	Pass-through	Pass-Through Grantor	Contract/Award or Pass-Through Num	Total Expenditures	Passed to Subrecipients
Emergency Medical Services for Children	93.127	-	12,423		C80113104-H33MC06713	12,423	
Emergency Medical Services for Children CFDA 93.127 Total	93.127		1,685	ALABAMA DEPT OF PUBLIC HEALTH	C70115071	1,685	<del></del>
Human Genome Research	93.172	1.254	14,106	-		1,254	<u>-</u>
CFDA 93.172 Total	30.172	1,254	-	•		1,254	
Research Related to Deafness and Communication Disorders	93.173	796	-			796	
CFDA 93.173 Total		796	-			796	
Disabilities Prevention Disabilities Prevention	93.184 93.184	2,010,465	15,456	ALABAMA DEPT OF PUBLIC HEALTH	C90116142-5NU27DD000017-03-00	2,010,465 15.456	1,145,537
CFDA 93.184 Total		2,010,465	15,456			2,025,921	1,145,537
Substance Abuse and Mental Health Services_Projects of Regional and National Significance	93.243	-	302,916	JEFFERSON COUNTY COMMISSION	1H79TI081163-01	302,916	
Substance Abuse and Mental Health Services_Projects of Regional and National Significance	93.243	-	259,257	JEFFERSON COUNTY COMMISSION	5H79T1025496-03	259,257	26,198
Substance Abuse and Mental Health Services_Projects of Regional and National Significance	93.243	-	224,253	JEFFERSON COUNTY COMMISSION	5H79T1026406-03	224,253	
Substance Abuse and Mental Health Services_Projects of Regional and National Significance	93.243	181,336	-			181,336	
Substance Abuse and Mental Health Services_Projects of Regional and National Significance	93.243	-	169,798	JEFFERSON COUNTY COMMISSION	5H79TI026130-03	169,798	
Substance Abuse and Mental Health Services_Projects of Regional and National Significance	93.243	-	78,366	ALABAMA DEPT OF MENTAL HEALTH	5H79SM061560-05	78,366	
Substance Abuse and Mental Health Services_Projects of Regional and National Significance	93.243	-	8,791	ALABAMA DEPT OF PUBLIC HEALTH	C801103060-5H79SM062921-02	8,791	
Substance Abuse and Mental Health Services_Projects of Regional and National Significance	93.243	-	6,967	ALABAMA DEPT OF HUMAN RESOURCES	4547	6,967	
Substance Abuse and Mental Health Services_Projects of Regional and National Significance	93.243	-	4,064	ALABAMA DEPT OF MENTAL HEALTH	LAUNCH	4,064	
Substance Abuse and Mental Health Services_Projects of Regional and National Significance	93.243	-	2,636	ALABAMA DEPT OF PUBLIC HEALTH	C90116084-5H79SM062921-03	2,636	
Substance Abuse and Mental Health Services_Projects of Regional and National Significance	93.243	-	(2,118)	JEFFERSON COUNTY COMMISSION	5H79T1026406-02	(2,118)	
Substance Abuse and Mental Health Services_Projects of Regional and National Significance CFDA 93.243 Total	93.243	181,336	(4,125) 1,050,805		5H79T1026130-02	(4,125) 1,232,141	26,198
Advanced Nursing Education Grant Program CFDA 93.247 Total	93.247	1,229,203 1,229,203	-	-		1,229,203 1,229,203	290,966 290,966
Universal Newborn Hearing Screening	93.251	-	37,500		C80113209-H61MC00054	37,500	<u> </u>
Universal Newborn Hearing Screening CFDA 93.251 Total	93.251		17,752 55,252	ALABAMA DEPT OF PUBLIC HEALTH	C90116157-H61MC00054	17,752 55,252	
Health Systems Strengthening and HIV/AIDS Prevention, Care and Treatment under the President's Emergency Plan for AIDS Relief CFDA 93.266 Total	93.266		210 210		1R13HS024660-01A1	210 210	<u>-</u>
Drug Abuse and Addiction Research Programs CFDA 93.279 Total	93.279		19,698 19,698	UNIVERSITY OF CALIFORNIA IN SAN FRANCISCO	5R25DA028567-09	19,698 19,698	-
The Affordable Care Act: Centers for Disease Control and Prevention_Investigations and Technical Assistance	93.283	-	113,318	LOUISIANA STATE UNIVERSITY	5NU58DP005412-05-00	113,318	
The Affordable Care Act: Centers for Disease Control and Prevention_Investigations and Technical Assistance	93.283	-	4,919	LOUISIANA STATE UNIVERSITY	5NU58DP005412-04-00	4,919	
The Affordable Care Act: Centers for Disease Control and Prevention_Investigations and Technical Assistance	93.283		758		5N58DP004975-05-00	758	
CFDA 93.283 Total Trans-NIH Research Support	93.310	6,357	118,995			118,995 6,357	
CFDA 93.310 Total		6,357	-	-		6,357	
Behavioral Risk Factor Surveillance System	93.336		127,944	ALABAMA DEPT OF PUBLIC HEALTH	C90116144-NU58DP006015	127,944	
CFDA 93.336 Total  Nurse Education, Practice Quality and Retention Grants	93.359	1,153,299	127,944	•		1,153,299	
CFDA 93.359 Total	33.333	1,153,299		-		1,153,299	_
				-			

Federal Program	CFDA Number	Direct	Pass-through	Pass-Through Grantor	Contract/Award or Pass-Through Num	Total Expenditures	Passed to Subrecipients
Sickle Cell Treatment Demonstration Program	93.365	-	51,741	CAROLINAS HEALTHCARE SYSTEM	6U1EMC31108-02-04	51,741	
Sickle Cell Treatment Demonstration Program CFDA 93.365 Total	93.365		42,822 94,563	. CAROLINAS HEALTHCARE SYSTEM	6U1EMC31108-02-01	42,822 94,563	
			94,563	•		94,563	<u>-</u>
Prevention and Control of Chronic Disease and Associated Risk Factors in the U.S. Affiliated Pacific Islands, U.S. Virgin Islands, and Puerto Rico	93.377	220,312	-			220,312	79,374
CFDA 93.377 Total		220,312	-	•		220,312	79,374
Cancer Research Manpower	93.398	322,934				322,934	
CFDA 93.398 Total		322,934				322,934	<u> </u>
NON-ACA/PPHF Building Capacity of the Public Health System to Improve Population Health through National Nonprofit Organizations	93.424	_	86.754	ASSOCIATION OF UNIVERSITY CENTERS ON DISABILITIES	6 NU38OT000140-05-02	86,754	
CFDA 93.424 Total	00.121		86,754	, recognition of chirelion recent and chireles	0 110000 10001 10 00 02	86,754	-
Affordable Care Act (ACA) Public Health Training Centers Program, Resources Development and Academic Support to the Public Health Training Centers Program and Public Health Infrastructure and Systems Support Affordable Care Act (ACA) Public Health Training Centers Program, Resources Development	93.516	-	69,314	EMORY UNIVERSITY	1UB6HP31680-01-00	69,314	
and Academic Support to the Public Health Training Centers Program and Public Health Infrastructure and Systems Support Affordable Care Act (ACA) Public Health Training Centers Program, Resources Development	93.516	-	22,459	EMORY UNIVERSITY	5UB6HP31680-02-00	22,459	
and Academic Support to the Public Health Training Centers Program and Public Health Infrastructure and Systems Support	93.516		(3,205)	EMORY UNIVERSITY	UB6HP27875-04-00	(3,205)	
CFDA 93.516 Total			88,568	•		88,568	-
Affordable Care Act Initiative to Reduce Avoidable Hospitalizations among Nursing Facility							
Residents	93.621		(102,064)	ALABAMA QUALITY ASSURANCE FOUNDATION	1E1CMS331493-01-00	(102,064)	
CFDA 93.621 Total			(102,064)	•		(102,064)	
University Centers for Excellence in Developmental Disabilities Education, Research, and Service	93.632	571,740				571,740	
CFDA 93.632 Total		571,740	_	•		571,740	-
ACA - Reinvestment of Civil Money Penalties to Benefit Nursing Home Residents	93.636		270,934	ALABAMA DEPT OF PUBLIC HEALTH	C80629636	270,934	
CFDA 93.636 Total			270,934	•		270,934	
PPHF-2012 Mental and Behavioral Health Education and Training Grants CFDA 93.732 Total	93.732	7,717 7,717		• •		7,717 7,717	<u> </u>
PPHF 2012: Racial and Ethnic Approaches to Community Health Program financed solely by							
2012 Public Prevention and Health Funds CFDA 93.738 Total	93.738	23,266	-	•		23,266	22,354 22,354
PPHF-2012: Health Care Surveillance/Health Statistics - Surveillance Program Announcement: Behavioral Risk Factor Surveillance System Financed in Part by 2012 Prevention and Public		23,200					22,004
Health Funds (PPHF-2012) CFDA 93.745 Total	93.745		205,330	ALABAMA DEPT OF PUBLIC HEALTH	C8011309-NU58DP006015	205,330	
Children's Health Insurance Program	93.767	-	180,548	ALABAMA DEPT OF PUBLIC HEALTH	C90116151-7590515	180,548	
Children's Health Insurance Program Children's Health Insurance Program	93.767	-	49,230 38,200	ALABAMA DEPT OF PUBLIC HEALTH ALABAMA DEPT OF PUBLIC HEALTH	C80113063-7500515 C80113037-7500515	49,230 38,200	25.518
CFDA 93.767 Total	93.767		267,978	ALABAMA DEPT OF PUBLIC HEALTH	C80113037-7500515	267,978	25,518
Hospital Preparedness Program (HPP) Ebola Preparedness and Response Activities	93.817		20,917	ALABAMA DEPT OF PUBLIC HEALTH	C80113152-1U3REP150509-01-00	20,917	
CFDA 93.817 Total			20,917	•		20,917	-
Cardiovascular Diseases Research	93.837	68,317				68,317	
CFDA 93.837 Total		68,317		•		68,317	<u>-</u>
Arthritis, Musculoskeletal and Skin Diseases Research CFDA 93.846 Total	93.846	25,000 25,000		•		25,000 25,000	<del></del>
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	173.588	-	•		173.588	
CFDA 93.847 Total		173,588				173,588	
Extramural Research Programs in the Neurosciences and Neurological Disorders CFDA 93.853 Total	93.853	314,729 314,729				314,729 314,729	
Allergy, Immunology and Transplantation Research	93.855	20,978	· <del></del>	•		20,978	
CFDA 93.855 Total		20,978				20,978	
Biomedical Research and Research Training	93.859	135,876				135,876	
CFDA 93.859 Total		135,876				135,876	
Maternal, Infant and Early Childhood Home visiting Grant Program CFDA 93.870 Total	93.870		5,866 5,866	ALABAMA DEPT OF CHILDREN'S AFFAIRS	X10MC29458	5,866 5,866	
OF DA 35.070 Total			3,000	•		3,000	

Federal Program	CFDA Number	Direct	Pass-through	Pass-Through Grantor	Contract/Award or Pass-Through Num	Total Expenditures	Passed to Subrecipients
Grants for Primary Care Training and Enhancement	93.884	(1,710)	-			(1,710)	
CFDA 93.884 Total		(1,710)				(1,710)	
National Bioterrorism Hospital Preparedness Program CFDA 93.889 Total	93.889		1,242 1,242	ALABAMA DEPT OF PUBLIC HEALTH	C60112116	1,242	
Cancer Prevention and Control Programs for State, Territorial and Tribal Organizations	93.898		41,590	ALABAMA DEPT OF PUBLIC HEALTH	C80113168-NU58DP006301	41,590	
Cancer Prevention and Control Programs for State, Territorial and Tribal Organizations CFDA 93.898 Total	93.898		24,487 66,077	ALABAMA DEPT OF PUBLIC HEALTH	C80113172-1NU58DP006301-01	24,487	-
HIV Care Formula Grants	93.917		363,198	UNITED WAY OF CENTRAL ALABAMA INC	X07HA00049	363,198	
HIV Care Formula Grants	93.917	-	82,071	ALABAMA DEPT OF PUBLIC HEALTH	C90116120-X07HA00049	82,071	
HIV Care Formula Grants HIV Care Formula Grants	93.917 93.917	-	(2,849) (6,899)	UNITED WAY OF CENTRAL ALABAMA INC UNITED WAY OF CENTRAL ALABAMA INC	HRSA-10-055/X07HA00049 HRSA-10-055	(2,849) (6,899)	
CFDA 93.917 Total	93.917		435,521	UNITED WAT OF CENTRAL ALABAMA INC	HK3A-10-033	435,521	
GI DA 93.517 Total			433,321			433,321	
Grants to Provide Outpatient Early Intervention Services with Respect to HIV Disease	93.918	188,964	-			188,964	
CFDA 93.918 Total		188,964	-			188,964	
HIV Prevention Activities_Health Department Based	93.940		291,087	ALABAMA DEPT OF PUBLIC HEALTH	C90116143-5NU62PS924533-02-00	291,087	
HIV Prevention Activities_Health Department Based	93.940		273.165	ALABAMA DEPT OF PUBLIC HEALTH	C80113210-6NU62PS924533	273.165	
HIV Prevention Activities_Health Department Based	93.940	-	200,000	ALABAMA DEPT OF PUBLIC HEALTH	C80113206-6NU62PS924533	200,000	
HIV Prevention Activities_Health Department Based	93.940	-	179,065	ALABAMA DEPT OF PUBLIC HEALTH	C90116115-5NU62PS924533-02-00	179,065	
HIV Prevention Activities_Health Department Based HIV Prevention Activities Health Department Based	93.940 93.940	-	91,665 79,401	ALABAMA DEPT OF PUBLIC HEALTH ALABAMA DEPT OF PUBLIC HEALTH	C90116138-5NU62PS924533-02-00 C80113238-6NU62PS924533	91,665 79,401	
HIV Prevention Activities Health Department Based	93.940	-	66,054	ALABAMA DEPT OF PUBLIC HEALTH	C80113207-6NU62PS924533	66,054	
HIV Prevention Activities_Health Department Based	93.940	_	15	ALABAMA DEPT OF PUBLIC HEALTH	C60112030-1U62PS003632-02	15	
HIV Prevention Activities_Health Department Based	93.940	-	(456)	ALABAMA DEPT OF PUBLIC HEALTH	C70115114	(456)	
HIV Prevention Activities_Health Department Based	93.940		(1,212)	ALABAMA DEPT OF PUBLIC HEALTH	C60112005	(1,212)	
CFDA 93.940 Total			1,178,784			1,178,784	<del>-</del>
Cooperative Agreements to Support State-Based Safe Motherhood and Infant Health Initiative Programs	93.946	-	13,513	ALABAMA DEPT OF PUBLIC HEALTH	C80113147-1U01DP006235-01	13,513	
Cooperative Agreements to Support State-Based Safe Motherhood and Infant Health Initiative Programs	93.946	-	1,413	ALABAMA DEPT OF PUBLIC HEALTH	C70115162-U01DP006235	1,413	
Cooperative Agreements to Support State-Based Safe Motherhood and Infant Health Initiative Programs	93.946		(005)	ALABAMA DEPT OF PUBLIC HEALTH	C60112050	(235)	
CFDA 93.946 Total	93.946		14,691	ALABAWA DEPT OF PUBLIC REALTH	C60112050	14,691	
Preventive Health and Health Services Block Grant CFDA 93.991 Total	93.991		3,402 3,402	ALABAMA DEPT OF PUBLIC HEALTH	C90116028-6NB01OT009196-01-01	3,402	
				MODERN PERFORMAN	D. 1110011100		
Maternal and Child Health Services Block Grant to the States  Maternal and Child Health Services Block Grant to the States	93.994	-	36,245 6.349	MISSISSIPPI DEPT OF HEALTH ALABAMA DEPT OF PUBLIC HEALTH	B04MC31497 C90116088-B04MC32523	36,245 6.349	
Maternal and Child Health Services Block Grant to the States	93.994	_	3,032	ALABAMA DEPT OF PUBLIC HEALTH	C90116113-B04MC32523	3,032	
Maternal and Child Health Services Block Grant to the States	93.994		(571)	ALABAMA DEPT OF PUBLIC HEALTH	C80113008-B04MC30595	(571)	
CFDA 93.994 Total			45,055			45,055	<u> </u>
Contract	93.U17	-	257,913	ALABAMA DEPT OF EDUCATION	X10MC31125	257,913	
Contract	93.U18	-	86,851	ALABAMA DEPT OF EDUCATION	SP1AH000058	86,851	
Contract Contract #18IPA1811220	93.U19 93.U20	53.320	76,268	ALABAMA DEPT OF EDUCATION	X10MC32174	76,268 53.320	
Contract	93.U21	- 33,320	22,999	BAVARIAN NORDIC A/S	HHSO100201700019C	22,999	
Contract	93.U22	-	13,863	MISSISSIPPI DEPT OF HEALTH	PRAMS	13,863	
Contract	93.U23	-	5,415	ADDIS ABABA UNIVERSITY	1R25TW011214-011	5,415	
Unknown Unknown	93.U24	-	601,000 108,906	ALABAMA MEDICAID AGENCY	C1900000006 X10MC31125	601,000 108,906	
Oliniowii	93.U25	53,320	1,173,215	ALABAMA DEPT OF EDUCATION	X TOWCST 125	1,226,535	
Total Department of Health and Human Services		11,020,112	5,443,136			16,463,248	2,770,284
Corporation for National and Community Services							
Volunteers in Service to America	94.013	1,418	-			1,418	
Total Corporation for National and Community Services Total Other Programs		1,418	6,399,151			1,418 23,689,431	3,453,894
Special Federal Appropriations		17,200,200	0,000,101			20,000,401	0,700,004
Miscellaneous							
John J. Sparkman Center Lister Hill Center for Health Policy	93.U26 93.U27	367,956 241,990	-			367,956 241,990	
Total Miscellaneous	33.021	609,946				609,946	
Total Special Federal Appropriations		609,946				609,946	<del></del>
Total Special Regeral Appropriations  Total Federal			\$ 45,478,553			\$ 590,588,433	\$ 69,483,393
rount odolai		Ψ 040,100,000	÷ +0,410,000			ψ 000,000, <del>4</del> 00	ψ 00, <del>1</del> 00,000

#### 1. Basis of Presentation

The accompanying Schedule of Expenditures of Federal Awards (the "Schedule") summarizes the federal expenditures of The University of Alabama at Birmingham ("UAB"), a campus of the University of Alabama System, under programs of the federal government for the year ended September 30, 2019. Other campuses of the University of Alabama System are presented in separate reports. The amounts reported as federal expenditures were obtained from UAB's general ledger. The information in this Schedule is presented in accordance with the requirements of Title 2 U.S. Code of Federal Regulations Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards (Uniform Guidance). Therefore, some amounts presented in this Schedule may differ from amounts presented in, or used in the preparation of, the statements of net position, the related statements of revenues, expenses, and changes in net position and cash flows of UAB. The federal expenditures of Southern Research Institute ("SRI"), a discretely presented component unit of UAB, have not been included within the Schedule as they have been included in a separate schedule of expenditures of federal awards that has been audited by other auditors.

The blended component units of UAB include UAB Research Foundation, UAB Athletics Foundation, Alabama Care Plan, UAB Hospital Management, L.L.C, and Triton Health Systems, L.L.C. These component units do not expend federal awards and therefore are not subject to requirements of the Uniform Guidance.

For purposes of the Schedule, federal awards include all grants, contracts, and similar agreements entered into directly between UAB and agencies and departments of the federal government and all subawards to UAB by nonfederal organizations pursuant to federal grants, contracts, and similar agreements. Negative amounts represent adjustments or credits to amounts reported as expenditures in prior years. Catalog of Federal Domestic Assistance ("CFDA") numbers and pass-through numbers are provided when available.

#### 2. Summary of Significant Accounting Policies

For purposes of the Schedule, expenditures for federal award programs are recognized on the accrual basis of accounting. Such expenditures are recognized following the cost principles contained in the Uniform Guidance where certain types of expenditures are not allowable or are limited to reimbursement.

#### 3. Facilities and Administrative Costs ("F&A Costs")

UAB applies its predetermined approved facilities and administrative rate when charging indirect cost to federal awards rather than the 10% de minimis cost rate described in Section 200.414 of the Uniform Guidance. UAB operates under predetermined fixed F&A cost rates which are effective from October 1, 2015 through September 30, 2019. The predetermined fixed rates were based on 2014 financial information. The base rate for on-campus research is 48.5% for the year ended September 30, 2019. Base rates for other F&A cost recoveries range from 5.4% to 48.5% for the year ended September 30, 2019.

#### 4. Federal Student Loan Programs

#### **Direct Loan Programs**

The Perkins, Health Professions Student Loan ("HPSL"), Nurse Faculty Loan Program ("NFLP"), and Loans to Disadvantaged Students ("LDS") programs are administered directly by UAB, and balances and transactions relating to these programs are included in UAB's basic financial statements.

The balances of loans outstanding at September 30, 2019 under the federal student loan programs are summarized as follows:

	Perkins (CFDA#84.0	38)	 IPSL A#93.342)	NFLP (A#93.264)	(0	LDS CFDA#93.342)	NFLP-ARRA FDA#93.408)	Total
Total loan balance outstanding, September 30, 2019	\$ 9,685	5,873	\$ 1,251,242	\$ 2,772,883	\$	144,088	\$ 74,064	\$ 13,928,150

#### **Federal Direct Loans**

The Federal Direct Student Loan (FDSL) program (CFDA Number 84.268) was established under the Higher Education Act of 1965, as amended in the Student Loan Reform Act of 1993. The FDSL enables an eligible student or parent to obtain a loan to pay for the student's cost of attendance directly through UAB rather than through private lenders. UAB began participation in the FDSL on July 1, 1994. As a university qualified to originate loans, UAB is responsible for handling the complete loan origination process, including funds management and promissory note functions. UAB is not responsible for collection of these loans.

Part II
Schedule of Findings and Questioned Costs

## University of Alabama at Birmingham Schedule of Findings and Questioned Costs Year Ended September 30, 2019

#### Section I – Summary of Auditor's Results

Financial Statements				
Type of auditor's report issued:	Unmodified			
Internal control over financial reportin Material weakness(es) identified? Significant deficiency(ies) identified Noncompliance material to financia Federal Awards	yes _x no yes _x none reported _yes _x no			
Internal control over major programs Material weakness(es) identified? Significant deficiency(ies) identified	: d that are not considered to be material weaknesses?	yes x no yes x none reported		
Type of auditor's report issued on co	Unmodified			
Any audit findings disclosed that are with 2 CFR 200.516(a)?	required to be reported in accordance the	yes _x_no		
Identification of major programs: CFDA Number(s) Various 84.334	Name of Federal Program or Cluster Student Financial Assistance Cluster Gaining Early Awareness and Readiness for Undergraduate Programs			
93.153 93.600	Ryan White Part D Head Start			
Dollar threshold used to distinguish	n between Type A and Type B Programs:	\$ 3,000,000		
Auditee qualified as low-risk auditee'	?	<b>x</b> yes no		

## Section II – Financial Statement Findings

No matters were noted

#### Section III – Federal Award Findings and Questioned Costs

No matters were noted

Part III
Summary Schedule of Prior Audit Findings

## University of Alabama at Birmingham Summary Schedule of Prior Audit Findings Year Ended September 30, 2019

There are no findings from prior years that require an update in this report.

Part IV 2019 Financial Report



2019 Financial Report University of Alabama at Birmingham



UAB is an equal education opportunity institution, and an equal employment opportunity employer.

This report is published by the UAB Senior Vice President for Finance and Administration. Obtain additional copies by writing:

Senior Vice President for Finance and Administration The University of Alabama at Birmingham Birmingham, Alabama 35294

## **University of Alabama at Birmingham**

# **2019 Financial Report Table of Contents**

Introduction to UAB	2
Overview/Vision/Mission	
Highlights	4
Student Profile and Headcount	
Faculty and Staff Profile	
State Appropriations	
Sponsored Grants and Contracts	
Hospital	
Financial Section	
Management's Responsibility for Financial Reporting	9
Report of Independent Auditors	10
Management's Discussion and Analysis (Unaudited)	12
Financial Statements	
Statements of Net Position	20
Statements of Revenues, Expenses, and Changes in Net Position	21
Statements of Cash Flows	22
Discretely Presented Component Unit	
Statements of Net Position	24
Statements of Revenues, Expenses, and Changes in Net Position.	25
Notes to Financial Statements	26
Required Supplementary Information (Unaudited).	65
UAB Administration	68
The Board of Trustees of The University of Alabama	69

## Introduction to UAB

#### Vision

To be an internationally renowned research university — a first choice for education and health care.

#### Mission

UAB serves students, patients, the community and the global need for discovery, knowledge dissemination, education, creativity and the application of groundbreaking solutions. We are a leader among comprehensive public urban research universities with academic medical centers.

The University of Alabama at Birmingham (UAB) became an autonomous campus within The University of Alabama System in 1969 and, in the five decades since, has grown into a world-renowned research university and medical center, occupying more than 100 city blocks in Alabama's largest metropolitan area. UAB is the state's largest single-site employer with more than 23,000 employees. One in four Birmingham residents are UAB employees, students or patients.

#### 2019 Overview

In fall 2019 UAB achieved a fourth consecutive year of record enrollment with 22,080 students. This includes a freshman class that is the largest (2,346 students) and most academically prepared ever, with an average ACT of 25.6 and an average high school GPA of 3.78. Underrepresented students make up nearly 42 percent of the enrollment and 21 percent of undergraduates are first-generation college students.

Students are engaged in unrivaled research opportunities and academic programs. New programs begun over the past two years include a B.S. in Immunology (the only degree of its kind in Southeast), B.S. in Genetics and Genomic Sciences, B.S. in Bioinformatics, M.S. in Data Science and M.S. in Engineering Management.

In the 2020 U.S. News & World Report "Best Graduate Schools," UAB has 14 programs in the top 25 nationally, including a master's in health administration that ranks number one in the nation.

UAB received the 2018 Higher Education Excellence in Diversity Award from INSIGHT into Diversity Magazine and is one of only 14 universities named a Diversity Champion.

In 2019 UAB was named the Top Young University in the nation for the second consecutive year (and 12th globally) in The Times Higher Education World University Rankings. With a record \$562 million in total research expenditures, UAB ranks 15th (top 4 percent) in federal research funding among public universities and 8th (top 2 percent) in National Institutes of Health (NIH) funding. UAB is among only eight schools of medicine nationally to Increase their NIH funding by more than \$100 million over the past five years.

UAB is home to the 3rd largest public hospital in the U.S. and the state's only level 1 adult trauma center. In the U.S. News & World Report "Best Hospitals" UAB again ranked as the number one hospital in Alabama and its ongoing live donor kidney chain is the longest ever conducted anywhere on the globe, reaching 114 transplants in FY19.

As a globally respected academic medical center, UAB excels at translating research into leading-edge patient care. UAB's Comprehensive Cancer Center, among the first eight such centers to be designated by the National Cancer Institute (NCI) in the early 1970s, remains the only one in Alabama and a four-state region. In December 2018, UAB received \$30 million, the largest philanthropic gift in university history, to name the O'Neal Comprehensive Cancer Center at UAB.

At the beginning of fiscal year 2019, UAB concluded its biggest ever capital campaign by receiving gifts or pledges of \$1.02 billion.

UAB has an economic impact on Alabama that exceeds \$7.15 billion annually and is key in growing a robust tech- and knowledge-based economy. In FY19, the UAB Bill L. Harbert Institute for Innovation & Entrepreneurship generated over \$6 million in revenue, 11 start-up companies, 37 licenses and 15 U.S. patents. Innovation Depot, in which UAB is a founding partner, is the largest high-tech business incubator in the Southeast, with 100 start-up companies and more than 1,000 employees.

UAB is also deeply engaged in the Birmingham community. As examples, UAB concluded the Grand Challenge in 2019 to make Alabama a model of healthy living. By expanding proven innovations and changing policies, neighborhoods, schools and workplaces, Healthy Alabama 2030 aims to dramatically improve the health of all Alabamians by elevating our state out of the bottom 10 in national health rankings by the year 2030.

Further, for the fifth consecutive year UAB earned the Arbor Day Foundations and Three Campus USA designation, highlighting some of our beatification and sustainability efforts.

The information included in this introduction (pages 2-8) does not include data related to component units of UAB that are discussed in the notes to the financial statements.

### UAB's 50th Anniversary Year

UAB celebrated its 50th anniversary throughout the year 2019. Alabama Governor Kay Ivey issued a proclamation that read in part:
"WHEREAS, The University of
Alabama at Birmingham (UAB) was established as an autonomous campus of the University of Alabama System in 1969 and has, over five decades, forged ahead in all areas of its mission and earned global renown.... I encourage all Alabamians to join in celebrating UAB and its role in improving education, health and economic development, and in forging an even brighter future for our state." A dedicated 50th Anniversary website (www. uab.edu/50), "50 years of Dreams and Discoveries" showcased historical and contemporary photos, resources from UAB Archives, and a podcast with recordings from UAB Memory Booth, which circulated around campus recording brief reflections from faculty, staff, students, alumni and friends. Special events were held throughout the year and promoted on social media and other platforms, as were community engagement projects initiated through the commemorative "50 Acts of Service" program. The anniversary celebration culminated at homecoming week 2019 with a free concert on the Campus Green, which drew attendance of more than 20,000 - the largest crowd ever assembled on UAB's campus.

On the cover: The Chevrolet Blazer was born in 1969, the same year as UAB. To celebrate our shared 50th anniversary we have brought an original Blazer home....in its original Blazer green. To book the 1969 Blazer for a UAB event inquire at msmartin@uab.edu.



# **Proclamation**

By the Governor of Alabama

WHEREAS, The University of Alabama at Birmingham (UAB) was established as an autonomous campus of the University of Alabama System in 1969 and has, over five decades, forged ahead in all areas of its mission and earned global renown, currently ranking as the Top Young University in the U.S. for a second consecutive year (and 12th globalty) in the Times Higher Education World University Rankings; and

WHEREAS, VAB is expanding educational opportunity with four consecutive years of record enrollment (with 21 percent of undergraduates being first-generation) and developing novel, interdisciplinary academic programs, with 14 graduate programs ranked in the nation's top 25 by U.S. News E.World Report; and

WHEREAS, UAB is vastly improving health and quality of life statewide by securing record research awards of 5527 million and ranking eighth among public universities (top 2 percent) in National Institutes of Health funding, treating a record 1.7 million patients in FY18, and advancing precision medicine; and

WHEREAS, as our state's largest single employer, is helping grow a robust knowledge-based economy by commercializing research discoveries and generating an annual economic impact exceeding \$7.1 billion;

NOW, THEREFORE, I, Kay Ivey, Governor of Alabama, do hereby proclaim the year 2019,

as

# UAB's 50th Anniversary Year

in the state of Alabama and encourage all Alabamians to join in celebrating UAB and its role in improving education, health and economic development, and in forging an even brighter future for our state



Given Under My Hand and the Great Seal of the Office of the Governor at the State Capitol in the City of Montgomery on the 15th day of October 2019.

Kay vey


The Ever Faithful 50



# **Highlights**

# **Student Profile**

Total 21,923 As of Fall 2018



# **Student Headcount**


Enrollment for the fall semester of the 2018-2019 school year is outlined in the following table.


Fall 2018				
	UNDERGRADUATE	GRADUATE	FIRST PROFESSIONAL/ ADVANCED PROFESSIONAL *	TOTAL
SCHOOL OF ARTS AND SCIENCES	6,814	580	273	7,667
SCHOOL OF BUSINESS	2,690	742	_	3,432
SCHOOL OF EDUCATION	1,015	662	98	1,775
SCHOOL OF ENGINEERING	903	474	112	1,489
UNCLASSIFIED	<u> </u>	166	<u> </u>	166
SUBTOTAL	11,422	2,624	483	14,529
ACADEMIC HEALTH CENTER:				
SCHOOL OF MEDICINE	_	_	1,856	1,856
SCHOOL OF DENTISTRY	_	1	333	334
SCHOOL OF OPTOMETRY	_	2	231	233
SCHOOL OF NURSING	1,021	1,397	318	2,736
SCHOOL OF HEALTH PROFESSIONS	1,056	1,093	296	2,445
SCHOOL OF PUBLIC HEALTH	337	328	90	755
JOINT HEALTH SCIENCES	_	27	392	419
SUBTOTAL, ACADEMIC HEALTH CENTER	2,414	2,848	3,516	8,778
TOTAL ENROLLMENT	13,836	5,472	3,999	23,307


<sup>\*</sup> Includes 1,146 first professionals and 1,384 advanced professionals.

# **Faculty Profile**

Total 2,605 As of Fall 2018







<sup>\*</sup> Non-Hospital includes Hospital Management LLC.


# **State Appropriations**

State Appropriations for UAB are made by the Alabama State Legislature based upon a process which involves requests from the Board of Trustees of The University of Alabama, and budget recommendations by the Alabama Commission on Higher Educations and the Governor. State funds are appropriated annually from the Educational Trust Fund (ETF) to UAB.

For the fiscal year ended September 30, 2019, UAB received \$287.7 million in State educational appropriation for operating purposes.

# **Appropriations Received**

Fiscal Years Ended September 30 (Dollars in millions)




# **Sponsored Grants and Contracts**

During fiscal year 2019, UAB recognized \$529.5 million in sponsored grants and contracts revenues (including \$99.4 million of indirect cost recovery). Various federal agencies provided the majority of support for these projects, with the National Institutes of Health (NIH) being the primary sponsor. Nonfederal funding sources include state agencies, local governmental agencies, and a wide variety of private sponsors.

Revenues from grants and contracts (including indirect cost recovery) increased from \$496.3 million during fiscal year 2018 to \$529.5 million during fiscal year 2019, an increase of 6.7% for the period.

### **Grants and Contracts Revenues**

Fiscal Years Ended September 30 (Dollars in millions)



# Hospital

### Overview

The University of Alabama Hospital (the "Hospital"), a 1,157bed quaternary and tertiary care medical facility is the flagship of the UAB Health System and is the primary teaching hospital for University of Alabama School of Medicine. Its facilities consist of the UAB Women and Infants Center, the Hazelrig-Salter Radiation Oncology Center, the North Pavilion Diagnostic and Treatment Center, Spain Rehabilitation Center, the Center for Psychiatric Medicine, UAB Highlands, and the Gardendale Freestanding Emergency Department. University Hospital operates The Kirklin Clinic and The Whitaker Clinic. The Hospital also has strong ties with other governmental and private non-profit institutions located within and adjacent to the UAB campus, including Veterans Affairs Medical Center and Children's Hospital. Other healthcare facilities in the UAB Health System include the UAB Callahan Eye Hospital Authority, Medical West Hospital Authority, and The Health Care Authority for Baptist Health.

### Hospital Awards and Accolades

This year's U.S. News and World Report's "Best Hospitals" special edition issue ranked six UAB Medicine specialties among the nation's top 50 and two specialties among the top 20. U.S. News and World Report also ranked hospitals in adult procedures and conditions. University of Alabama Hospital was ranked high performing, which was the highest ranking conferred, in seven adult procedures and conditions. Becker's Hospital Review named University of Alabama Hospital as one of the 2019 "100 Great Hospitals in America", a compilation of hospitals that are considered industry innovators and known nationally for excellence in clinical care. The Hospital continued to be certified as a magnet hospital by The American Nurses Credentialing Center through 2024. Magnet hospitals are recognized for excellence in nursing care and patient outcomes. In August 2018, the hospital was fully reaccredited by The Joint Commission.

## Operations

Inpatient discharges increased 4.3% and adjusted patient discharges increased 3.0%. Operating room cases increased 2.9% over fiscal year 2018. Also emergency room visits increased 13.8% during fiscal year 2019. The Hospital had an increase in net position of \$101 million in fiscal year 2019.

Selected Hospital operating statistics are outlined below:

	2019	2018
Beds in service	1,128	1,099
Patient discharges	52,602	50,442
Adjusted patient discharges	88,273	85,722
Patient days	378,744	359,889
Adjusted patient days	635,578	611,603
Operating room cases	37,529	36,456
Emergency department visits	125,065	109,852
Patient origin:		
Jefferson County	46.6%	47.5%
Other Alabama counties	47.3%	46.6%
Out of state	6.1%	5.9%



Office of the Senior Vice President for Finance and Administration

# Management's Responsibility for Financial Reporting

The accompanying financial statements of the University of Alabama at Birmingham (UAB) for the years ended September 30, 2019 and 2018 were prepared by UAB's management in conformity with accounting principles generally accepted in the United States of America.

The management of UAB is responsible for the integrity and objectivity of these financial statements, which are presented on the accrual basis of accounting and, accordingly, include some amounts based upon judgement. Other financial information in the annual report is consistent with that in the financial statements. The system of internal accounting controls is designed to help ensure that the financial reports and the books properly reflect the transactions of the institution, in accordance with established policies and procedures as implemented by qualified personnel.

The Board of Trustees of The University of Alabama, through its Audit, Risk and Compliance Committee, monitors the financial and accounting operations of the institution, including the review and discussion of periodic financial statements and the evaluation and adoption of budgets. The Board of Trustees of The University of Alabama, through its Audit, Risk and Compliance Committee, monitors the basis of engagement and reporting of independent auditors.

G. Allen Bolton, Jr.

I. Alla botta, fr.

Senior Vice President for Finance

and Administration

Stephanie Mullins

**UAB Chief Financial Officer** 

Stephanie Mullins

1030 Administration Building 701 20th Street South 205.934.5493 Fax 205.934.3610 Mailing Address: AB 1030 1720 2ND AVE S BIRMINGHAM AL 35294-0110



#### **Report of Independent Auditors**

To the Board of Trustees of The University of Alabama:

### **Report on the Financial Statements**

We have audited the accompanying financial statements of the business-type activities and the discretely presented component unit of The University of Alabama at Birmingham ("UAB"), a campus of The University of Alabama System, which is a component unit of the State of Alabama, which comprise the statements of net position as of September 30, 2019 and 2018, and the related statements of revenues, expenses, and changes in net position and of cash flows (where applicable) for the years then ended, and the related notes to the financial statements, which collectively comprise UAB's basic financial statements.

### Management's Responsibility for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

### Auditors' Responsibility

Our responsibility is to express opinions on the financial statements based on our audits. We did not audit the financial statements of Southern Research Institute ("SRI"), UAB's discretely presented component unit, as of December 28, 2018 and December 29, 2017 and for the years then ended. Those statements were audited by other auditors whose report thereon has been furnished to us, and our opinion, insofar as it relates to the amounts included for SRI, is based solely on the report of the other auditors. We conducted our audits in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement. The financial statements of Triton Health Systems, L.L.C., UAB Athletics Foundation, and UAB Research Foundation were not audited in accordance with *Government Auditing Standards*.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on our judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, we consider internal control relevant to UAB's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of UAB's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall



presentation of the financial statements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinions.

#### **Opinions**

In our opinion, based on our audits and the report of other auditors, the financial statements referred to above present fairly, in all material respects, the respective financial position of the business-type activities and the discretely presented component unit of The University of Alabama at Birmingham as of September 30, 2019 and 2018 and the respective changes in financial position and, where applicable, cash flows thereof for the years then ended in accordance with accounting principles generally accepted in the United States of America.

### Emphasis of Matter

As discussed in Note 1, the financial statements of UAB are intended to present the financial position, the changes in financial position and the cash flows of only that portion of the business-type activities of the financial reporting entity of The University of Alabama System that is attributable to the transactions of UAB. They do not purport to, and do not, present fairly the financial position of The University of Alabama System as of September 30, 2019 and 2018, the changes in its financial position, or, its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America. Our opinion is not modified with respect to this matter.

#### Other Matters

### Required Supplementary Information

The accompanying management's discussion and analysis on pages 12 through 19 and the accompanying supplementary information on pages 65 through 67 are required by accounting principles generally accepted in the United States of America to supplement the basic financial statements. Such information, although not a part of the basic financial statements, is required by the Governmental Accounting Standards Board who considers it to be an essential part of financial reporting for placing the basic financial statements in an appropriate operational, economic, or historical context. We have applied certain limited procedures to the required supplementary information in accordance with auditing standards generally accepted in the United States of America, which consisted of inquiries of management about the methods of preparing the information and comparing the information for consistency with management's responses to our inquiries, the basic financial statements, and other knowledge we obtained during our audits of the basic financial statements. We do not express an opinion or provide any assurance on the information because the limited procedures do not provide us with sufficient evidence to express an opinion or provide any assurance.

### Other Information

Our audits were conducted for the purpose of forming opinions on the financial statements that collectively comprise the University's basic financial statements. The introductory information on pages 2 through 8 and the management's report on page 9 are presented for purposes of additional analysis and are not a required part of the basic financial statements. Such information



has not been subjected to the auditing procedures applied in the audits of the basic financial statements, and accordingly, we do not express an opinion or provide any assurance on it.

### Other Reporting Required by Government Auditing Standards

Pricewaterhouse Coopers LLP

In accordance with *Government Auditing Standards*, we have also issued our report dated January 20, 2020, on our consideration of UAB's internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts, grant agreements, and other matters for the year ended September 30, 2019. The purpose of that report is to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing, and not to provide an opinion on internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the UAB's internal control over financial reporting and compliance.

January 20, 2020

# Management's Discussion and Analysis (Unaudited)

The objective of management's discussion and analysis is to help readers of UAB's financial statements better understand the financial position and operating activities for the fiscal years ended September 30, 2019 and 2018. UAB's financial statements present the financial position, changes in financial position, and the cash flows of the University, the University of Alabama Hospital (the Hospital), and UAB's blended component units. Condensed financial information of UAB's reportable segments is presented at Note 16. GASB Statement No. 14, The Financial Reporting Entity (GASB Statement No. 14), as amended by GASB Statement No. 61, The Financial Reporting Entity: Omnibus-an amendment of GASB Statements No. 14 and No. 34 (GASB Statement No. 61), requires governmental entities to include in their financial statements as component units, organizations that are legally separate entities for which the governmental entity, as a primary organization, is financially accountable. Southern Research Institute (SRI) is a discretely presented component unit of UAB. SRI's performance is not discussed below. However, SRI's Statement of Net Position and Statements of Revenues, Expenses, and Changes in Net Position are disclosed on pages 24-25. Blended component units include UAB Research Foundation (UABRF), UAB Athletics Foundation (UABAF), Alabama Care Plan (ACP), Triton Health Systems, L.L.C. (Triton), and Hospital Management LLC (LLC). The following discussion and analysis provides an overview of UAB's financial activities. This discussion should be read in conjunction with the financial statements and notes to the financial statements.

## Financial Overview

UAB's financial position remained strong, as assets totaled \$5.53, \$5.05, and \$4.82 billion at September 30, 2019, 2018, and 2017, respectively. Increases of \$479.0 million or 9.5% from September 30, 2018 to September 30, 2019 were primarily due to increases in investments, cash designated for capital activities, and capital assets. Increases of \$231.8 million or 4.8% from September 30, 2017 to September 30, 2018 were primarily due to increases in investments and capital assets.

Total liabilities increased \$255.7 million or 7.8% from September 30, 2018 to September 30, 2019. The increase results primarily from the issuance of bonds during fiscal year 2019. The increase also relates to growth in accounts payable and accrued liabilities as well as an increase in the OPEB liability. Total liabilities increased \$471.1 million or 16.7% from September 30, 2017 to September 30, 2018. The increase results primarily from the implementation of GASB Statement No. 75, Accounting and Financial Reporting for Postemployment Benefits Other Than Pensions.

The change in net position reflects the operating, nonoperating and other activity of UAB, which results from revenues, expenses, and gains and losses, and is summarized for the years ended September 30, 2019, 2018, and 2017, as follows:

	2019	2018	2017
TOTAL OPERATING REVENUES	\$ 3,602,383,812	\$ 3,404,474,421	\$ 3,084,238,857
TOTAL OPERATING EXPENSES	3,772,700,839	3,583,867,788	3,353,597,836
NET OPERATING LOSS	(170,317,027)	(179,393,367)	(269,358,979)
TOTAL NONOPERATING INCOME, CAPITAL, ENDOWMENT AND OTHER ACTIVITIES	403,275,983	 415,697,356	 499,741,609
INCREASE IN NET POSITION	\$ 232,958,956	\$ 236,303,989	\$ 230,382,630

## Statements of Net Position

The statement of net position presents the financial position of UAB at the end of the fiscal year, and includes all assets, deferred outflows, liabilities, and deferred inflows recorded on the accrual basis of accounting.

The changes in net position are indicators of whether the overall financial condition of UAB has improved or worsened during the year. A summarized comparison of UAB's assets, deferred outflows, liabilities, deferred inflows, and net position at September 30, 2019, 2018, and 2017, is as follows:

	2	019		2018	2017
ASSETS AND DEFERRED OUTFLOWS OF RESOURCES					
Capital assets, net	\$ 1,72	3,027,158	\$	1,647,560,771	\$ 1,600,940,041
Other assets	3,80	8,937,016		3,405,412,231	3,220,278,123
TOTAL ASSETS	5,53	31,964,174		5,052,973,002	4,821,218,164
Deferred outflows from debt refundings	12	2,305,553		13,259,304	14,238,497
Deferred outflows pension and OPEB related	30	1,435,989		284,267,363	197,907,000
TOTAL DEFERRED OUTFLOWS OF RESOURCES	3	13,741,542		297,526,667	212,145,497
TOTAL ASSETS AND DEFERRED OUTFLOWS OF RESOURCES	\$ 5,84	<u>5,705,716</u>	\$ 5	5,350,499,669	\$ 5,033,363,661
LIABILITIES, DEFERRED INFLOWS OF RESOURCES AND NET POSITION					
Current liabilities	\$ 54	14,331,398	\$	532,298,414	\$ 564,064,026
Noncurrent liabilities	2,99	8,164,006		2,754,500,058	2,251,669,042
TOTAL LIABILITIES	3,54	2,495,404		3,286,798,472	2,815,733,068
Deferred inflows from debt refundings		40,878		54,307	69,653
Deferred inflows pension and OPEB related	22	4,773,994		218,210,406	 70,055,000
TOTAL DEFERRED INFLOWS OF RESOURCES	22	24,814,872		218,264,713	70,124,653
Net position	2,07	8,395,440		1,845,436,484	2,147,505,940
TOTAL LIABILITIES, DEFERRED INFLOWS OF RESOURCES AND NET POSITION	\$ 5.84	5.705.716	\$ 5	5,350,499,669	\$ 5,033,363,661

At September 30, 2019, the major categories of current assets consist primarily of cash and cash equivalents, short-term investments, and accounts receivable, which totaled \$1.95 billion of the \$2.07 billion and increased \$242.4 million or 13.3% from 2018. The increase is a result of growth in short term investments and accounts receivable.

At September 30, 2018, the major categories of current assets consist primarily of cash and cash equivalents, short-term investments, and accounts receivable, which totaled \$1.72 billion of the \$1.83 billion and increased \$81.5 million or 5.0% from 2017. The increase is a result of growth in cash and short term investments.

At September 30, 2019, total current liabilities of \$544.3 million consist primarily of accounts payable, accrued payroll and related benefits, and unearned revenue, which totaled \$493.2 million, compared to \$483.4 million at September 30, 2018, an increase of \$10 million or 2.0% from 2018. The increase is a result of an increase in salary and benefits related accruals.

At September 30, 2018, total current liabilities of \$532.3 million consist primarily of accounts payable, accrued payroll and related benefits, and unearned revenue, which totaled \$483.4 million, compared to \$513.8 million at September 30, 2017, a decrease of \$30 million or 5.9% from 2017. The decrease is a result of timing of accrued biweekly payroll and increase in payables related to construction project completions.

UAB's endowment and life income investments increased \$12.7 million or 2.4% to \$537.5 million from September 30, 2018 to September 30, 2019. This increase resulted from the establishment of new endowment funds through gifts and the creation of Board-designated quasi-endowments throughout the year, offset by investment performance.

UAB's endowment and life income investments increased \$29.3 million or 5.9% to \$524.8 million from September 30, 2017 to September 30, 2018. This increase resulted from net investment gains and by the establishment of new endowment funds through gifts and the creation of Board-designated quasi-endowments.

UAB's endowment funds are invested in common investment pools established by The Board of Trustees of The University of Alabama (the Board). The funds are invested to maximize total return over the long term, with an appropriate level of risk. Any short term reduction in the fair value of the endowment portfolio will not have a meaningful immediate impact on the portion of investment income available to support current year operating expenses since such distributions are made pursuant to The University of Alabama System's (the System) spending rate policy. UAB's endowment funds consists of both permanent and quasi-endowments. Permanent endowment funds are those funds received from donors with the requirement that the principal remain unspent and invested in perpetuity to produce income to be expended for the purposes specified by the donor. Quasi- endowments consist of restricted or unrestricted funds that have been set aside by actions of the Board to produce income for an established purpose until the time the Board reverses its action. Endowment income supports scholarships, fellowships, professorships, research efforts, and other programs and activities of UAB.

At September 30, 2019, 2018, and 2017 respectively, UAB's investment in the Professional Liability Trust Fund (PLTF) totaled approximately \$60.3, \$67.3, and \$69.4 million. The \$7.0 million decrease from September 30, 2018 to September 30, 2019 is a result of a decline in investment values at September 30, 2019. The \$2.1 million decrease from September 30, 2017 to September 30, 2018 is a result of a decline in investment values at September 30, 2018.

At September 30, 2019, deferred outflows from pension obligations were \$185.1 million and deferred inflows from pension obligations were \$142.7 million. At September 30, 2018, deferred outflows from pension obligations were \$160.5 million and deferred inflows from pension obligations were \$147.1 million. The increase in deferred outflows from pension obligations is a result of an increase in differences between expected and actual experience. The decrease in deferred inflows from pension obligations is the result of a decrease in differences between expected and actual experience, changes in proportion, and differences between employer contributions proportionate share of contributions.

At September 30, 2018, deferred outflows from pension obligations were \$160.5 million and deferred inflows from pension obligations were \$147.1 million. At September 30, 2017, deferred outflows from pension obligations were \$197.9 million and deferred inflows from pension obligations were \$70.1 million. The decrease in deferred outflows from pension obligations is a result of a decrease in changes in actuarial and other assumptions. The increase in deferred inflows from pension obligations is the result of an increase in net difference between projected and actual earnings on pension plan investments.

At September 30, 2019, deferred outflows from OPEB obligations were \$116.4 million and deferred inflows from OPEB obligations were \$82.1 million. At September 30, 2018, deferred outflows from OPEB obligations were \$123.7 million and deferred inflows from OPEB obligations were \$71.1 million. The decrease in the deferred outflows from OPEB obligations is a result of a changes in proportion and differences between employer contributions and proportionate share of contributions. The increase in deferred inflows from OPEB obligation is a result of a change in proportion and differences between employer contributions and proportionate share of contributions.

At September 30, 2018, deferred outflows from OPEB obligations were \$123.7 million and deferred inflows from OPEB obligations were \$71.1 million. UAB recorded these balances for the first time in fiscal year 2018 upon implementation of GASB Statement No. 75, Accounting and Financial Reporting for Postemployment Benefits Other Than Pensions (GASB 75).

GASB Statements No. 68 and 75 require governmental employers participating in multi-employer cost-sharing pension and healthcare benefit plans to recognize liabilities for their proportionate share of the unfunded liability for plans whose actuarial liabilities exceed the plan's net assets. As required by Alabama statute, all eligible employees of a qualifying public educational employer must be a member of the Teacher's Retirement System of Alabama (TRS). As a qualifying employer, UAB is required to make certain employer contributions on behalf of its employees participating in TRS's defined benefit pension plan. Additionally, Alabama statutes permitted UAB to opt-in to provide its eligible retirees with healthcare benefits through

the Public Education Employees' Health Insurance Plan (PEEHIP).

The employer contribution rates for both plans are established annually by TRS and PEEHIP, and adopted by the Alabama Legislature. Both the TRS employer contribution rate and the employer's PEEHIP cost for retiree coverage are based upon the actuarial valuations performed by TRS and PEEHIP, respectively. Although the liabilities recognized under GASB 68 and 75 meet GASB's definition of a liability within GASB's framework for accounting standards, UAB does not believe that the associated recorded liabilities constitute legal liability for UAB, nor do they open UAB to other claims on its resources.

At September 30, 2019, deferred outflows from debt refundings were \$12.3 million and deferred inflows from debt refundings were \$41 thousand. At September 30, 2018, deferred outflows from debt refundings were \$13.3 million and deferred inflows from debt refundings were \$54 thousand. The decrease of \$1.0 million in deferred outflows from September 30, 2018 to September 30, 2019 is the result of the annual amortization of the debt refunding. At September 30, 2018, deferred outflows from debt refundings were \$13 million and deferred inflows from debt refundings were \$54 thousand. At September 30, 2017, deferred outflows from debt refundings were \$14 million and deferred inflows from debt refundings were \$70 thousand. These changes from September 30, 2017 to September 30, 2018 are related to the annual amortization of these balances.

# Capital and Debt Activities

An aspect of UAB's continued growth is an emphasis on the expansion and maintenance of capital assets. UAB continues to implement its long-range capital plan. Capital assets primarily include land, buildings, fixed equipment systems, and inventoried equipment. The original costs of capital assets increased approximately \$188.3 million and \$132.8 million from September 30, 2018 to September 30, 2019 and from September 30, 2017 to September 30, 2018, respectively. The year over year increase consists primarily of additions totaling \$227.0 million (offset primarily by \$38.7 million in disposals) and \$211.8 million (offset primarily by \$78.9 million in disposals) in 2019 and 2018, respectively. Capital additions are comprised primarily of renovation and new construction of student, research and health care facilities, as well as additions to improve information technology systems. Annual additions were funded with capital funds, grants, gifts of \$0.8 million and \$2.3 million, debt proceeds of \$29.6 million and \$45.4 million, and the remainder by UAB funds designated for capital purchases in 2019 and 2018, respectively.

Capital projects in process at September 30, 2019 include Central Utilities, McCallum Building renovations, Science and Engineering Building, Honors College, and Information and Technology Center. Capital projects in process at September 30, 2018 included construction of the Arts and Sciences Building, Central Utilities, and the Gardendale Emergency Clinic.

UAB's long-term debt related to capital assets, consisting of bonds and capital leases, totaled \$1.16, \$0.94, and \$0.98 billion at September 30, 2019, 2018, and 2017, respectively. The increase in debt during 2019 consisted primarily of the \$170.7 million General Revenue Bonds, Series 2019 issued during the year. The decrease in debt during 2018 consisted primarily of the principal payments made in accordance with the debt instruments.

### **Net Position**

Net position represents the residual interest in UAB's assets and deferred outflows after liabilities and deferred inflows are deducted. UAB's net position at September 30, 2019, 2018, and 2017, is summarized as follows:

		2019	2018	2017
NET INVESTMENT IN CAPITAL ASSETS	\$	759,496,749	\$ 744,768,861	\$ 704,791,969
RESTRICTED				
Nonexpendable		401,733,396	386,738,832	359,844,678
Expendable		377,422,933	354,341,414	337,272,370
UNRESTRICTED		539,742,362	359,587,377	745,596,923
TOTAL NET POSITION	<u>\$ 2</u>	078,395,440	\$ 1,845,436,484	\$ 2,147,505,940

Net position invested in capital assets represent UAB's capital assets, net of accumulated depreciation and outstanding principal of debt in excess of related bond proceeds attributable to the acquisition, construction, or improvement of those assets. The \$14.7 million increase in 2019 reflects continued capital asset development in accordance with UAB's long-range capital plan, offset by the increase in debt related to the bonds issued during the year. The \$40.0 million increase in 2018 reflects the growth in capital assets net of annual depreciation expense, along with the decrease in total debt related to the annual principal payments.

Restricted nonexpendable net position includes UAB's permanent endowment funds and annuity and life income assets that will ultimately become pure endowment funds. The \$15.0 million increase in 2019 and the \$26.9 million increase in 2018 relates to contributions made and investment performance at year-end.

Restricted expendable net position is subject to externally imposed restrictions governing its use. Restricted expendable net position includes UAB's assets whose use is restricted by an external restriction. The \$23.1 million increase in 2019 and \$17.1 million increase in 2018 result primarily from new gifts received during each respective year.

Unrestricted net position includes UAB's assets whose use is not restricted by an external entity. Unrestricted net position increased by \$180.2 million or 50.1% in 2019 and decreased by \$386.0 million or 51.8% in 2018. The decrease was primarily the result of implementing GASB 75 during 2018.


Although unrestricted net position is not subject to externally imposed restrictions, UAB has designated available unrestricted net position to be used for academic and research programs as well as capital projects.

# Statements of Revenues, Expenses, and Changes in Net Position

The statement of revenues, expenses, and changes in net position presents UAB's results of operations, as well as the nonoperating revenues and expenses. Annual state appropriations are classified as nonoperating revenues according to governmental accounting standards, even though the state-appropriated funds are used to support the operations of UAB. Without the nonoperating revenues, in particular the state appropriations and private gifts, UAB would not be able to cover its costs of operations. A summarized comparison of UAB's revenues, expenses and changes in net position for the years ended September 30, 2019, 2018, and 2017 is presented on the following page:

	2019	2018	2017
OPERATING REVENUES	2019	2018	2017
Student tuition and fees, net	\$ 239,912,344	\$ 253,707,923	\$ 208,481,228
Grants and contracts	494,047,342	461,633,394	439,678,012
Sales and services	2,791,635,652	2,623,643,380	2,377,662,013
Other revenues	76,788,474	65,489,724	58,417,604
TOTAL OPERATING REVENUES	3,602,383,812	3,404,474,421	3,084,238,857
OPERATING EXPENSES			
Operating expenses	3,772,700,839	3,583,867,788	3,353,597,836
OPERATING LOSS	(170,317,027)	(179,393,367)	(269,358,979)
NONOPERATING REVENUES (EXPENSES)			
State educational appropriations	287,691,735	273,351,124	272,166,253
Grants and contracts	35,451,482	34,611,638	30,638,381
Private gifts	48,327,432	37,989,901	35,726,160
Investment income	32,247,107	90,152,323	157,849,551
Interest expense	(29,755,042)	(28,964,461)	(33,472,892)
Net other nonoperating revenue (expense)	419,384	(11,334,915)	424,477
NET NONOPERATING REVENUES	374,382,098	395,805,610	463,331,930
OTHER CHANGES IN NET POSITION	28,893,885	19,891,746	36,409,679
INCREASE IN NET POSITION	232,958,956	236,303,989	230,382,630
Net Position, beginning of year as previously reported	1,845,436,484	2,147,505,940	1,917,123,310
Adoption of GASB 75	_	(538,373,445)	_
Net Position, beginning of year as restated as of October 1, 2017	1,845,436,484	1,609,132,495	1,917,123,310
NET POSITION, END OF YEAR	\$ 2,078,395,440	\$ 1,845,436,484	\$ 2,147,505,940

Figures A and A1 are graphic illustrations of revenues by source (both operating and nonoperating), which are used to fund UAB's operating activities for the years ended September 30, 2019 and 2018, respectively.



Gross tuition and fees revenue increased by \$17.1 million and \$30.4 million in 2019 and 2018, respectively. Tuition rates increased 3.5% in 2019 and in 2018. Total student headcount of 21,923 and 20,902 increased by 1,021 or 4.9% in Fall 2018 and increased by 1,367 or 7.0% in Fall 2017. Gross tuition and fees revenue in 2019 and 2018 is offset by scholarship allowances of \$80.2 million and \$49.3 million, respectively.

Figures B and B1 below are illustrations of the breakout of the funding sources for grant and contract revenue for the years ended September 30, 2019 and 2018, respectively. UAB receives grant and contract revenue from federal, state, local, and private agencies. These funds are used to further the mission of UAB: research, education, and public service. In addition to the funds received in exchange for services performed, UAB received \$296 thousand and \$142 thousand in 2018, and 2017, respectively, in funds to be used to acquire capital assets. UAB did not receive such funds in 2019.

Net hospital sales and service revenue totaled \$2.01, \$1.86, and \$1.71 billion, an increase of 7.7% and 9.1% from 2018 to 2019 and 2017 to 2018, respectively. This increase results from increased volume, contract improvements, and ongoing revenue-cycle improvement activities.

UAB receives state educational appropriations and capital funding from the State of Alabama. UAB recognized educational appropriations and capital funding from the State of Alabama totaling \$287.7, \$273.4, and \$272.7 million, of which \$287.7, \$273.4, and \$272.2 million was primarily from the Educational Trust Fund (ETF), which is included as nonoperating revenue in 2019, 2018, and 2017, respectively. The 0.6 million remaining in 2017 represents Public School and College Authority funds and other state capital funds.

Net investment income decreased \$57.9 million from 2018 to 2019 and decreased \$67.7 million from 2017 to 2018. The decrease was a result of a decrease in the fair value of investments at the end of the year.

UAB recognized \$77, \$59, and \$72 million in gift revenue (composed partially of \$28, \$18, and \$20 million and \$0.8, \$2.3, and \$16.0 million in capital and endowment gifts, respectively) for the years ended September 30, 2019, 2018, and 2017, respectively.

Figure B: Grants and Contract Revenues 2019





Figure B1: Grants and Contract Revenues 2018



A comparative summary of UAB's operating expenses for the years ended September 30, 2019, 2018, and 2017, is as follows:

	 2019	2018	2017
Salaries, wages, and benefits	\$ 1,749,060,938	\$ 1,674,990,688	\$ 1,598,699,146
Supplies and services	1,846,254,490	1,734,410,959	1,590,907,613
Depreciation	148,344,143	146,686,513	137,431,750
Scholarships and fellowships	 29,041,268	27,779,628	26,559,327
	\$ 3,772,700,839	\$ 3,583,867,788	\$ 3,353,597,836


Salaries, wages, and benefits increased \$74.1 million or 4.4% during 2019 and \$76.3 million or 4.8% during 2018. These increases are primarily due to the growth of UAB's salary base and rising benefit costs related to growth in salary base.


Supplies and services expenses increased \$111.8 million or 6.4% and \$143.5 million or 9.0% during 2019 and 2018, respectively. This increase is primarily attributable to UAB's continued growth.

In addition to their natural classification, it is also informative to review operating expenses by function. Graphic illustrations of UAB's operating expenses by function for the years ended September 30, 2019 and 2018, respectively, are presented as follows:

### **2019 Operating Expenses by Function**

### **2018 Operating Expesnes by Function**







# Economic Factors That Will Affect The Future

As a labor-intensive organization, UAB faces competitive pressures related to attracting and retaining faculty and staff.

The State of Alabama appropriates money each year to UAB for operating costs and nonoperating cash requirements, including capital expenditures. Because the State is mandated by its Constitution to operate with a balanced budget, the State occasionally has reduced its appropriations, through a process known as "proration," when its annual revenues are not expected to meet budgeted appropriations. As the State could implement proration in future years, UAB continues implementing costsaving measures in order to minimize the impact of any future proration.

Private gifts are an important part of the fundamental support of UAB. Economic pressures affecting donors may also affect the future level of support UAB receives from corporate and individual giving. In fiscal year 2014, UAB launched its largest fundraising campaign to date known as "Give something change everything." The fundraising goal of \$1 billion was surpassed by UAB in November 2018, reaching it's stated goal of achieving the milestone by the end of 2018.

During fiscal year 2019, 67.6% of UAB students received financial aid, including \$195.4 million of Federal Financial Aid. In recent years, financial aid reform and reauthorization of existing aid programs have been topics in legislative sessions. Management is monitoring proposed future legislation in order to respond in a manner to assist current and future students.

The Hospital faces significant challenges in a dynamic healthcare sector and volatile economic environment. The demand for health care services and the cost of providing them are increasing significantly while the revenues to support these services are diminishing. In addition to cost increases such as rising salary and benefit costs, the Hospital also faces additional costs associated with new technologies, the education and training of health care professionals and provision of care for a disproportionate share of the medically underserved in Alabama. In recent years, federal legislation has been enacted to slow future rate increases in Medicare and Medicaid and reduce medical education and disproportionate share funding. Management is committed to staying abreast of pertinent issues; implementing appropriate management actions and continuing to provide quality care for all patients.

Refer within footnote 1 for further information related to COVID 19 impact.

These financial statements are designed to provide a general overview of the University of Alabama at Birmingham and to demonstrate UAB's accountability. Questions concerning any information provided in this report or requests for additional information should be addressed to the Office of the Senior Vice President for Finance and Administration, The University of Alabama at Birmingham, AB 1030, 1720 2ND AVE S, BIRMINGHAM AL 35294-0106.

# The University of Alabama at Birmingham Statements of Net Position

# **September 30, 2019 and 2018**

ASSETS	2019	2018
Current Assets:		
Cash and cash equivalents	\$ 380,593,397	\$ 341,288,837
Short term investments	1,084,308,490	999,762,476
Accounts receivable, net	481,727,985	379,353,664
Loans receivable, current portion Pledges receivable, current portion	2,272,848 18,436,977	2,607,520 18,141,677
Inventories	30,625,249	24,485,532
Prepaid expenses and unearned scholarships	62,681,894	56,506,374
Other current assets	11,213,343	7,305,367
Total current assets	2.071.860.183	1,829,451,447
Noncurrent Assets:		
Cash designated for capital activities	141,695,284	12,303,298
Restricted cash and cash equivalents	169,594	1,275,012
Investments for capital activities	825,529,381	807,541,053
Endowment and life income investments	537,457,828	524,782,469
Investment in Professional Liability Trust Fund	60,291,989	67,279,238
Other long-term investments	115,426,770	104,167,675
Loans receivable, net	10,980,614	12,186,968
Pledges receivable	45,409,739	46,369,919
Capital assets, net	1,723,027,158	1,647,560,771
Other noncurrent assets	115,634	55,152
Total noncurrent assets	3,460,103,991	3,223,521,555
Total Assets	5.531.964.174	5.052.973.002
DEFERRED OUTFLOWS OF RESOURCES		
Bond deferred refundings	12,305,553	13,259,304
Pension and OPEB related obligations	301,435,989	284,267,363
Total Deferred Outflows of Resources	313.741.542	297.526.667
Total Assets and Deferred Outflows of Resources	\$ 5,845,705,716	\$ 5,350,499,669
LIABILITIES		
Current Liabilities:	¢ 242,020,427	¢ 220,004,227
Accounts payable and accrued liabilities	\$ 342,830,127	\$ 338,881,337
Deposits	15,788,813	13,912,936
Unearned revenue-grants	44,550,216	38,376,263
Unearned revenue-other	105,781,493	106,176,792
Long-term debt, current portion	35,380,749	34,951,086
Total current liabilities	544,331,398	532,298,414
Noncurrent Liabilities:	11.056.522	12 274 410
Federal advances-loan funds	1,127,090,695	12,374,410 902,290,484
Long-term debt, noncurrent portion Pension liability		
OPEB liability	1,168,305,000	1,161,162,000
Other noncurrent liabilities	677,611,841 14.099,948	664,329,034 14.344.130
Total noncurrent liabilities	2.998.164.006	2.754.500.058
Total Liabilities	3,542,495,404	3,286,798,472
DEFERRED INFLOWS OF RESOURCES	3,5 12, 133, 10 1	0,200,700,172
Bond deferred refundings	40,878	54,307
Pension and OPEB related obligations	224,773,994	218,210,406
Total Deferred Inflows Of Resources NET POSITION	224.814.872	218.264.713
Net investment in capital assets	759,496,749	744,768,861
Restricted	, , , , ,	
Nonexpendable	401,733,396	386,738,832
Expendable	377,422,933	354,341,414
Experiedble		
Unrestricted	539.742.362	<u>359.587.377</u>
•	539.742.362 <b>2,078,395,440</b>	359.587.377 1,845,436,484

# The University of Alabama at Birmingham Statements of Revenues, Expenses, and Changes in Net Position

# Year Ended September 30, 2019 and 2018

	2019	2018
Operating Revenues		
Tuition and fees	\$ 320,141,055	\$ 303,042,374
Less: scholarship allowance	(80,228,711)	(49,334,451)
Tuition and fees, net	239,912,344	253,707,923
Grants and contracts:		
Federal	399,343,773	370,528,637
State	10,967,871	8,057,617
Local	2,535,753	2,999,958
Private	81,199,945	80,047,182
Sales and services:		
Educational activities	67,616,490	68,464,868
Hospital, net of bad debt expense of \$157,700,738 in 2019 and \$152,151,403 in 2018	2,008,319,151	1,864,755,549
Other auxiliary enterprises, net of scholarship allowance of \$2,938,161 in 2019 and \$3,137,826 in 2018	715,700,011	690,422,963
Other operating revenues	76,788,474	65,489,724
Total operating revenues	3,602,383,812	3,404,474,421
Operating Expenses		
Salaries, wages and benefits	1,749,060,938	1,674,990,688
Supplies and services	1,846,254,490	1,734,410,959
Depreciation	148,344,143	146,686,513
Scholarships and fellowships	29,041,268	27,779,628
Total operating expenses	3,772,700,839	3,583,867,788
Operating loss	(170,317,027)	(179,393,367)
Nonoperating Revenues (Expenses)		
State educational appropriations	287,691,735	273,351,124
Grants and contracts	35,451,482	34,713,042
Gifts	48,327,432	37,888,497
Investment income	32,247,107	90,152,323
Interest expense	(29,755,042)	(28,964,461)
Loss on asset dispositions, net	(112,196)	(6,760,763)
Other nonoperating income (loss), net	531,580	(4,574,152)
Net nonoperating revenues	374,382,098	395,805,610
Income before other changes in net position	204,065,071	216,412,243
Other Changes in Net Position		
Capital gifts and grants	789,319	2,285,326
Endowment gifts	28,104,566	18,401,517
Intergovernmental transfers		(795,097)
Total other changes in net position	28,893,885	19,891,746
Increase in net position	232,958,956	236,303,989
Net Position, beginning of year, as previously reported	1,845,436,484	2,147,505,940
Adoption of GASB 75	_	(538,373,445)
Net Position, beginning of year as restated as of October 1, 2017	1,845,436,484	1,609,132,495
Net Position, end of year	\$ 2,078,395,440	\$ 1,845,436,484

# The University of Alabama at Birmingham Statements of Cash Flows Years Ended September 30, 2019 and 2018

	2019	2018
Cash flows from operating activities		
Student tuition and fees	\$ 222,500,106	\$ 231,115,150
Grants and contracts:		
Federal	392,986,127	361,592,330
State	10,493,650	9,111,345.33
Local	3,007,393	2,814,960
Private	83,027,558	85,374,305
Receipts from sales and services of:		
Educational activities	68,089,396	68,246,848
Patient services	1,988,861,614	1,848,364,473
Auxiliary enterprises, net	47,914,492	45,259,777
Premium and administrative fees collected	669,167,299	645,859,222
Payment to employees and related benefits	(1,337,749,307)	(1,290,542,381)
Payment for contract labor	(402,775,436)	(369,838,457)
Payment to suppliers	(1,874,194,939)	(1,735,169,599)
Payment for scholarships and fellowships	(29,041,268)	(27,779,628)
Other receipts	71,385,889	61,456,951
Net cash used in operating activities	(86,327,426)	(64,134,704)
Cash flows from noncapital financing activities		
State educational appropriations	287,691,735	273,351,124
Private gifts	74,368,931	54,483,523
Student direct lending receipts	169,048,223	168,122,333
Student direct lending disbursements	(167,141,859)	(167,268,364)
Other deposits	39,131,649	37,358,070
Deposits from affiliates	1,374,539	5,225,155
Net cash provided by noncapital financing activities	404,473,218	371,271,841
Cash flows from investing activities		
Interest and dividends from investments, net	90,095,472	76,512,231
Proceeds from notes receivable	139,076	126,747
Proceeds from sales and maturities of investments	30,531,014	56,285,307
Purchases of investments	(206,880,373)	(233,897,521)
Net cash used in investing activities	(86,114,811)	(100,973,236)
-	(00,114,011)	(100,373,230)
Cash flows from capital and related financing activities	247.042.400	
Proceeds from issuance of capital debt	217,842,498	-
State capital funds		127,678
Capital gifts, grants and contracts	3,517,265	4,831,473
Proceeds from sale of capital assets	3,267,701	510,769
Purchases of capital assets	(219,539,415)	(209,155,014)
Principal payments on capital debt	(35,308,922)	(37,773,553)
Interest payments on capital debt	(34,218,980)	(34,374,966)
Net cash used in capital and related financing activities	(64,439,853)	(275,833,613)
Net increase (decrease) in cash and cash equivalents	167,591,128	(69,669,712)
Cash and cash equivalents, beginning of year	354,867,147	424,536,859
Cash and cash equivalents, end of year	\$ 522,458,275	\$ 354,867,147

# The University of Alabama at Birmingham Statements of Cash Flows (continued) Years Ended September 30, 2019 and 2018

Reconciliation of cash and cash equivalents to the statements of net position         \$ 380,593,397         \$ 341,288,837           Cash and cash equivalents         141,695,284         12,303,298           Restricted cash and cash equivalents         169,594         1,275,012           Total cash and cash equivalents         522,458,275         \$ 354,867,147           Reconciliation of operating loss to net cash used in operating activities         \$ (170,317,027)         \$ (179,393,367)           Operating loss         \$ (170,317,027)         \$ (179,393,367)           Adjustments to reconcile operating loss to net cash used in operating activities         148,344,143         146,686,513           Pension expense         76,255,000         86,199,000           OPEB expense         52,845,769         58,415,453           Changes in assets and liabilities:         4(49,790,075)         (27,603,792)           Prepaid expenses and other assets         (17,744,379)         (29,914,634)           Accounts payable and accrued liabilities         (12,188,034)         (11,048,056)           Pension obligations         (97,999,000)         (95,055,000)           OPEB obligations         (21,360,942)         (22,216,217)           Unearned Revenue         5,627,119         9,795,396           Supplemental noncash activities information <t< th=""><th></th><th>2019</th><th>2018</th></t<>		2019	2018
Cash designated for capital activities       141,695,284       12,303,298         Restricted cash and cash equivalents       169,594       1,275,012         Total cash and cash equivalents       522,458,275       \$ 354,867,147         Reconciliation of operating loss to net cash used in operating activities       \$ (170,317,027)       \$ (179,393,367)         Adjustments to reconcile operating loss to net cash used in operating activities       \$ (170,317,027)       \$ (179,393,367)         Adjustments to reconcile operating loss to net cash used in operating activities       \$ (170,317,027)       \$ (179,393,367)         Depreciation expense       148,344,143       146,686,513         Pension expense       76,255,000       86,199,000         OPEB expense       52,845,769       58,415,453         Changes in assets and liabilities:       (49,790,075)       (27,603,792)         Prepaid expenses and other assets       (17,744,379)       (29,914,634)         Accounts payable and accrued liabilities       (12,188,034)       (11,048,056)         Pension obligations       (97,999,000)       (95,055,000)         OPEB obligations       (21,360,942)       (22,216,217)         Unearned Revenue       5,627,119       9,795,396         Net cash used in operating activities information       (86,327,426)       \$ (64,134,704)	Reconciliation of cash and cash equivalents to the statements of net position		
Restricted cash and cash equivalents   169,594   522,458,275   354,867,147	Cash and cash equivalents	\$ 380,593,397	\$ 341,288,837
Total cash and cash equivalents   522,458,275   \$354,867,147	Cash designated for capital activities	141,695,284	12,303,298
Reconciliation of operating loss         \$ (170,317,027)         \$ (179,393,367)           Adjustments to reconcile operating loss to net cash used in operating activities         148,344,143         146,686,513           Depreciation expense         76,255,000         86,199,000           OPEB expense         52,845,769         58,415,453           Changes in assets and liabilities:         (49,790,075)         (27,603,792)           Prepaid expenses and other assets         (17,744,379)         (29,914,634)           Accounts payable and accrued liabilities         (12,188,034)         (11,048,056)           Pension obligations         (97,999,000)         (95,055,000)           OPEB obligations         (21,360,942)         (22,216,217)           Unearned Revenue         5,627,119         9,795,396           Net cash used in operating activities information         (86,327,426)         \$ (64,134,704)           Supplemental noncash activities information         23,431,082         \$ (64,134,704)           Capital assets acquired included in accounts payable         \$ 23,431,082         \$ 16,241,114           Capital assets acquired through capital lease         341,253         309,508           Interest capitalized         2,722,115         3,134,791	Restricted cash and cash equivalents	169,594	1,275,012
Operating loss         \$ (170,317,027)         \$ (179,393,367)           Adjustments to reconcile operating loss to net cash used in operating activities         148,344,143         146,686,513           Depreciation expense         76,255,000         86,199,000           OPEB expense         52,845,769         58,415,453           Changes in assets and liabilities:         (49,790,075)         (27,603,792)           Prepaid expenses and other assets         (17,744,379)         (29,914,634)           Accounts payable and accrued liabilities         (12,188,034)         (11,048,056)           Pension obligations         (97,999,000)         (95,055,000)           OPEB obligations         (21,360,942)         (22,216,217)           Unearned Revenue         5,627,119         9,795,396           Net cash used in operating activities         (86,327,426)         \$ (64,134,704)           Supplemental noncash activities information         \$ 23,431,082         \$ 16,241,114           Capital assets acquired included in accounts payable         \$ 23,431,082         \$ 16,241,114           Capital assets acquired through capital lease         341,253         309,508           Interest capitalized         2,722,115         3,134,791	Total cash and cash equivalents	522,458,275	\$ 354,867,147
Operating loss         \$ (170,317,027)         \$ (179,393,367)           Adjustments to reconcile operating loss to net cash used in operating activities         148,344,143         146,686,513           Depreciation expense         76,255,000         86,199,000           OPEB expense         52,845,769         58,415,453           Changes in assets and liabilities:         (49,790,075)         (27,603,792)           Prepaid expenses and other assets         (17,744,379)         (29,914,634)           Accounts payable and accrued liabilities         (12,188,034)         (11,048,056)           Pension obligations         (97,999,000)         (95,055,000)           OPEB obligations         (21,360,942)         (22,216,217)           Unearned Revenue         5,627,119         9,795,396           Net cash used in operating activities         (86,327,426)         \$ (64,134,704)           Supplemental noncash activities information         \$ 23,431,082         \$ 16,241,114           Capital assets acquired included in accounts payable         \$ 23,431,082         \$ 16,241,114           Capital assets acquired through capital lease         341,253         309,508           Interest capitalized         2,722,115         3,134,791			
Adjustments to reconcile operating loss to net cash used in operating activities  Depreciation expense	Reconciliation of operating loss to net cash used in operating activities		
Depreciation expense       148,344,143       146,686,513         Pension expense       76,255,000       86,199,000         OPEB expense       52,845,769       58,415,453         Changes in assets and liabilities:	Operating loss	\$ (170,317,027)	\$ (179,393,367)
Pension expense       76,255,000       86,199,000         OPEB expense       52,845,769       58,415,453         Changes in assets and liabilities:       Accounts receivable, net       (49,790,075)       (27,603,792)         Prepaid expenses and other assets       (17,744,379)       (29,914,634)         Accounts payable and accrued liabilities       (12,188,034)       (11,048,056)         Pension obligations       (97,999,000)       (95,055,000)         OPEB obligations       (21,360,942)       (22,216,217)         Unearned Revenue       5,627,119       9,795,396         Net cash used in operating activities       (86,327,426)       \$ (64,134,704)         Supplemental noncash activities information         Capital assets acquired included in accounts payable       \$ 23,431,082       \$ 16,241,114         Capital assets acquired through capital lease       341,253       309,508         Interest capitalized       2,722,115       3,134,791	Adjustments to reconcile operating loss to net cash used in operating activities		
OPEB expense       52,845,769       58,415,453         Changes in assets and liabilities:       (49,790,075)       (27,603,792)         Accounts receivable, net       (49,790,075)       (27,603,792)         Prepaid expenses and other assets       (17,744,379)       (29,914,634)         Accounts payable and accrued liabilities       (12,188,034)       (11,048,056)         Pension obligations       (97,999,000)       (95,055,000)         OPEB obligations       (21,360,942)       (22,216,217)         Unearned Revenue       5,627,119       9,795,396         Net cash used in operating activities       (86,327,426)       \$ (64,134,704)         Supplemental noncash activities information       \$ 23,431,082       \$ 16,241,114         Capital assets acquired included in accounts payable       \$ 23,431,082       \$ 16,241,114         Capital assets acquired through capital lease       341,253       309,508         Interest capitalized       2,722,115       3,134,791	Depreciation expense	148,344,143	146,686,513
Changes in assets and liabilities:       (49,790,075)       (27,603,792)         Accounts receivable, net       (49,790,075)       (27,603,792)         Prepaid expenses and other assets       (17,744,379)       (29,914,634)         Accounts payable and accrued liabilities       (12,188,034)       (11,048,056)         Pension obligations       (97,999,000)       (95,055,000)         OPEB obligations       (21,360,942)       (22,216,217)         Unearned Revenue       5,627,119       9,795,396         Net cash used in operating activities       (86,327,426)       \$ (64,134,704)         Supplemental noncash activities information       23,431,082       \$ 16,241,114         Capital assets acquired included in accounts payable       \$ 23,431,082       \$ 16,241,114         Capital assets acquired through capital lease       341,253       309,508         Interest capitalized       2,722,115       3,134,791	Pension expense	76,255,000	86,199,000
Accounts receivable, net  Prepaid expenses and other assets  (17,744,379)  Accounts payable and accrued liabilities  (12,188,034)  Pension obligations  (12,188,034)  (14,188,034)  (11,048,056)  Pension obligations  (12,360,942)  Unearned Revenue  5,627,119  Net cash used in operating activities  (86,327,426)  Supplemental noncash activities information  Capital assets acquired included in accounts payable  Capital assets acquired through capital lease  Interest capitalized  (49,790,075)  (27,603,792)  (29,914,634)  (11,048,056)  (97,999,000)  (95,055,000)  (96,055,000)	OPEB expense	52,845,769	58,415,453
Prepaid expenses and other assets       (17,744,379)       (29,914,634)         Accounts payable and accrued liabilities       (12,188,034)       (11,048,056)         Pension obligations       (97,999,000)       (95,055,000)         OPEB obligations       (21,360,942)       (22,216,217)         Unearned Revenue       5,627,119       9,795,396         Net cash used in operating activities       (86,327,426)       \$ (64,134,704)         Supplemental noncash activities information       \$ 23,431,082       \$ 16,241,114         Capital assets acquired included in accounts payable       \$ 341,253       309,508         Interest capitalized       2,722,115       3,134,791	Changes in assets and liabilities:		
Accounts payable and accrued liabilities (12,188,034) (11,048,056) Pension obligations (97,999,000) (95,055,000) OPEB obligations (21,360,942) (22,216,217) Unearned Revenue 5,627,119 9,795,396 Net cash used in operating activities (86,327,426) \$ (64,134,704)  Supplemental noncash activities information Capital assets acquired included in accounts payable \$ 23,431,082 \$ 16,241,114 Capital assets acquired through capital lease 341,253 309,508 Interest capitalized 2,722,115 3,134,791	Accounts receivable, net	(49,790,075)	(27,603,792)
Pension obligations         (97,999,000)         (95,055,000)           OPEB obligations         (21,360,942)         (22,216,217)           Unearned Revenue         5,627,119         9,795,396           Net cash used in operating activities         (86,327,426)         \$ (64,134,704)           Supplemental noncash activities information         Capital assets acquired included in accounts payable         \$ 23,431,082         \$ 16,241,114           Capital assets acquired through capital lease         341,253         309,508           Interest capitalized         2,722,115         3,134,791	Prepaid expenses and other assets	(17,744,379)	(29,914,634)
OPEB obligations         (21,360,942)         (22,216,217)           Unearned Revenue         5,627,119         9,795,396           Net cash used in operating activities         (86,327,426)         \$ (64,134,704)           Supplemental noncash activities information         Capital assets acquired included in accounts payable         \$ 23,431,082         \$ 16,241,114           Capital assets acquired through capital lease         341,253         309,508           Interest capitalized         2,722,115         3,134,791	Accounts payable and accrued liabilities	(12,188,034)	(11,048,056)
Unearned Revenue  Net cash used in operating activities  Supplemental noncash activities information  Capital assets acquired included in accounts payable Capital assets acquired through capital lease Interest capitalized  S,627,119 9,795,396 (64,134,704)  \$ 23,431,082 \$ 16,241,114 2,722,115 3,134,791	Pension obligations	(97,999,000)	(95,055,000)
Net cash used in operating activities  (86,327,426)  \$ (64,134,704)  Supplemental noncash activities information  Capital assets acquired included in accounts payable Capital assets acquired through capital lease Interest capitalized  \$ 23,431,082 \$ 16,241,114  \$ 309,508 \$ 341,253 \$ 309,508  \$ 2,722,115 \$ 3,134,791	OPEB obligations	(21,360,942)	(22,216,217)
Supplemental noncash activities information  Capital assets acquired included in accounts payable \$ 23,431,082 \$ 16,241,114  Capital assets acquired through capital lease 341,253 309,508  Interest capitalized 2,722,115 3,134,791	Unearned Revenue	5,627,119	9,795,396
Capital assets acquired included in accounts payable \$ 23,431,082 \$ 16,241,114 Capital assets acquired through capital lease 341,253 Interest capitalized \$ 2,722,115 \$ 3,134,791	Net cash used in operating activities	(86,327,426)	\$ (64,134,704)
Capital assets acquired included in accounts payable \$ 23,431,082 \$ 16,241,114 Capital assets acquired through capital lease 341,253 Interest capitalized \$ 2,722,115 \$ 3,134,791			
Capital assets acquired included in accounts payable \$ 23,431,082 \$ 16,241,114 Capital assets acquired through capital lease 341,253 Interest capitalized \$ 2,722,115 \$ 3,134,791			
Capital assets acquired through capital lease 341,253 309,508 Interest capitalized 2,722,115 3,134,791	Supplemental noncash activities information		
Interest capitalized 2,722,115 3,134,791	Capital assets acquired included in accounts payable	\$ 23,431,082	\$ 16,241,114
	Capital assets acquired through capital lease	341,253	309,508
Noncash intergovernmental transfers — 795,098	Interest capitalized	2,722,115	3,134,791
	Noncash intergovernmental transfers	_	795,098

# Southern Research Institute A Discretely Presented Component Unit Statements of Net Position

# December 28, 2018 and December 29, 2017

	2019	2018
ASSETS		
Current Assets:		
Cash and cash equivalents	\$ 24,474	\$ 5,368,718
Investments Restricted cash and investments	19,911,409	29,820,863
Accounts receivable, net	10,721,291	12,077,419
Other receivables	16,109,295	14,918,349 3,899,764
Materials and supplies, net	2,008,305 1,073,368	916,804
Prepayments and other current assets	839.722	1.016.594
Total current assets	50,687,864	68,018,511
Noncurrent Assets:	30,007,001	33,013,311
Net OPEB asset	623,594	360.231
Capital assets:		
Land and improvements	6,273,110	7,468,288
Buildings and major plant equipment	68,640,869	62,311,367
Laboratory equipment and fixtures	61,419,728	66,512,027
Office furniture and equipment	3,559,598	3,665,424
Intangible assets, net	2,466,397	2,241,644
	142,359,702	142,198,750
Less accumulated depreciation	(88,734,253)	(88,983,010)
2000 decumulated depreciation	53,625,449	53,215,740
Construction-in-progress	1,777,846	5,136,775
Total capital assets, net	55,403,295	58.352.515
Total noncurrent assets	56,026,889	58,712,746
Total Assets	106,714,753	126,731,257
DEFERRED OUTFLOWS OF RESOURCES		
OPEB	403.238	
Total Assets and Deferred Outflows of Resources	\$ 107,117,991	\$ 126,731,257
LIABILITIES		
Current Liabilities:		
Accounts payable	\$ 5,382,732	\$ 4,663,917
Accrued liabilities	6,302,610	6,763,147
Unearned contract revenue	4,790,805	3,414,680
Current maturities of long-term debt and capital lease obligations	625,110	624,597
Note payable	806.353	<u> </u>
Total current liabilities	17.907.610	15.466.341
Noncurrent Liabilities:		
Long-term debt and capital lease obligations	14,050,649	14,675,759
Total noncurrent liabilities	14,050,649	14,675,759
Total Liabilities	31,958,259	30,142,100
DEEEDDED INELOWS OF DESCRIPCES		
OPEB	1,079,066	_
NET POSITION		
Net investment in capital assets	40,727,536	43,052,159
Restricted		
Expendable	11,939,885	14,220,150
Unrestricted	21,413,245	39,316,848
Total Net Position	74,080,666	96,589,157
Total Liabilities, Deferred Inflows Of Resources, and Net Position	<u>\$ 107,117,991</u>	<u>\$ 126,731,257</u>

# Southern Research Institute A Discretely Presented Component Unit Statements of Revenues, Expenses, and Changes in Net Position Years Ended December 28, 2018 and December 29, 2017

	2019	2018
Operating Revenues		
Contract revenues	\$ 65,188,876	\$ 63,221,909
Intellectual property revenues, net of direct expenses	2,333,215	3,032,179
Total operating revenues	67,522,091	66,254,088
Operating Expenses		
Salaries, wages and benefits	46,596,897	48,519,346
Supplies and services	29,358,326	24,366,091
Depreciation and amortization	6,949,310	7,445,212
Total operating expenses	82,904,533	80,330,649
Operating loss	(15,382,442)	(14,076,561)
Nonoperating Revenues (Expenses)		
Contributions	491,792	358,792
Investment income (loss)	(1,724,659)	4,272,965
Interest expense	(369,510)	(517,725)
Gain (loss) on disposal of assets	(5,523,672)	1,515,282
Net nonoperating revenues (expenses)	(7,126,049)	5,629,314
Change in net position	(22,508,491)	(8,447,247)
Net Position, beginning of year	96,589,157	105,036,404
Net Position, end of year	\$ 74,080,666	\$ 96,589,157

# The University of Alabama at Birmingham Notes to Financial Statements

# September 30, 2019 and 2018

# Organization and Summary of Significant Accounting Policies

The University of Alabama at Birmingham (UAB) is one of three universities of The University of Alabama System (the System), which is a discretely presented component unit of the State of Alabama (the State). The financial statements of UAB are intended to present the financial position, changes in financial position, and the cash flows of only that portion of the business-type activities of the financial reporting entity of the System that is attributable to the transactions of UAB. They do not purport to, and do not, present fairly the financial position of the System, its changes in financial position or cash flows in accordance with accounting principles generally accepted in the United States of America. The System is recognized as an organization exempt from Federal income tax under Section 501(a) of the Internal Revenue Code as an organization described in Section 501(c)(3) of the Internal Revenue Code.

UAB, as a public institution, prepares its financial statements in accordance with accounting principles generally accepted in the United States of America, as prescribed by the Governmental Accounting Standards Board (GASB).

GASB Statement No. 35, Basic Financial Statements and Management's Discussion and Analysis for Public Colleges and Universities, establishes standards for external financial reporting for public colleges and universities and requires that resources be classified for accounting and reporting purposes into the following three net position categories:

#### • Net Investment in Capital Assets:

Capital assets, net of accumulated depreciation and outstanding principal balances of debt attributable to the acquisition, construction, or improvement of those assets.

#### · Restricted:

Nonexpendable: Net position subject to externally imposed stipulations that they be maintained permanently by UAB. Such assets include UAB's permanent endowment funds.

Expendable: Net position whose use by UAB is subject to externally imposed stipulations that can be fulfilled by actions of UAB pursuant to those stipulations or that expire by the passage of time.

#### Unrestricted:

The net position that is not subject to externally imposed stipulations. Unrestricted net position may be designated

for specific purposes by action of management. Substantially all of the unrestricted net position is designated for academic and research programs and initiatives and capital programs.

UAB reports as a business type activity, as defined by GASB Statement No. 35. Business type activities are those financed in whole or in part by fees charged to external parties for goods or services.

UAB policy states that operating activities as reported by the statement of revenues, expenses, and changes in net position are those that generally result from exchange transactions such as payments received for providing services and payments made for services or goods received. Certain significant revenue streams relied upon for operations are recorded as nonoperating revenues, as defined by GASB Statement No. 35.

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. The estimates susceptible to significant changes include those used in determining the allowance for contractual adjustments and uncollectible accounts, valuation of investments, accruals related to compensated absences, allowance for self-insurance, estimated amounts due to or from third-party payors, and reserves for general and professional liability claims. Although some variability is inherent in these estimates, management believes that the amounts provided are adequate.

#### **Scope of Statements**

UAB is principally comprised of a university (the University) and the University of Alabama Hospital (the Hospital or University Hospital) which are UAB's reportable segments as defined by GASB Statement No. 37, Basic Financial Statements and Management's Discussion and Analysis-For State and Local Governments: Omnibus an Amendment of GASB Statements No. 21 and No. 34. UAB's financial statements present the financial position, changes in financial position, and the cash flows of the University, the Hospital, and UAB's blended component units. Condensed financial information of UAB's reportable segments is presented at Note 16. Refer to Note 2 for information regarding UAB's component units.

UAB is affiliated with the UAB Educational Foundation (UABEF), the University of Alabama Health Services Foundation, P.C. (HSF), UAB Health System (UABHS), and

the Valley Foundation (VF). UAB is not financially accountable for UABEF, HSF, UABHS or VF; therefore, they do not constitute component units under the provisions of GASB Statement No. 14, *The Financial Reporting Entity*, as amended. These entities are not required to be presented as component units under GASB Statement No. 39, *Determining Whether Certain Organizations are Component Units – an Amendment of GASB Statement No.* 14 and No. 61, *The Financial Reporting Entity –* an *Amendment of GASB Statement No.* 14 and 34. More information regarding HSF, UABHS and VF can be found at Note 15.

UABEF provides funds and certain facilities to UAB for its educational and scientific functions. UABEF has 13 board members, including seven outside members not affiliated with UAB. UABEF leases certain facilities to UAB, with rental expense of approximately \$2.1 million for the year ended September 30, 2019 and \$2.3 million for the year ended September 30, 2018. UABEF made contributions to UAB which totaled approximately \$4.6 million for the year ended June 30, 2019 and approximately \$7.2 million for the year ended June 30, 2018.

Implementation of new standards: During 2019, UAB adopted GASB Statement No. 83, Certain Asset Retirement Obligations and GASB Statement No. 88, Certain Disclosures Related to Debt, including Direct Borrowings and Direct Placements. GASB Statement No. 83, addresses accounting and financial reporting for certain asset retirement obligations (AROs). The impact from its adoption of GASB 83 was not material to the financial statements. GASB Statement No. 88 aims to improve the information that is disclosed in notes to government financial statements related to debt, including direct borrowings and direct placements. It also clarifies which liabilities governments should include when disclosing information related to debt. Refer to Note 7 for enhanced disclosures related to UAB's long-term debt.

Other significant accounting policies are as follows:

Cash and cash equivalents: For purposes of the statement of cash flows, UAB considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. Cash equivalents representing assets of UAB's endowment, life income, and other long-term investments are included in noncurrent assets.

Investments: UAB's investments are reported at fair value. The majority of UAB's investment portfolio is invested in separate investment pools sponsored by the System. Fair value for the investment pools is provided by the System, based on the fair value of the underlying investment securities held by each investment pool. Fair value of the underlying securities held in each investment pool is based on quoted market prices or dealer quotes, where available, or determined using net asset values provided by underlying investment partnerships or companies. Fair value for equity securities, debt securities, mutual funds and U.S. government and agency obligations held by UAB is

determined from quoted market prices or market prices of similar instruments. Real estate held as investments is reported at fair value based upon appraisals, acquisition value at the date of donation, and other valuations typically based on management assumptions or expectations. Investments received by gift are reported at fair value at date of receipt. Net investment income, including realized and unrealized gains and losses, is reported as nonoperating revenues (expenses) in the statements of revenues, expenses, and changes in net position.

Investments are reported in four categories in the statement of net position. Investments recorded as endowment and life income investments are those invested funds that cannot be used to fund current operations and thus are included in noncurrent assets. Investments held for future capital projects are included in noncurrent assets. Other long-term investments include amounts resulting from UAB's equity investment in other entities, as discussed in Note 4 and Note 8. All other investments are included as short-term investments.

**Inventories:** Inventories are carried at the lower of cost or market. Inventories consist primarily of medical supplies and pharmaceuticals.

**Accounts receivable:** Accounts receivable consist primarily of patient receivables, tuition charged to students and amounts due from federal, state, and local governments, or private sources, in connection with reimbursement of allowable expenditures made pursuant to UAB's contracts and grants.

Capital assets: All capital assets are carried at cost on date of acquisition (or in the case of gifts, at acquisition value on the date of donation), less accumulated depreciation (or in the case of assets leased under capital leases, net of accumulated amortization). UAB computes depreciation for buildings and building improvements (15-40 years) and for fixed equipment systems (3-20 years) using a component method. Depreciation of land improvements (40 years), library collection (10 years), and inventoried equipment (3-20 years) is computed on a straight-line basis. The Hospital uses guidelines established by the American Hospital Association to assign useful lives to inventoried equipment.

Capital assets acquired under capital leases are amortized over the shorter of the lives of the respective leases or the estimated useful lives of the assets. Capital assets acquired through federal grants and contracts in which the Federal government retains a reversionary interest are capitalized and depreciated. Interest costs, net of any related investment earnings, for certain assets acquired with the proceeds of tax-exempt borrowings are capitalized as a component of the cost of acquiring those assets.

Computer software capitalization, which is included as inventoried equipment, includes the costs of software and implementation. Implementation costs include consulting

expenses and allocation of internal salaries and fringes for the core implementation team.

**Pledges:** UAB receives gift pledges and bequests of financial support. Revenue is recognized when a pledge representing an unconditional promise to give is received and all eligibility requirements, including time requirements, have been met. In the absence of such a promise, revenue is recognized when the gift is received. Pledges are recorded at their gross, undiscounted amount. Endowment pledges do not meet eligibility requirements and are not recorded as assets until the related gift is received in accordance with the requirements of GASB Statement No. 33, Accounting and Financial Reporting for Nonexchange Transactions. Due to uncertainties with regard to their realization and valuation, bequest intentions and other conditional promises are not recognized as assets until the specified conditions are met.

Endowment spending: The State Legislature adopted the Alabama Uniform Prudent Management of Institutional Funds Act (UPMIFA), effective January 1, 2009, which permits the Board of Trustees of the University of Alabama (the "Board") to appropriate an amount of realized and unrealized endowment appreciation as the Board determines to be prudent. UPMIFA prescribes guidelines for the expenditure of donor-restricted endowment funds in the absence of overriding, explicit donor stipulations. UPMIFA focuses on the entirety of a donor-restricted endowment fund, that is, both the original gift amount(s) and net appreciation. UPMIFA eliminates UMIFA's historicdollar-value threshold, an amount below which an organization could not spend from the fund, in favor of a more robust set of guidelines about what constitutes prudent spending, explicitly requiring consideration of the duration and preservation of the fund.

UAB's policy is to retain the endowment realized and unrealized appreciation within an endowment after the spending rate distributions in a manner consistent with the standards of prudence prescribed by UPMIFA. The Board approved a spending rate for fiscal years September 30, 2019 and 2018 of 4.5%, based on a moving five-year average of the market (unit) value, and return of gains for underwater endowments.

Prepaid Expenses and Unearned Scholarships: Prepaid expenses are composed of future expenses that have been paid in advance and include prepaid postage, travel, and other miscellaneous expenses. Unearned scholarship expense results from the Fall academic term spanning across the fiscal year-end. UAB prorates scholarship expense to recognize only the amounts incurred in each fiscal year.

**Unearned revenue:** Unearned revenue consists primarily of student fees related predominantly to future fiscal years and amounts received from grant and contract sponsors that have not yet been earned under the terms of the agreements and, therefore, have not yet been included in the net position.

Federal refundable loans: Certain loans to students are administered by UAB with funding primarily supported by the federal government. UAB's statements of net position include both the notes receivable and the related federal refundable loan liability representing federal capital contributions and related activity owed upon termination of the program. The Federal Perkins Loan Program expired June 30, 2018. The University will continue operating the program and remit any excess cash annually for the pro rata federal and institutional capital contributions. As of September 30, 2019, \$1.7 million is payable to the Department of Education for its portion of the excess cash available at June 30, 2019.

**Compensated absences:** UAB accrues annual leave for employees at rates based upon length of service and job classification. UAB accrues compensatory time based upon job classification and hours worked. These amounts are included in accounts payable and accrued liabilities.

Deferred Outflows of Resources: Deferred outflows of resources consist of bond deferred refunding amounts, pension obligations, and OPEB obligations (Trust and UAB Plan). Pension obligations include employer contributions to the Teachers' Retirement System subsequent to the Plan's measurement date, differences between expected and actual experience, and changes in actuarial and other assumptions. The Trust's obligations include employer contributions to the Alabama Retired Education Employees' Health Care Trust subsequent to the Trust's measurement date, differences between expected and actual experience, and changes in proportion and differences between employer contributions and proportionate share of contributions. The UAB Plan's obligations include employer contributions to the UAB Health Care Plan subsequent to the Plan's measurement date for eligible disabled retirees.

Deferred Inflows of Resources: Deferred inflows of resources are composed of bond deferred refunding amounts, pension obligations, and OPEB obligations (Trust and UAB Plan). Pension obligations include differences between expected and actual experience, changes in proportion differences between contributions and proportionate share of contributions, and net difference between projected and actual earnings on pension plan investments. The Trust's obligations include changes in actuarial and other assumptions and net difference between projected and actual earnings on OPEB plan investments. The UAB Plan's obligations include differences between expected and actual experience and changes in actuarial and other assumptions.

Student tuition and fees and Scholarship Allowances and Student Aid: Student tuition and fees are presented net of scholarships and fellowships applied to student accounts, while stipends and other payments made directly to students are presented as scholarships and fellowships expense.

**Grant and contract revenue:** UAB receives grant and contract revenue from governmental and private sources. UAB recognizes revenue associated with the sponsored programs in accordance with GASB Statement No. 33, based on the terms of the individual grant or contract.

Hospital revenue: Net patient service revenue is reported at the Hospital's estimated net realizable amounts from patients, third-party payors, and others for services rendered, including estimated retroactive revenue adjustments due to revenue audits, reviews, and investigations. Retroactive adjustments are considered in the recognition of revenue on an estimated basis in the period the related services are rendered.

The Hospital provides care to patients who meet certain criteria under its charity care policy without charge or at amounts less than its estimated rates. Because the Hospital does not pursue collection of amounts determined to qualify as charity care, they are not reported as revenue.

**Auxiliary enterprise revenue:** Auxiliary enterprise revenues primarily represent revenues generated by intercollegiate athletics and parking as well as subscriber premiums for Triton Health Systems LLC.

**Other revenue:** Other revenue represents primarily revenues generated by UAB for activities such as intellectual property income and the University of Alabama Health Services Foundation, P.C. (HSF) transfers.

**Equity investments:** Investments in affiliated companies where UAB can exercise significant influence and for which UAB's ownership interest is 50% or less are accounted for using the equity method. The investment in the Professional Liability Trust Fund (PLTF) also is accounted for using the equity method. See Notes 4 and 8.

**Nonoperating revenues (expenses):** Nonoperating revenues and expenses include State educational appropriations, Federal Pell grants, private gifts for other than capital purposes, investment income, net unrealized appreciation or depreciation in the fair value of investments, interest expense, and loss on asset dispositions.

Events subsequent to original issuance of financial statements (Unaudited): In January 2020, the World Health Organization declared the novel Coronavirus (COVID-19) a Public Health Emergency of International Concern. The outbreak of COVID-19 has caused domestic and global disruption in operations for institutions of higher education and health care providers. The outbreak has also negatively impacted both the global financial markets and UAB's investments, including the investments held within the System Pools, and may continue to do so. Other adverse consequences of COVID-19 in the future may include, but are not limited to, decline in enrollment, decline in demand for UAB housing, decline in demand for UAB programs that involve travel, additional volatility within the UAB's investments, and the rescheduling of elective or non-critical medical procedures. UAB believes it has sufficient liquidity to meet its operating and financing needs; however, given the difficulty in predicting the ultimate duration and severity of the impact of COVID-19 on UAB, the economy and the financial markets, the ultimate impact is unknown and cannot be reasonably quantified at this time.

# (2) Component Unit(s)

GASB Statement No. 14, The Financial Reporting Entity, as amended by GASB Statement No. 39, Determining Whether Certain Organizations are Component Units – an Amendment of GASB Statement No. 14, No. 61, The Financial Reporting Entity – an Amendment of GASB Statement No. 14 and 34 and No. 80, Blending Requirements for Certain Component Units – an amendment of GASB Statement No. 14, requires governmental entities to include in their financial statements as a component unit, organizations that are legally separate entities for which the governmental entity, as a primary organization, is financially accountable. The primary objective of these statements is to determine whether all entities associated with a primary government are potential component units and should be evaluated for inclusion in the financial reporting entity. The statements as amended provide additional guidance to determine whether certain organizations for which the primary government is not financially accountable should be reported as component units based on the nature and significance of their relationship with the primary government.

The by-laws and corporate charter of the Southern Research Institute (SRI) allow UAB to appoint a majority of the board of directors. Management has determined that SRI is a discretely presented component unit of UAB under GASB Statements No. 14 and No. 61. SRI reports financial results under principles prescribed under the GASB. SRI offers research and technology services to support industry and federal government agencies primarily in the areas of drug design and evaluation, environmental controls, materials engineering, and chemical and biological defense. The activities of SRI are maintained using a fiscal calendar year-end that ends prior to UAB's fiscal year-end of September 30. The financial results of SRI are discretely presented in these financial statements.

UAB includes five blended component units, as follows: UAB Research Foundation (UABRF), UAB Athletics Foundation (UABAF), Alabama Care Plan (ACP), UAB Hospital Management, L.L.C. (LLC) and Triton Health Systems, L.L.C. (Triton). The by-laws and corporate charters of UABRF allow UAB to appoint a majority of the board of directors and allow UAB to impose its will on the entity. UABRF operates for the exclusive benefit of UAB. UABAF was organized to support the UAB Athletics Department in its quest for excellence in all programs. UABAF operates as an extension of the UAB Athletics Department and it almost exclusively benefits the University. The by- laws of ACP

allow UAB to appoint a majority of the members of the Member Board, as defined, which operates in a consultory capacity with the ACP Board of Directors. The by-laws allow the ACP Member Board certain operational and financial protective rights. Additionally, Triton and LLC have governing bodies that are substantively the same as the governing body of UAB and there is a financial benefit or burden relationship between UAB and these entities. Therefore, management has determined that UABRF, UABAF, ACP, LLC and Triton (the Blended Component Units) constitute blended component units of UAB under GASB Statements No. 14 and No. 61. The Blended Component Units report financial results under principles prescribed under the GASB.

UABRF was organized exclusively for charitable, scientific, and educational purposes in order to benefit UAB. UABAF was formed in November 2015 as a nonprofit corporation organized to build loyalty and philanthropic support for the UAB athletic program and support the staff in coordinating, developing and improving a superior inter-collegiate athletics program. UABAF encourages alumni and friends to generously support the Athletics Department and contribute to scholarship funding for UAB's student athletes. ACP was formed in September 2014 to apply to become certified by the Alabama Medicaid Agency as a probationary regional care organization (RCO), with the goal at the time of being eligible to become a fully certified RCO by July 1, 2017. Effective October 17, 2016, ACP resolved to cease its

pursuit of full regional care organization certification from the Alabama Medicaid Agency and cease efforts to enter into a risk contract with Medicaid to provide RCO services to Medicaid beneficiaries. On July 27, 2017, the Alabama Medicaid Agency abandoned its development of regional care organizations. The current Alabama Medicaid Health Home program will end on September 30, 2019 and the new Medicaid program Alabama Coordinated Health Network (ACHN), will begin October 1, 2019. members are the University of Alabama Hospital, St. Vincent's Health System and Triton. Triton was formed to advance the educational and research mission of UAB and to educate and train physicians and other health care professionals. Triton is owned 99% by UAB and 1% by The UABEF. The LLC was organized for the exclusive purpose of supporting UAB in connection with the management, administration, and operation of the Hospital, including, without limitation, providing management, administrative, and staffing services to the Hospital. UABRF, ACP and LLC maintain a September 30 year-end. UABAF maintains a June 30 year-end. The activities of Triton are maintained using a fiscal calendar year-end that ends prior to UAB's fiscal year-end of September 30. However, interfund cash transactions during the period from January 1 through September 30 have been eliminated. Since Triton qualifies as a major component unit under GASB Statement No. 61, financial information for the years ended December 31, 2018 and 2017 is presented as follows:

TRITON HEALTH SYSTEMS, LLC		2019	2018
CONDENSED STATEMENT OF NET POSITION			
Current assets	\$	238,243,098	\$ 234,179,153
Capital assets, net		4,242,844	2,747,841
Other assets		115,104,269	103,915,226
TOTAL ASSETS		357,590,211	340,842,220
Current liabilities		101,474,939	115,545,528
Other noncurrent liabilities		1,169,296	1,250,612
TOTAL LIABILITIES		102,644,235	116,796,140
Net investment in capital assets		4,242,844	2,747,841
Restricted nonexpendable		100,000	100,000
Unrestricted		250,603,132	221,198,239
TOTAL NET POSITION		254,945,976	224,046,080
TOTAL LIABILITIES AND NET POSITION	\$	357,590,211	\$ 340,842,220
CONDENSED STATEMENT OF REVENUES, EXPENSES AND CHANGES IN NET POSITION  Operating revenues Operating expenses Depreciation and amortization expense OPERATING INCOME Investment income	\$	760,532,147 (709,709,115) (955,707) <b>49,867,325</b> 3,426,512	\$ 736,180,155 (675,366,070) (1,232,394) <b>59,581,691</b> 502,257
Interest expense		(200)	(7.202.402)
Income tax benefit (expense)  INCOME BEFORE OTHER CHANGES IN NET POSITION		(3,698,885) <b>49,594,752</b>	 (7,382,182) <b>52,701,766</b>
Distributions to members		(18,694,856)	 (37,660,354)
INCREASE IN NET POSITION		30,899,896	15,041,412
Net position, beginning of year		224,046,080	 209,004,668
NET POSITION, END OF YEAR	<u>\$</u>	254,945,976	\$ 224,046,080
CONDENSED STATEMENT OF CASH FLOWS			
Net cash provided by (used in): Operating activities	\$	20,705,580	\$ 70,689,345
Noncapital financing activities		(18,694,856)	(37,660,354)
Capital and related financing activities		(2,450,710)	(208,777)
Investing activities		(16,453,527)	 (102,478,582)
NET (DECREASE) IN CASH AND CASH EQUIVALENTS		(16,893,513)	(69,658,368)
Cash and cash equivalents, beginning of year		187,920,412	257,578,780
CASH AND CASH EQUIVALENTS, END OF YEAR	\$	171,026,899	\$ 187,920,412

# (3) Cash and Cash Equivalents

The Board approves, by resolution, all banks or other financial institutions utilized as depositories for UAB funds. Prior to approval, each proposed depository must provide evidence of its designation by the Alabama state treasurer as a qualified public depository under the Security for Alabama Funds Enhancement Act (SAFE). From time to time, the Board may request that the depository provide evidence of its continuing designation as a qualified public depository. In the past, the bank pledged collateral directly to each individual public entity. Under the mandatory SAFE program, each qualified public depository (QPD) is required to hold collateral for all its public deposits on a pooled basis in a custody account established for the State Treasurer as SAFE administrator. In the unlikely event a public entity should suffer a deposit loss due to QPD insolvency or default, a claim form would be filed with the state treasurer. who would use the SAFE pool collateral or other means to reimburse the loss. As of September 30, 2019 and 2018, respectively, UAB had cash and cash equivalents totaling \$522.5 million and \$354.9 million.

# (4) Investments

The Board has the responsibility for the establishment of the investment policy and the oversight of the investments for the System and related entities. In order to facilitate System-wide investment objectives and achieve economies of scale, the Board has established three distinct investment pools based primarily on the projected investment timehorizons for System funds. These investment pools are the Pooled Endowment Fund, Long Term Reserve Pool Fund and the Short Term Liquidity Pool Fund (collectively, the "System Pools"). Pursuant to Board investment policies, each System or related entity may include all or a portion of their investments within the System sponsored investment pools. These investment funds are considered 'internal' investment pools under GASB Statement No. 31, Accounting and Financial Reporting for Certain Investments and for External Investment Pools with the assets pooled on a market value basis. Separately managed funds that reside with each entity are to be invested consistent with the asset mix of the corresponding System investment pool.

UAB applies the same investment policies for separately held investments as those of the System Pools.

The following disclosures relate to both the System Pools, which include the investments of other System entities and other affiliated entities, and the UAB-specific investment portfolio.

#### **Pooled Endowment Fund**

The purpose of the Pooled Endowment Fund (PEF) is to pool endowment and similar funds to support the System universities, the Hospital and related entities in carrying out their respective missions over a perpetual time frame. Accordingly, the primary investment objectives of the PEF are to preserve the purchasing power of the principal and provide a stable source of perpetual financial support to the endowment beneficiaries. To satisfy the long-term rate of return objective, the PEF relies on a total return strategy in which investment returns are achieved through both capital appreciation and natural income. Asset allocation targets are established to meet return objectives while providing adequate diversification in order to minimize investment volatility.

### **Long Term Reserve Pool Fund**

The Long Term Reserve Pool Fund (LTRP) is a longer-term pool used as an investment vehicle to manage operating reserves with a time horizon of three to seven years. This fund has an investment objective of growth and income and is invested in a diversified asset mix of liquid, semiliquid and illiquid securities. This fund can invest no more than 10% in illiquid assets.

#### **Short Term Liquidity Pool Fund**

The Short Term Liquidity Pool Fund (STLP) serves as an investment vehicle to manage operating reserves with a time horizon of one to three years. This fund is also used to balance the other funds when looking at the System's entire asset allocation of operating reserves relative to its investment objectives. The STLP has an investment objective of income with preservation of capital and is invested in intermediate term fixed income securities. The fund holds at least one large mutual fund to provide daily liquidity.

### Fair Value Measurements

GASB 72 sets forth the framework for measuring fair value. That framework provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy under GASB 72 are described as follows:

- Level 1 Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets that UAB has the ability to access.
- Level 2 Inputs to the valuation methodology include:
  - Quoted prices for similar assets or liabilities in active markets;
  - Quoted prices for identical or similar assets or liabilities in inactive markets;
  - Inputs other than quoted prices that are observable for the assets or liabilities;

- Inputs that are derived principally from or corroborated by observable market data by correlation or other means.
- Level 3 Inputs to the valuation methodology are unobservable and significant to the fair value measurement. Unobservable inputs reflect UAB's own assumptions about the inputs market participants would use in pricing the asset or liability (including assumptions about risk). Unobservable inputs are developed based on the best information available in the circumstances and may include UAB's own data.

GASB 72 allows for the use of net asset value ("NAV") as a practical expedient for valuation purposes for investment that do not have readily determinable fair value. Investments that use NAV in determining fair value are disclosed separately from the valuation hierarchy as presented herein.

The level within the hierarchy is based on the lowest level of input that is significant to the fair value measurement. Valuation techniques used need to maximize the use of observable inputs and minimize the use of unobservable inputs.

The determination of what constitutes observable requires judgment by UAB's management. UAB management considers observable data to be that market data which is readily available, regularly distributed or updated, reliable, and verifiable, not proprietary, and provided by multiple independent sources that are actively involved in the relevant market.

The categorization of an investment within the hierarchy is based upon the relative observability of the inputs to its fair value measurement and does not necessarily correspond to UAB management's perceived risk of that investment.

The following is a description of the valuation methods and assumptions used by UAB to estimate the fair value of its

investments. There have been no changes in the methods and assumptions used at September 30, 2019. The methods described may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. UAB management believes its valuation methods are appropriate and consistent with other market participants. The use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.

When available, quoted prices are used to determine fair value. When quoted prices in active markets are available, investments are classified within Level 1 of the fair value hierarchy. UAB's Level 1 investments primarily consist of investments in mutual funds, exchange traded funds, and both domestic and foreign equity funds. When quoted prices in active markets are not available, fair values are based on evaluated prices received from UAB's custodian of investments.

UAB's Level 2 investments consist of mutual funds that are priced or traded at the end of the day.

UAB's Level 3 investments primarily consist of very illiquid securities. The inputs or methodologies used for valuing securities are not necessarily an indication of the risks associated with investing in those securities. Changes in valuation techniques may result in transfers into or out of an assigned level within the disclosure hierarchy. Valuation techniques utilized by UAB are appraisals, entry price at the date of donation, and other valuations typically based on management assumptions or expectations.

At September 30, 2019 and 2018, the fair value of UAB's investments based on the inputs used to value them is summarized as follows:

	Level 1		2019 Level 2		Level 3	NAV	Total
Cash and equivalents: Commercial paper	\$ 100,000	\$	_	\$	-	\$ -	\$ 100,000
Equities: Common Stock	371,776		-		-	-	371,776
Fixed Income Securities: U.S. Government Obligations Corporate bonds	_ _		— 136,048,332		_ 	_ _ _	— 136,048,332
Commingled Funds: U.S. equity funds Non-U.S. equity funds	_ _		1,197,867 278,220		_ _ _	_ _ _	1,197,867 278,220
Real Estate	 	_		_	159,600		 159,600
	\$ 471,776	\$	137,524,419				\$ 138,155,795 60,291,989
					 	ystem Pool Investments: Endowment Fund Long Term Reserve Pool Short Term Liquidity Pool	538,535,105 1,347,111,275 538,920,294
			Tota	ΙN	let Asset Value with Sys	tem Pooled Investments	\$ 2,623,014,458

	Level 1	2018 Level 2		Level 3	NAV	Total
Cash and equivalents: Commercial paper	\$ 100,000	\$ _	\$	_	\$ -	\$ 100,000
Equities: Common Stock	371,611	_		_	-	371,611
Fixed Income Securities: U.S. Government Obligations Corporate bonds	_	8,941,395 116,369,065		_ _	_	8,941,395 116,369,065
Comminaled Funds: U.S. equity funds Non-U.S. equity funds	_ _	1,023,218		_ _	_ _	1,023,218
Real Estate	\$ <u> </u>	\$ 126,692,264	\$	159.600 159,600	<u> </u>	\$ 159.600 127,323,475
				Equity inve	estments in partnerships	67,279,238
		Tota	ıl Ne	l S	ystem Pool Investments: Endowment Fund Ong Term Reserve Pool short Term Liquidity Pool tem Pooled Investments	\$ 525,298,896 1,252,655,537 530,975,765 <b>2,503,532,911</b>

At September 30, 2019 and 2018, the fair value of investments for the System Pools based on the inputs used to value them is summarized as follows:

	POO	OLED ENDOWMENT FU	IND		
		2019			
Receivables:	Level 1	Level 2	Level 3	NAV	Total
Accrued Income Receivables	\$ _	\$ -	\$ -	\$ -	\$ 794.850
Total Receivables				_	794,850
Cash Equivalents:					
Money Market Funds	45,659,810				45,659,810
Total Cash Equivalents	45,659,810	<u>-</u>			45,659,810
Equities:					
U.S. Common Stock	74,012,517	_	_	_	74,012,517
U.S. Preferred Stock	190,932	_	_	_	190,932
Foreign Stock	32,734,298				32,734,298
Total Equities	106,937,747				106,937,747
Fixed Income Securities:					
U.S. Government Obligations	-	9,526,821	-	-	9,526,821
Mortgage Backed Securities	_	16,998,880	_	_	16,998,880
Corporate Bonds	_	23,590,299	_	_	23,590,299
Non-U.S. Bonds		4,633,620			4,633,620
Total Fixed Income Securities		54,749,620			54,749,620
Commingled Funds:					
Non-U.S. Equity Funds	_	230,373,319	_	_	230,373,319
U.S. Bond Funds	_	53,608,300	_	_	53,608,300
Hedge Funds	_	_	_	476,844,586	476,844,586
Private Equity Funds	_	_	_	183,800,862	183,800,862
Real Asset Funds			28.480.271	312.302.228	340.782.499
Total Commingled Funds		283,981,619	28,480,271	972,947,676	1,285,409,566
Total Fund Investments	152,597,557	338,731,239	28,480,271	972,947,676	1,492,756,743
Total Fund Assets	\$ 152.597.557	\$ 338.731.239	\$ 28.480.271	\$ 972.947.676	\$ 1,493,551,593
Total Fund Liabilities					(283,955)
Affiliated Entity Investments					(237,774,790)
Total Net Asset Value					\$ 1,255,492,848

	POO	OLED ENDOWMENT FU	IND		
		2018			
	Level 1	Level 2	Level 3	NAV	Total
Receivables:					
Accrued Income Receivables	_\$	<u>\$</u>	_\$	_\$	\$ 941,965
Total Receivables					941,965
Cash Equivalents:					
Money Market Funds	48.621.460				48.621,460
Total Cash Equivalents	48,621,460				48.621.460
Equities:					
U.S. Common Stock	134,722,061	_	_	_	134,722,061
U.S. Preferred Stock	271,458	_	_	_	271,458
Foreign Stock	38,697,223				38,697,223
Total Equities	173,690,742				173,690,742
Fixed Income Securities:					
U.S. Government Obligations	_	8,197,916	_	_	8,197,916
Mortgage Backed Securities	_	14,232,582	_	_	14,232,582
Corporate Bonds	_	28,446,907	_	_	28,446,907
Non-U.S. Bonds		3,257,623			3,257,623
Total Fixed Income Securities		54,135,028			54,135,028
Commingled Funds:					
Non-U.S. Equity Funds	_	227,695,748	_	_	227,695,748
U.S. Bond Funds	_	56,400,000	_	_	56,400,000
Non-U.S. Bond Funds	_	27,184,600	_	_	27,184,600
Hedge Funds	_	_	_	429,859,604	429,859,604
Private Equity Funds	_	_	_	144,709,192	144,709,192
Real Asset Funds	<u>=</u>		15,904,425	305,862,240	321,766,665
Total Commingled Funds		311,280,348	15,904,425	880,431,036	1,207,615,809
Total Fund Investments	222,312,202	365,415,376	15,904,425	880,431,036	1,484,063,039
Total Fund Assets	\$ 222,312,202	\$ 365,415,376	\$ 15,904,425		
Total Fund Liabilities					(281,027)
Affiliated Entity Investments					(238,893,599)
Total Net Asset Value					\$ 1.245.830.378

	LONG	TERM RESERVE POOL	FUND		
		2019			
	Level 1	Level 2	Level 3	NAV	Total
Receivables:					
Accrued Income Receivables	<u>\$</u>	_\$	<u>\$</u>	<u>\$</u>	\$ 1,432,688
Total Receivables					1,432,688
Cash Equivalents:					
Money Market Funds	67,436,949				67,436,949
Total Cash Equivalents	67,436,949				67,436,949
Equities:					
U.S. Common Stock	176,170,860	_	_	_	176,170,860
U.S. Preferred Stock	376,551	_	_	_	376,551
Foreign Stock	60,626,225				60,626,225
Total Equities	237,173,636				237,173,636
Fixed Income Securities:					
U.S. Government Obligations	_	17,123,633	_	_	17,123,633
Mortgage Backed Securities	_	28,505,448	_	_	28,505,448
Corporate Bonds	_	43.571.551	_	_	43,571,551
Non-U.S. Bonds	<u>-</u> _	8.045.325			8.045.325
Total Fixed Income Securities		97.245.957			97.245.957
Commingled Funds:					
U.S. Equity Funds	_	80,732,164	_	_	80,732,164
Non-U.S. Equity Funds	_	443,683,561	_	_	443,683,561
U.S. Bond Funds	_	91,511,322	_	_	91,511,322
Non-U.S. Bond Funds	_	41,238,753	_	_	41,238,753
Hedge Funds	_	_	-	718,659,741	718,659,741
Real Asset Funds				194,011,040	194,011,040
Total Commingled Funds		657,165,800		912,670,781	1,569,836,581
Total Fund Investments	304,610,585	754,411,757	_	912,670,781	1,971,693,123
Total Fund Assets	\$ 304.610.585	<u>\$ 754.411.757</u>	<u> </u>	\$ 912.670.781	\$ 1,973,125,811
Total Fund Liabilities					(503,247)
Affiliated Entity Investments					(132,196,336)
Total Net Asset Value					\$ 1,840,426,228

	LONG	TERM RESERVE POOL	FUND		
		2018			
	Level 1	Level 2	Level 3	NAV	Total
Receivables:					
Accrued Income Receivables	_\$	_\$	_\$	\$	
Total Receivables					1,525,275
Cash Equivalents:					
Money Market Funds	100,476,683				100,476,683
Total Cash Equivalents	100,476,683				100,476,683
Equities:					
U.S. Common Stock	242,196,226	_	_	_	242,196,226
U.S. Preferred Stock	407,187	_	_	_	407.187
Foreign Stock	55,465,296				55,465,296
Total Equities	298.068.709				298,068,709
Fixed Income Securities:					
U.S. Government Obligations	_	12,738,159	_	_	12,738,159
Mortgage Backed Securities	_	21,717,846	_	_	21,717,846
Corporate Bonds	_	42,659,327	_	_	42,659,327
Non-U.S. Bonds		5,164,476			5,164,476
Total Fixed Income Securities		82,279,808			82,279,808
Commingled Funds:					
U.S. Equity Funds	_	67,935,522	_	_	67,935,522
Non-U.S. Equity Funds	_	404,044,223	_	_	404,044,223
U.S. Bond Funds	_	79,990,055	_	_	79,990,055
Non-U.S. Bond Funds	_	44,052,238	_	_	44,052,238
Hedge Funds	_	_	_	619,443,622	619,443,622
Real Asset Funds				200,220,778	200.220.778
Total Commingled Funds		596,022,038		819,664,400	1,415,686,438
Total Fund Investments	398,545,392	678,301,846	_	819,664,400	1,896,511,638
Total Fund Assets	\$ 398,545,392	\$ 678,301,846	<u>\$</u> _	\$ 819,664,400	\$ 1,898,036,913
Total Fund Liabilities					(460.596)
Affiliated Entity Investments					(134,087,788)
Total Net Asset Value					\$ 1,763,488,529

	SHORI	TERM LIQUIDITY POOL 2019	FUND		
	Level 1	Level 2	Level 3	NAV	TOTAL
Receivables: Accrued Income Receivables Total Receivables	\$ <u> </u>	\$ <u> </u>	\$ - -	- \$	\$ 3,481,503 3,481,503
Cash Equivalents: Money Market Funds <b>Total Cash Equivalents</b>	77,781,811 <b>77,781,811</b>			<u> </u>	77,781,811 77,781,811
Fixed Income Securities: U.S. Government Obligations Mortgage Backed Securities Collateralized Mortgage Obligations Corporate Bonds Non-U.S. Bonds Total Fixed Income Securities	- - - - - -	106.695.991 256.770.944 18.530.989 149.581.841 66.304.810 <b>597.884.575</b>	- - - - -		106.695.991 256.770.944 18.530.989 149.581.841 66.304.810 <b>597.884.575</b>
Commingled Funds: U.S. Bond Funds Total Commingled Funds Total Fund Investments Total Fund Assets		185,315,252 185,315,252 783,199,827 \$ 783,199,827			185,315,252 185,315,252 860,981,638 \$ 864,463,141
Total Fund Liabilities  Affiliated Entity Investments  Total Net Asset Value					(286,331) (100,903,160) \$ 763,273,650

	SHORT	TERM LIQUIDITY POO	L FUND		
	Level 1	Level 2	Level 3	NAV	Total
Receivables: Accrued Income Receivables Total Receivables	\$ <u> </u>			\$	\$ 3,378,475 3,378,475
Cash Equivalents: Money Market Funds Total Cash Equivalents	127,128,864 127,128,864				127,128,864 127,128,864
Fixed Income Securities: U.S. Government Obligations Mortaage Backed Securities Collateralized Mortgage Obligations Corporate Bonds Non-U.S. Bonds Total Fixed Income Securities	- - - - -	179.984.745 175.661.110 14.788.045 141.942.756 54.274.651 566.651,307	- - - - -		179.984,745 175.661,110 14.788.045 141.942.756 54.274.651 566.651,307
Commingled Funds: U.S. Bond Funds Total Commingled Funds Total Fund Investments	127,128,864	134,060,134 134,060,134 700,711,441			134,060,134 134,060,134 827,840,305
Total Fund Assets  Total Fund Liabilities  Affiliated Entity Investments	<u>\$ 127.128.864</u>	\$ 700.711.441	<u>\$ —</u>	<u>\$ —</u>	\$ 831,218,780 (277,839) (80,413,846)
Total Net Asset Value					\$ 750,527,095

Additional information on fair values, unfunded commitments, remaining life, and redemption for investments measured at the NAV for the System Pools at September 30, 2019 and 2018 is as follows:

POOLED ENDOWMENT FUND 2019									
	Fair Value			Remaining Life	Redemption Notice Period	Redemption Restrictions			
\$	476,844,586	\$	-	No limit	Monthly,Quarterly, and Annually	Lock-up provisions ranging from none to 2 years			
	183,800,862		151,340,710	1-10 years	Partnerships ineligible for redemption	Not redeemable			
	147,852,025		_	No limit	Monthly and Quarterly	None			
	164,450,203		99,981,416	1-15 years	Partnerships ineligible for redemption	Not redeemable			
		183,800,862 147,852,025	\$ 476,844,586 \$ 183,800,862 147,852,025	Fair Value     Unfunded Commitments       \$ 476,844,586     \$ —       183,800,862     151,340,710       147,852,025     —	Fair Value         Unfunded Commitments         Remaining Life           \$ 476,844,586         \$ — No limit           183,800,862         151,340,710         1-10 years           147,852,025         — No limit	Fair Value  Unfunded Commitments  Remaining Life  Redemption Notice Period  \$ 476,844,586 \$ — No limit  Monthly, Quarterly, and Annually  Partnerships ineligible for redemption  147,852,025 — No limit  Monthly and Quarterly  Partnerships ineligible for redemption  147,852,025 — No limit  Monthly and Quarterly  Partnerships ineligible for			

POOLED ENDOWMENT FUND  2018										
		Fair Value		Unfunded Commitments	Remaining Life	Redemption Notice Period	Redemption Restrictions			
Hedge funds - absolute return, credit, long/short equities	\$	429,859,604	\$	_	No limit	Monthly,Quarterly, and Annually	Lock-up provisions ranging from none to 2 years			
Private equity - private credit, buyouts, venture, secondary		144,709,192		112,546,521	1-10 years	Partnerships ineligible for redemption	Not redeemable			
Real assets - public natural resources, real estate, and infrastructure		152,056,360		_	No limit	Monthly and Quarterly	None			
Real assets - private real estate, natural resources, and infrastructure		153,805,880		64,559,680	1-15 years	Partnerships ineligible for redemption	Not redeemable			
	\$	880,431,036	\$	177,106,201						

	 LC	NG TE	RM RESERVE POO	L FUND		
			2019			
	 Fair Value		Unfunded Commitments	Remaining Life	Redemption Notice Period	Redemption Restrictions
Hedge funds - absolute return, credit, long/short equities	\$ 718,659,741	\$	_	No limit	Monthly,Quarterly, and Annually	Lock-up provisions ranging from none to 2 years
Real assets - public real estate, natural resources, and infrastructure	194,011,040		_	No limit	Monthly and Quarterly	None
	\$ 912,670,781	\$	_			

	 LC	NG	TERM RESERVE POO	L FUND		
			2018			
	Fair Value		Unfunded Commitments	Remaining Life	Redemption Notice Period	Redemption Restrictions
Hedge funds - absolute return, credit, long/short equities	\$ 619,443,622	\$	_	No limit	Monthly,Quarterly, and Annually	Lock-up provisions ranging from none to 2 years
Real assets - public real estate, natural resources, and infrastructure	200,211,837		_	No limit	Monthly and Quarterly	None
Real assets - private real estate, natural resources, and infrastructure	8,941		_	1-10 years	Partnerships ineligible for redemption	Not redeemable
	\$ 819,664,400	\$	_			

### **Investment Risk Factors**

There are many factors that can affect the value of investments. Some, such as custodial credit risk, concentration of credit risk and foreign currency risk, may affect both equity and fixed income securities. Equity securities respond to such factors as economic conditions, individual company earnings performance and market liquidity, while fixed income securities are particularly sensitive to credit risks and changes in interest rates.

#### **Credit Risk**

Fixed income securities are subject to credit risk, which is the chance that a bond issuer will fail to pay interest or principal in a timely manner, or that negative perceptions of the issuer's ability to make these payments will cause security prices to decline. These circumstances may arise due to a variety of factors such as financial weakness, bankruptcy, litigation, and/or adverse political developments. Certain fixed income securities, primarily obligations of the U.S. government or those explicitly guaranteed by the U.S. government, are not considered to have significant credit risk.

A bond's credit quality is an assessment of the issuer's ability to pay interest on the bond, and ultimately, to pay the principal. Credit quality is evaluated by one of the independent bond-rating agencies, for example Moody's Investors Service ("Moody's") or Standard and Poor's ("S&P"). The lower the rating, the greater the chance—in the rating agency's opinion—that the bond issuer will default, or fail to meet its payment obligations. Generally, the lower a bond's credit rating, the higher its yield should be to compensate for the additional risk.

Board policy recognizes that a limited amount of credit risk, properly managed and monitored, is prudent and provides incremental risk adjusted return over its benchmark. Credit risk in each investment pool is managed primarily by

diversifying across issuers and limiting the amount of portfolio assets that can be invested in non-investment grade securities. Fixed income holdings in a single entity (excluding obligations of the U.S. government and its agencies) may not exceed 5% of a manager's portfolio measured at market value.

The investment policy recognizes that credit risk is appropriate in balanced investment pools such as the PEF and LTRP, which are tracked against the Barclays U.S. High Yield Index for U.S. investments and the J.P. Morgan Non-U.S. GBI Index for international investments benchmarks for the fixed income portion of these pools. Fixed income investments within the PEF and LTRP include corporate, mortgage backed, and U.S. treasury and/or agency bonds. In addition, approximately \$39.4 million and \$35.2 million in the PEF and LTRP (collectively), at September 30, 2019 and 2018, respectively, is invested in unrated fixed income securities, excluding fixed income commingled funds. Fixed income commingled funds and money market funds were approximately \$299.5 million and \$356.7 million in the PEF and LTRP (collectively), at September 30, 2019 and 2018, respectively.

The STLP is benchmarked against the 1-3 Year Barclays Government Credit Index with funds invested with four separate fund managers. Fixed income investments include corporate, mortgage backed, asset backed, collateralized mortgage and U.S. treasury and/or agency bonds. For September 30, 2019 and 2018, approximately \$173.2 million and \$106 million, respectively, was invested by the STLP in unrated fixed income securities, excluding commingled bond funds, and money market funds. Fixed income commingled funds totaled approximately \$263.1 million and \$261.2 million at September 30, 2019 and 2018, respectively.

The credit risk for fixed and variable income securities, for the System Pools, at September 30, 2019 and 2018 is as follows:

	POOLED END	OWMENT FUND	LONG TERM RES	ERVE POOL FUND	SHORT TERM L	IQUIDITY POOL
	2019	2018	2019	2018	2019	2018
Fixed or Variable Income Securities						
U.S. Government Obligations	\$ 9,526,821	\$ 8,197,916	\$ 17,123,633	\$ 12,738,159	\$ 106,695,991	\$179,984,745
Other U.S. Denominated:						
AAA	1,445,545	779,600	2,399,062	968,280	82,360,918	70,741,960
AA	4,937,086	3,796,225	8,500,014	5,708,359	49,502,664	30,793,835
А	8,922,674	9,462,969	16,639,285	14,112,658	87,465,527	87,893,696
BBB	10,537,413	13,268,623	19,983,283	20,151,133	91,050,594	82,640,685
BB	4,105,601	4,245,245	6,954,906	6,381,065	6,106,262	6,436,205
В	595,375	548,625	963,425	807,975	1,140,474	1,955,776
C and < C	_	_	_	_	343,702	641,329
Unrated	14,679,105	13,835,825	24,682,349	21,412,180	173,218,443	105,563,075
Commingled Funds:						
U.S. Bond Funds: Unrated	53,608,300	56,400,000	91,511,322	79,990,055	185,315,252	134,060,134
Non-U.S. Bond Funds: Unrated	_	27,184,600	41,238,753	44,052,238	_	_
Money Market Funds: Unrated	45,659,810	48,621,460	67,436,949	100,476,683	77,781,811	127,128,864
TOTAL	\$ 154,017,730	\$ 186,341,088	\$ 297,432,981	\$ 306,798,785	\$ 860,981,638	\$ 827,840,304

In accordance with the Board policy disclosed previously, credit risk for UAB's fixed and variable income securities held outside of the System Pools is managed by diversifying across issuers and limiting the amount of portfolio assets that are invested in non-investment grade securities.

The credit risk for fixed and variable income securities of UAB's separately held investments at September 30, 2019 and 2018 is as follows:

	 2019	 2018
Fixed or Variable Income Securities		
U.S. Government Guaranteed	\$ _	\$ 8,941,395
Other U.S. and Non U.S.		
AAA	136,048,332	116,369,065
AA	_	_
А	_	_
BBB	_	_
BB	_	_
В	_	_
CCC	_	_
CC	_	_
Unrated	_	_
Commingled Funds:		
U.S. Bond Funds: Unrated	_	_
Non-U.S. Bond Funds: Unrated	_	_
Money Market Funds: Unrated	_	_
Commercial Paper: Unrated	100,000	100,000
TOTAL	\$ 136,148,332	\$ 125,410,460

### **Custodial Credit Risk**

Custodial credit risk is the risk that in the event of the corporate failure of the custodian, the investment securities may not be returned.

Investment securities in the System Pools and UAB's separately held investments are registered in the Board's name by the custodial bank as an agent for the System. Other types of investments (e.g. open-ended mutual funds, money market funds) represent ownership interests that do not exist in physical or book-entry form. As a result, custodial credit risk is remote.

### **Concentration of Credit Risk**

Concentration of credit risk is the risk associated with a lack of diversification, such as having substantial investments in a few individual issuers, thereby exposing the organization to greater risks resulting from adverse economic, political, regulatory, geographic, or credit developments.

As previously mentioned, credit risk in each investment pool and UAB's separately held portfolio is managed primarily by diversifying across issuers and limiting the amount of portfolio assets that can be invested in non-investment grade securities. As of September 30, 2019 and 2018, there was no investment in a single issuer that represents 5% or more of total investments held by any single investment manager of the System Pools or UAB's separately held

investment portfolio except for investments issued by the U.S. government and money market fund investments.

### **Interest Rate Risk**

Interest rate risk is the risk that the value of fixed income securities will decline because of changing interest rates. The prices of fixed income securities with a longer time to maturity, measured by effective duration, tend to be more sensitive to changes in interest rates and, therefore, more volatile than those with shorter durations. Effective duration is the approximate change in price of a security resulting from a 100 basis point (1 percentage point) change in the

level of interest rates. It is not a measure of time. The Board does not have a specific policy relative to interest rate risk. As such, there are no restrictions on weighted average maturity for each investment pool as they are managed relative to the investment objectives and liquidity demands of the investors.

The information presented does not take into account the relative weighting of the portfolio components to the total investment pool. The effective durations in years for fixed or variable income securities, for the System Pools at September 30, 2019 and 2018 are as follows:

_	POOLED ENDOWMENT FUND		LONG TERM RESE	RVE POOL FUND	SHORT TERM LIQUIDITY POOL			
_	2019	2018	2019	2018	2019	2018		
U.S. Government Obligations	9.2	11.3	9.2	11.2	2.1	2.0		
Corporate Bonds	6.3	5.2	6.3	5.1	1.8	1.8		
Non-US Bonds	6.3	5.2	6.3	5.1	1.8	1.8		
Commingled Bond Funds	3.6	2.4	2.0	2.3	2.7	2.7		

While the Board does not have a specific policy relative to interest rate risk, UAB has historically invested funds outside of the investment pools in fixed income and variable income securities with short maturity terms. The effective durations

for fixed or variable income securities for UAB's separately held investments at September 30, 2019 and 2018 are as follows:

	2019	2018
Commingled Bond Funds	_	_

Investments may also include mortgage pass through securities and collateralized mortgage obligations that may be considered to be highly sensitive to changes in interest rates due to the existence of prepayment or conversion features. At September 30, 2019 and 2018, the fair market values of these investments in the System Pools are as follows:

_	POOLED ENDOWMENT FUND					ONG TERM RESE	POOL FUND	SHORT TERM LIQUIDITY POOL FUND				
		2019	19 2018			2019	2018			2019	2018	
Mortgage Backed Securities	\$	16,998,880	\$	14,232,582	\$	28,505,448	\$	21,717,846	\$	256,770,944	\$	175,661,110
Collateralized Mortgage Obligations		<u> </u>		<u> </u>		<u> </u>		<u> </u>		18,530,989		14,788,045
Total Fixed	\$	16,998,880	\$	14,232,582	\$	28,505,448	\$	21,717,846	\$	275,301,933	\$	190,449,155

Mortgage Backed Securities. These securities are issued by the Federal National Mortgage Association ("Fannie Mae"), Government National Mortgage Association ("Ginnie Mae") and Federal Home Loan Mortgage Association ("Freddie Mac") and include short embedded prepayment options. Unanticipated prepayments by the obligees of the underlying asset reduce the total expected rate of return.

Collateralized Mortgage Obligations. Collateralized mortgage obligations ("CMOs") generate a return based upon either the payment of interest or principal on mortgages in an underlying pool. The relationship between interest rates and prepayments makes the fair value highly sensitive to changes in interest rates. In falling interest rate environments, the underlying mortgages are subject to a higher propensity of prepayments. In a rising interest rate environment, the opposite is true.

At September 30, 2019 and 2018, the effective durations for these securities held in the System Pools are as follows:

_	POOLED END	WMENT FUND	LONG TERM RESI	ERVE POOL FUND	SHORT TERM LIQUIDITY POOL FUND		
	2019	2018	2019	2018	2019	2018	
Mortgage Backed Securities	3.6	5.3	3.7	5.3	1.5	1.1	
Collateralized Mortgage Obligations	_	_	_	_	1.7	2.6	

There are no mortgage backed securities or CMOs in UAB's separately held investments at September 30, 2019 and 2018.

### **Foreign Currency Risk**

The strategic asset allocation policy for the PEF, the LTRP, and UAB's separately held investments includes an allocation to non-United States equity and fixed income securities. Currency hedging of foreign bonds and stocks is allowed under System policy. As of September 30, 2019 and 2018, all foreign investments in the System Pools and UAB's separately held investments are denominated in U.S. dollars and are in international commingled funds, which in turn invest in equity securities and bonds of foreign issuers except for foreign stock and non-U.S. bond funds denominated in U.S. dollars and held by each of the three pools as disclosed in previous tables.

### **Securities Lending**

The System permits security lending as a mechanism to augment income. Loans of the securities are required to be collateralized by cash, letters of credit or securities issued or guaranteed by the U.S. Government or its agencies. The collateral must equal at least 102% of the current market value of the loaned securities. Securities lending contracts must state acceptable collateral for securities loaned, duties of the borrower, delivery of loaned securities and acceptable investment of the collateral.

At September 30, 2019 and 2018, there were no securities on loan from the investment pools.

### **Joint Ventures**

UAB accounts for its ownership of the PLTF as a joint venture, using the equity method in the amount of approximately \$60.3 million and \$67.3 million at September 30, 2019 and 2018, respectively. See Note 8 for further discussion of the PLTF.



Accounts receivable consist of patient receivables, tuition charged to students and amounts due from federal, state and local governments, or private sources, in connection with reimbursement of allowable expenditures made pursuant to UAB's contracts and grants. The composition of accounts receivable at September 30, 2019 and 2018 is summarized as follows:

ACCOUNTS RECEIVABLE:	2019	2018
Patient care	\$ 397,838,014	\$ 369,621,511
Receivables from sponsoring agencies	84,934,092	73,677,226
Student accounts	64,237,628	47,453,418
Other	95,222,427	45,947,939
Total accounts receivable	\$ 642,232,161	\$ 536,700,094
Less: Allowances for doubtful accounts from patient care	153,011,998	151,532,091
Less: Allowances for doubtful accounts from student accounts	4,427,039	3,203,474
Less: Allowances for doubtful accounts other	3,065,139	2,610,865
Accounts receivable, net	\$ 481,727,985	\$ 379,353,664

Loans receivable represent all amounts owed on promissory notes from debtors, including student loans made under the Federal Perkins Loan Program and other loan programs. The principal repayment and interest rate terms of federal and university loans vary considerably. The allowance for doubtful accounts only applies to University-funded notes and the University portion of federal student loans, since the University is not obligated to fund the federal portion of uncollected student loans. Federal loan programs are funded principally with federal advances to UAB under the Perkins and various health professions loan programs.

Pledges receivable represent unconditional promises to give from third party donors. Pledges for permanent endowments do not meet eligibility requirements, as defined by GASB Statement No. 33, until the related gift is received. Due to uncertainties with regard to their realization and valuation, bequest intentions and other conditional promises are not recognized as assets until the specified conditions are met.

The composition of loans and pledges receivable at September 30, 2019 and 2018 is summarized in the following table.

	2019	2018
LOANS RECEIVABLE:		
Federal loan program	13,928,150	15,596,718
University loan funds	2,348,143	2,326,445
Other	 317,153	 454,539
Total loans receivable	\$ 16,593,446	\$ 18,377,702
Less allowance for doubtful accounts	 3,339,984	 3,583,214
Total loans receivable, net	\$ 13,253,462	\$ 14,794,488
Less: current portion	 2,272,848	 2,607,520
Total loans receivable outstanding, noncurrent	\$ 10,980,614	\$ 12,186,968
PLEDGES RECEIVABLE:		
GIFT PLEDGES OUTSTANDING:		
Operations	52,842,041	50,778,975
Capital	11,004,675	13,732,621
Total gift pledges	63,846,716	64,511,596
Less: current portion	18,436,977	18,141,677
Total gift pledges, noncurrent	\$ 45,409,739	\$ 46,369,919

## (6) Capital Assets

Capital assets as of September 30, 2019 and 2018 are summarized as follows: Net interest costs capitalized for the University and component units in 2019 and 2018, respectively, were approximately \$2.7 million and \$3.1 million (net of \$0.58 million and \$0.60 million investment earnings in 2019 and 2018, respectively). There were no net interest costs capitalized in 2019 or 2018 for the Hospital.

September 30, 2019								
		BEGINNING BALANCE		ADDITIONS		SALES/ ETIREMENTS/ TRANSFERS	EN	DING BALANCE
UNIVERSITY AND BLENDED COMPONENT UNITS								
Capital assets not being depreciated								
Land	\$	85,662,783	\$	404,187	\$	_	\$	86,066,970
Construction in progress		59,110,295		42,263,313		(49,061,333)		52,312,27
		144,773,078		42,667,500		(49,061,333)		138,379,24
Capital assets being depreciated								
Land Improvements		42,895,811		9,836,818		_		52,732,62
Buildings		1,602,407,782		108,657,687		(16,825,041)		1,694,240,42
Fixed Equipment Systems		88,052,934		546,789		-		88,599,72
Equipment		373,701,621		20,366,246		(9,764,929)		384,302,93
Library Materials		119,960,486		6,416,946				126,377,43
		2,227,018,634		145,824,486		(26,589,970)		2,346,253,15
Total Capital Assets		2,371,791,712		188,491,986		(75,651,303)		2,484,632,39
Less: Accumulated Depreciation		1,303,919,327		76,202,181		(23,938,072)		1,356,183,43
Total Net Capital Assets	\$	1,067,872,385	\$	112,289,805	\$	(51,713,231)	\$	1,128,448,95
HOSPITAL								
Capital assets not being depreciated								
Land	\$	20,813,545	\$	_	\$	_	\$	20,813,54
Construction in progress		15,341,646		16,866,103		(12,357,791)		19,849,95
	_	36,155,191		16,866,103		(12,357,791)		40,663,50
Capital assets being depreciated								
Land Improvements		656,874		_		_		656,87
Buildings		929,151,630		24,598,102		_		953,749,73
Fixed Equipment Systems		10,217,842		_		_		10,217,84
Equipment		482,842,594		58,468,886		(12,082,244)		529,229,23
		1,422,868,940		83,066,988		(12,082,244)		1,493,853,68
Total Capital Assets		1,459,024,131		99,933,091		(24,440,035)		1,534,517,18
Less: Accumulated Depreciation		879,335,745		72,137,318		(11,534,075)		939,938,98
Total Net Capital Assets	\$	579,688,386	\$	27,795,773	\$	(12,905,960)	\$	594,578,19
TOTAL UAB								
Capital assets not being depreciated								
Land	\$	106,476,328	\$	404,187	\$	_	\$	106,880,51
Construction in progress		74,451,941		59,129,416		(61,419,124)		72,162,23
h 12 11111	_	180,928,269	_	59,533,603	_	(61,419,124)	_	179,042,74
Capital assets being depreciated								
Land Improvements		43,552,685		9,836,818		_		53,389,50
Buildings		2,531,559,412		133,255,789		(16,825,041)		2,647,990,16
Fixed Equipment Systems		98,270,776		546,789		_		98,817,56
Equipment		856,544,215		78,835,132		(21,847,173)		913,532,17
Library Materials		119,960,486		6,416,946		_		126,377,43
		3,649,887,574		228,891,474		(38,672,214)		3,840,106,83
Total Capital Assets		3,830,815,843		288,425,077		(100,091,338)		4,019,149,58
Less: Accumulated Depreciation		2,183,255,072		148,339,499		(35,472,147)		2,296,122,42
Total Net Capital Assets	\$	1,647,560,771	\$	140,085,578	\$	(64,619,191)	\$	1,723,027,15

September 30, 2018								
		BEGINNING BALANCE		ADDITIONS		SALES/ ETIREMENTS/ FRANSFERS	EN	DING BALANCE
UNIVERSITY AND BLENDED COMPONENT UNITS	_		_		_		_	
Capital assets not being depreciated								
Land	\$	84,782,036	\$	1,039,608	\$	(158,861)	\$	85,662,783
Construction in progress		45,786,482		52,646,709		(39,322,896)		59,110,295
	_	130,568,518		53,686,317		(39,481,757)		144,773,078
Capital assets being depreciated								
Land Improvements		40,035,668		2,860,143		_		42,895,811
Buildings		1,508,744,034		119,815,652		(26,151,904)		1,602,407,782
Fixed Equipment Systems		87,484,453		568,481		_		88,052,934
Equipment		383,463,045		15,710,714		(25,472,138)		373,701,621
Library Materials		114,400,497		5,559,989		_		119,960,486
		2,134,127,697		144,514,979		(51,624,042)		2,227,018,634
Total Capital Assets		2,264,696,215		198,201,296		(91,105,799)		2,371,791,712
Less: Accumulated Depreciation		1,263,589,129		76,098,299		(35,768,101)		1,303,919,327
Total Net Capital Assets	\$	1,001,107,086	\$	122,102,997	\$	(55,337,698)	\$	1,067,872,385
HOSPITAL								
Capital assets not being depreciated								
Land	\$	20,862,268	\$	_	\$	(48,723)	\$	20.813.545
Construction in progress	Ψ	6,850,161	Ψ	11,484,536	Ψ	(2,993,051)	Ψ	15,341,646
Construction in progress	_	27,712,429		11,484,536		(3,041,774)	_	36,155,191
Capital assets being depreciated		,_,,_,		.,,,,		(2,2 : 3, : : )		
Land Improvements		656,874		_		_		656,874
Buildings		921,784,216		7,367,415		_		929,151,631
Fixed Equipment Systems		10,217,842				_		10,217,842
Equipment		472,994,687		37,085,486		(27,237,579)		482,842,594
Hall Control	_	1,405,653,619	_	44,452,901		(27,237,579)	_	1,422,868,941
Total Capital Assets		1,433,366,048		55,937,437		(30,279,353)		1,459,024,132
Less: Accumulated Depreciation		833,533,093		70,588,214		(24,785,561)		879,335,746
Total Net Capital Assets	\$	599,832,955	\$	(14,650,777)	\$	(5,493,792)	\$	579,688,386
TOTAL HAD	_		_				_	
TOTAL UAB								
Capital assets not being depreciated	Φ.	405.044.004	<b>.</b>	4.000.000	<b>.</b>	(207.504)	Φ.	400 470 220
Land	\$	105,644,304	\$	1,039,608	\$	(207,584)	\$	106,476,328
Construction in progress	_	52,636,643		64,131,245		(42,315,947)		74,451,941
Capital assets hains depus sisted		158,280,947		65,170,853		(42,523,531)		180,928,269
Capital assets being depreciated		40.002.542		2.000.142				42.552.605
Land Improvements		40,692,542		2,860,143		(26.454.00.4)		43,552,685
Buildings		2,430,528,250		127,183,067		(26,151,904)		2,531,559,413
Fixed Equipment Systems		97,702,295		568,481		(52.700.747)		98,270,776
Equipment		856,457,732 114,400,497		52,796,200 5,559,989		(52,709,717)		856,544,215
Library Materials	_		_		_	(79.964.634)	_	119,960,486
Total Capital Accord		<b>3,539,781,316</b> <b>3,698,062,263</b>		188,967,880		(78,861,621)		3,649,887,575
Total Capital Assets				254,138,733 146,686,513		(121,385,152)		3,830,815,844
Less: Accumulated Depreciation	_	2,097,122,222	_		_		_	2,183,255,073
Total Net Capital Assets	<u>\$</u>	1,600,940,041	\$	107,452,220	<u>\$</u>	(60,831,490)	<u>\$</u>	1,647,560,771



During fiscal year 2019, Standard & Poor's Ratings Services reaffirmed its AA rating on UAB's general revenue bonds. The outlook is stable. Long-term debt activity for the years ended September 30, 2019 and 2018 is summarized as follows:

September 30, 2019								
September 30, 2013	BEGINNING BALANCE	N	IEW DEBT	PRINCIPAL PAYMENT		ENDING BALANCE		CURRENT
UNIVERSITY	BALANCE			 PATMENT		BALANCE		PORTION
Direct Borrowings and Direct Placement Other								
Leases Payable, 3.19% due annually through 2019 and 4.47% due monthly through 2020	\$ 434,443	\$	341,253	\$ 430,357	\$	345,339	\$	135,538
General Receipts Bonds								
Birmingham General Revenue Bonds Series 2005A, 3.0% to 5.0% due annually from 2007 through 2021	9,710,000		_	3,090,000		6,620,000		3,230,000
Birmingham General Revenue Bonds Series 2010A, 2.0% to 5.0% due annually through 2041	46,430,000		_	1,715,000		44,715,000		1,800,000
Birmingham General Revenue Bonds Series 2010B, 1.0% to 5.8% due annually through 2041	46,590,000		_	1,550,000		45,040,000		1,605,000
Birmingham General Revenue Bonds Series 2010C, 2.0% to 5.0% due annually through 2028	12,165,000		_	1,520,000		10,645,000		1,600,000
Birmingham General Revenue Bonds Series 2013A-1, 1.1.% due annually through 2020	9,730,000		-	3,205,000		6,525,000		3,245,000
Birmingham General Revenue Bonds Series 2013A-2, 2.25% to 5.0% due annually from 2022 through 2044	72,595,000	ı	_	_		72,595,000		-
Birmingham General Revenue Bonds Series 2013B, 1.99% due annually through 2029	33,465,000	1	_	3,085,000		30,380,000		3,135,000
Birmingham General Revenue Bonds Series 2013C, 1.0% to 1.45% due annually through 2019	1,030,000	ı	_	505,000		525,000		525,000
Birmingham General Revenue Bonds Series 2013D-1, 1.97% due annually through 2023	13,855,000	ı	_	2,200,000		11,655,000		2,240,000
Birmingham General Revenue Bonds Series 2013D-2, 4.0% to 5.0% due annually from 2025 through 2044	78,325,000	1	_	_		78,325,000		_
Birmingham General Revenue Bonds Series 2015A, 2.0% to 5.0% due annually through 2028	27,090,000	1	_	2,605,000		24,485,000		2,730,000
Birmingham General Revenue Bonds Series 2016A, 1.94% due annually from 2021 through 2027	24,495,000	ı	_	_		24,495,000		_
Birmingham General Revenue Bonds Series 2016B, 4.0% to 5.0% due annually from 2028 through 2044	95,585,000		-	_		95,585,000		_
Birmingham General Revenue Bonds Series 2019A, 4.0% to 5.0% due annually from 2028 through 2030	-		24,775,000	_		24,775,000		_
Birmingham General Revenue Bonds Series 2019B, 3.0% to 5.0% due annually from 2028 through 2049			145,940,000			145,940,000		
	\$ 471,499,443	\$	171,056,253	\$ 19,905,357	\$	622,650,339	\$	20,245,538
Less (Plus): unamortized bond discount (premium)  TOTAL UNIVERSITY DEBT					\$	(22,534,845)	<u> </u>	20,245,538
TOTAL GRAVERSHY DEBT					Ť	0.10,100,10	•	20,2 10,000
HOSPITAL								
Direct Borrowings and Direct Placement Other	A 7550007			0.000.740		4504470		4500.450
Lease Payable, 2.0% to 3.75% due monthly through 2020  Note payable UAB Health System, 3.0% to 5.0% due annually through 2048	\$ 7,556,927	\$	77,000,000	\$ 2,992,749 138,818	\$	4,564,178 76.861.182	\$	1,590,450 1,106,761
General Receipts Bonds			77,000,000	130,010		70,001,102		1,100,701
Birmingham Hospital Revenue Bonds Series 2012A, 2.57% due annually through 2027	13,316,000	ı	_	1,327,000		11,989,000		1,363,000
UAB Medicine Financing Authority Revenue Bonds Series 2016A, 1.2% due annually through 2022	44,565,000		_	10,945,000		33,620,000		11,075,000
UAB Medicine Financing Authority Revenue Bonds Series 2016B, 3.125% to 5.0% due annually from 2023 through 2041	302,530,000		_	_		302,530,000		_
UAB Medicine Financing Authority Revenue Bonds Series 2017A, 2.13% due annually from 2025 through 2027	18,385,000		_	_		18,385,000		_
UAB Medicine Financing Authority Revenue Bonds Series 2017B, 3.0% to 5.0% due annually from 2028 through 2042	44,810,000		_	_		44,810,000		_
·	\$ 431,162,927		77,000,000	\$ 15,403,567	\$	492,759,360	\$	15,135,211
Less (Plus): unamortized bond discount (premium)						(24,526,900)		_
TOTAL HOSPITAL DEBT					\$	517,286,260	\$	15,135,211
TOTAL UAB	\$ 902,662,369	\$	248,056,253	\$ 35,308,922	\$	1,115,409,699	\$	35,380,749
Less (Plus): unamortized bond discount (premium)						(47,061,745)		_
TOTAL UAB DEBT					\$	1,162,471,444	\$	35,380,749

September 30, 2018						
	BEGINNING BALANCE	N	EW DEBT	PRINCIPAL EPAYMENT	ENDING BALANCE	URRENT
UNIVERSITY						
Direct Borrowings and Direct Placement Other						
Leases Payable, 3.19% due annually through 2019 and 4.47% due monthly through 2020	\$ 287,794	\$	309,508	\$ 162,859	\$ 434,443	\$ 211,337
General Receipts Bonds						
Birmingham General Revenue Bonds Series 2005A, 3.0% to 5.0% due annually from 2007 through 2021	12,665,000		-	2,955,000	9,710,000	3,090,000
Birmingham General Revenue Bonds Series 2010A, 2.0% to 5.0% due annually through 2041	48,060,000		-	1,630,000	46,430,000	1,715,000
Birmingham General Revenue Bonds Series 2010B, 1.0% to 5.8% due annually through 2041	48,100,000		_	1,510,000	46,590,000	1,550,000
Birmingham General Revenue Bonds Series 2010C, 2.0% to 5.0% due annually through 2028	15,467,896		_	3,302,897	12,164,999	1,520,000
Birmingham General Revenue Bonds Series 2013A-1, 1.1.% due annually through 2020	12,925,000		_	3,195,000	9,730,000	3,205,000
Birmingham General Revenue Bonds Series 2013A-2, 2.25% to 5.0% due annually from 2022 through 2044	72,595,000		_	_	72,595,000	_
Birmingham General Revenue Bonds Series 2013B, 1.99% due annually through 2029	36,485,000		-	3,020,000	33,465,000	3,085,000
Birmingham General Revenue Bonds Series 2013C, 1.0% to 1.45% due annually through 2019	1,525,000		-	495,000	1,030,000	505,000
Birmingham General Revenue Bonds Series 2013D-1, 1.97% due annually through 2023	16,010,000		_	2,155,000	13,855,000	2,200,000
Birmingham General Revenue Bonds Series 2013D-2, 4.0% to 5.0% due annually from 2025 through 2044	78,325,000		-	_	78,325,000	_
Birmingham General Revenue Bonds Series 2015A, 2.0% to 5.0% due annually through 2028	29,595,000		_	2,505,000	27,090,000	2,605,000
Birmingham General Revenue Bonds Series 2016A, 1.94% due annually from 2021 through 2027	24,495,000		_	_	24,495,000	_
Birmingham General Revenue Bonds Series 2016B, 4.0% to 5.0% due annually from 2028 through 2044	95,585,000		_	_	95,585,000	_
	\$ 492,120,690	\$	309,508	\$ 20,930,756	\$ 471,499,442	\$ 19,686,337
Less (Plus): unamortized bond discount (premium)					(8,816,063)	
TOTAL UNIVERSITY DEBT					\$ 480,315,505	\$ 19,686,338
HOSPITAL						
Direct Borrowings and Direct Placement Other						
Lease Payable, 2.0% to 3.75% due monthly through 2020	\$ 12,029,620	\$	_	\$ 4,472,693	\$ 7,556,927	\$ 2,992,749
General Receipts Bonds						
Birmingham General Revenue Bonds Series 2010C, 2.0% to 4.0% due annually through	262.104			262.104		
2018  Birmingham Hospital Revenue Bonds Series 2012A, 2.57% due annually through 2027	262,104 14,609,000		_	262,104 1,293,000	13,316,000	1,327,000
UAB Medicine Financing Authority Revenue Bonds Series 2016A, 1.2% due annually						
through 2022  UAB Medicine Financing Authority Revenue Bonds Series 2016B, 3.125% to 5.0% due	55,380,000		_	10,815,000	44,565,000	10,945,000
annually from 2023 through 2041	302,530,000		_	_	302,530,000	_
UAB Medicine Financing Authority Revenue Bonds Series 2017A, 2.13% due annually from 2025 through 2027	18,385,000		_	_	18,385,000	_
UAB Medicine Financing Authority Revenue Bonds Series 2017B, 3.0% to 5.0% due annually from 2028 through 2042	44,810,000		_	_	44,810,000	_
	\$ 448,005,724	\$	_	\$ 16,842,797	\$ 431,162,927	\$ 15,264,749
Less (Plus): unamortized bond discount (premium)					(25,763,138)	_
TOTAL HOSPITAL DEBT					\$ 456,926,065	\$ 15,264,749
TOTAL UAB	\$ 940,126,414	\$	309,508	\$ 37,773,553	\$ 902,662,369	\$ 34,951,087
Less (Plus): unamortized bond discount (premium)					(34,579,201)	-
TOTAL UAB DEBT					\$ 937,241,570	\$ 34,951,087

Maturities and interest on Direct Borrowings and Direct Placement Other and General Receipts Bonds for the next five years and in subsequent five-year incremental periods are presented in the table below:

**Direct Borrowings and Direct Placement Other** 

		UNIVERSITY		HOSPITAL TOTAL					
FISCAL YEAR	PRINCIPAL	INTEREST	TOTAL	PRINCIPAL	INTEREST	TOTAL	PRINCIPAL	INTEREST	TOTAL
2020	\$ 135,538	\$ 21,015	\$ 156,552	\$ 2,685,251	\$ 2,464,859	\$ 5,150,110	\$ 2,820,790	\$ 2,485,874	\$ 5,306,663
2021	78,572	15,097	93,669	2,674,442	2,405,225	5,079,667	2,753,014	2,420,322	5,173,336
2022	81,160	10,174	91,334	2,577,944	2,344,524	4,922,468	2,659,104	2,354,698	5,013,802
2023	50,069	3,640	53,709	1,263,338	2,300,077	3,563,415	1,313,407	2,303,717	3,617,124
2024	_	_	_	1,244,791	2,274,672	3,519,463	1,244,791	2,274,672	3,519,463
2025-2029	_	_	_	10,003,730	10,874,409	20,878,139	10,003,730	10,874,409	20,878,139
2030-2034	_	_	_	15,397,444	9,518,826	24,916,270	15,397,444	9,518,826	24,916,270
2035-2039	_	_	_	15,184,870	7,460,679	22,645,549	15,184,870	7,460,679	22,645,549
2040-2044	_	_	_	17,992,503	4,781,744	22,774,247	17,992,503	4,781,744	22,774,247
2045-2049	_	_		12,401,047	1,479,473	13,880,520	12,401,047	1,479,473	13,880,520
Total	\$ 345,339	\$ 49,926	\$ 395,264	\$ 81,425,360	\$ 45,904,488	\$ 127,329,848	\$ 81,770,700	\$ 45,954,414	\$ 127,725,113

#### **General Receipts Bonds**

		UNIVERSITY			HOSPITAL			TOTAL	
FISCAL YEAR	PRINCIPAL	INTEREST	TOTAL	PRINCIPAL	INTEREST	TOTAL	PRINCIPAL	INTEREST	TOTAL
2020	\$ 20,110,000	\$ 22,140,157	\$ 42,250,157	\$ 12,438,000	\$ 16,137,024	\$ 28,575,024	\$ 32,548,000	\$ 38,277,181	\$ 70,825,181
2021	23,525,000	23,064,632	46,589,632	12,605,000	15,967,753	28,572,753	36,130,000	39,032,385	75,162,385
2022	21,795,000	22,371,650	44,166,650	12,777,000	15,796,814	28,573,814	34,572,000	38,168,464	72,740,464
2023	22,655,000	21,625,672	44,280,672	10,276,000	15,623,290	25,899,290	32,931,000	37,248,962	70,179,962
2024	22,505,000	20,878,985	43,383,985	10,711,000	15,145,280	25,856,280	33,216,000	36,024,265	69,240,265
2025-2029	115,035,000	92,583,453	207,618,453	70,392,000	69,662,368	140,054,368	185,427,000	162,245,821	347,672,821
2030-2034	109,475,000	69,955,591	179,430,591	93,105,000	52,014,780	145,119,780	202,580,000	121,970,371	324,550,371
2035-2039	113,345,000	45,250,896	158,595,896	119,080,000	29,672,925	148,752,925	232,425,000	74,923,821	307,348,821
2040-2044	118,635,000	21,165,463	139,800,463	69,950,000	5,237,313	75,187,313	188,585,000	26,402,776	214,987,776
2045-2049	55,225,000	4,720,731	59,945,731	_	_	_	55,225,000	4,720,731	59,945,731
Total	\$ 622,305,000	\$ 343,757,230	\$ 966,062,230	\$ 411,334,000	\$ 235,257,547	\$ 646,591,547	\$ 1,033,639,000	\$ 579,014,777	\$ 1,612,653,777

Pledged revenues for 2019 and 2018, as defined by the Series 2012A Hospital Revenue Trust Indenture, are as follows:

HOSPITAL BONDS	2019		2018
Total pledged revenues	\$ 2,046,900,133	\$	1,895,229,398

Pledged revenues for 2019 and 2018, as defined by the Series 2005A, 2010A, 2010B, 2010C, 2013A, 2013B, 2013C, 2013D, 2015A, 2016A, 2016B, 2019A and 2019B General Revenue Trust Indentures, are as follows:

UNIVERSITY BONDS	2019	2018
Tuition fees	\$ 320,141,055	\$ 303,042,374
Indirect cost recovery	99,408,108	91,761,073
Sales and service of educational activities	67,616,490	68,464,868
Auxiliary sales and service	46,959,821	44,253,545
Endowment and investment income	47,116,443	43,674,010
Other sources	 69,676,133	59,084,775
TOTAL PLEDGED REVENUES	\$ 650,918,050	\$ 610,280,645

In June 2019, the University issued \$24.8 million in Series 2019A General Revenue Bonds. The bonds pay interest at a rate of 4.00% with principal due annually through October 1, 2029. In June 2019, the University issued \$145.9 million in Series 2019B General Revenue Bonds, \$75.1 million of which was in the form of Serial Bonds and \$71.9 million of which was in the form of Term Bonds. The bonds pay interest at varying rates of 3.0% to 5.0% with principal due annually through October 1, 2041 and October 1, 2048, respectively.

The proceeds of both the Series 2019A and 2019B bonds will be used for the purposes of financing a portion of the cost of certain capital improvements to the UAB campus, as well as paying costs and expenses associated with this issue. These bonds were issued at a premium of \$16.4 million resulting in total cash received of \$187.1 million.

In June 2019, The UAB Medicine Finance Authority issued \$8.1 million in Series 2019A Revenue Bonds and \$103.4 million in Series 2019B Revenue Bonds, the proceeds of which were loaned to UAB Health System pursuant to Series 2019A and Series 2019B loan agreements. Concurrently, the Hospital entered into a loan agreement with UAB Health System to borrow \$77.0 million of the 2019A and 2019B bond proceeds for the purpose of financing capital improvement projects. Of this \$77.0 million, \$31.4 million was distributed to the Hospital as of September 30, 2019. As the Hospital is legally obligated to repay \$77.0 million and is currently paying principal and interest on this full amount, The Hospital has reflected the full \$77.0 million on its statement of net position as long-term debt and \$45.6 million as Due from UAB Health System which is classified as Due from affiliate on the statement of net position. the Hospital pays interest to UAB Health System on the entire amount borrowed, regardless of the amount outstanding. There are no financial covenants related to the loan between the Hospital and UAB Health System.

The UAB general revenue bonds and the Hospital Revenue Trust Indentures are subject to certain covenants with the most restrictive being those on the Hospital's 2012A series issuance. These covenants, among other things, require the Hospital to ensure pledged revenues are sufficient for debt service coverage by a ratio of 1.1 times. UAB and the Hospital are in compliance with all financial covenants as of September 30, 2019.

The UAB Medicine Financing Authority's Revenue Trust Indentures are also subject to certain covenants. These covenants require the obligated group to ensure pledged revenues are sufficient for debt service coverage by a ratio of 1.1 times. The obligated group is in compliance with all financial covenants as of September 30, 2019.

In November 2019, the University refunded certain of the outstanding Series 2010 Bonds through the issuance of \$39.8 million in Series 2019-C Bonds and \$35.7 million in Series 2019-D Bonds. The Series 2010 Bonds were issued to provide financing for various capital improvements on campus.

### (8) Self-Insurance

UAB manages risks related to medical malpractice, general liability, and employee health care through a combination of self-insurance, risk pooling arrangements, and commercial insurance coverage.

UAB's medical malpractice liability is managed by PLTF, a professional liability trust fund. PLTF functions as a risk-sharing vehicle for UAB and more than ten nongovernmental organizations. PLTF covers liabilities of the covered parties, including UAB, arising from reported claims, claims that are incurred but not reported, and future costs of handling these claims. The liabilities are generally based on present value actuarial valuations discounted using interest rates from 2% to 5%. The discount rate used in both 2019 and 2018 was 2%. The associated risks of claims are subject to aggregate limits, with excess liability coverage provided by independent insurers to protect participants against losses should a claim arise that exceeds PLTF coverage limits. Although UAB is the sponsor of PLTF, it is not the predominant participant in the fund.

The PLTF's policy committee establishes the premium rate of participants based on recommendations from consulting actuaries and considering the assumption of risk from the PLTF's date of inception. Premiums paid to the PLTF are provided by UAB, HSF, and other participants. In addition, certain legal and administrative services are provided to the PLTF by the University of Alabama System.

The PLTF agreement requires 10% of all PLTF assets to be held in liquid assets. At September 30, 2019 and 2018, the liquid assets of the PLTF, as defined by the agreement, were in compliance with the agreement.

As discussed in Note 4, UAB accounts for its ownership of the PLTF under the equity method of accounting and it is not included in the table below.

General liability is subject to various claims and aggregate limits, with excess liability coverage provided by an independent insurer. General liability and employee health care claims and expenses are reported when it is probable that a loss has occurred and the amount of the loss can be reasonably estimated. Those losses include an estimate of claims that have been incurred but not reported and the future costs of handling claims. The general liability liabilities are generally based on actuarial valuations and are reported at present value. The discount rate used for the general liability was 2% in both 2019 and 2018.

Changes in the total self-insured liabilities for the years ended September 30, 2019 and 2018 are presented as follows for UAB:

SELF INSURED LIABILITIES	2019	 2018
Balance, beginning of year	\$ 10,412,292	\$ 9,779,035
Claims incurred and changes in estimates	64,012,041	68,545,978
Claim payments	(66,754,598)	(67,912,722)
BALANCE, END OF YEAR	\$ 7,669,735	\$ 10,412,291

### (9) Employee Benefits

Most employees of the University and the Hospital, participate in the Teachers' Retirement System of Alabama (TRS), a cost-sharing, multiple-employer public retirement system. Certain employees also participate in an optional 403(b) plan (403(b) Plan). TRS is a defined benefit plan and the 403(b) Plan is a defined contribution plan.

### **Defined Benefit Plan - TRS**

Plan Description. The Teachers' Retirement System of Alabama, a cost-sharing multiple-employer employee retirement plan, was established as of September 15, 1939, under the provisions of Act 419 of the Legislature of 1939 for the purpose of providing retirement allowances and other specified benefits for qualified persons employed State-supported educational institutions. responsibility for the general administration and operation of the TRS is vested in its Board of Control. The TRS Board of Control consists of 15 members. The plan is administered by the Retirement Systems of Alabama (RSA). Title 16 Chapter 25 of the Code of Alabama grants the authority to establish and amend the benefit terms to the TRS Board of Control. The Plan issues a publicly available financial report that can be obtained at www.rsa-al.gov.

Benefits provided. State law establishes retirement benefits as well as death and disability benefits and any ad hoc increase in postretirement benefits for the TRS. Benefits for TRS members vest after 10 years of creditable service. TRS members who retire after age 60 with 10 years or more of creditable service or with 25 years of service (regardless of age) are entitled to an annual retirement benefit, payable monthly for life unless there is a return to full-time employment with a TRS or Employees' Retirement System (ERS) agency, or to temporary employment in excess of specified limits. Service and disability retirement benefits are based on a guaranteed minimum or a formula method, with the member receiving payment under the method that yields the highest monthly benefit. Under the formula method, Tier 1 members of the TRS are allowed 2.0125% of their average final compensation (highest 3 of the last 10 years) for each year of service.

Act 377 of the Legislature of 2012 established a new tier of benefits (Tier 2) for members hired on or after January 1, 2013. Tier 2 TRS members are eligible for retirement after age 62 with 10 years or more of creditable service and are entitled to an annual retirement benefit, payable monthly for life unless there is a return to full-time employment with a TRS or ERS agency, or to temporary employment in excess of specified limits. Service and disability retirement benefits are based on a guaranteed minimum or a formula method, with the member receiving payment under the method that yields the highest monthly benefit. Under formula method, Tier 2 members of the TRS are allowed 1.65% of their average final compensation (highest 5 of the last 10 years) for each year of service. Members are eligible for disability retirement if they have 10 years of creditable service, are currently in-service, and determined by the RSA Medical Board to be permanently incapacitated from further performance of duty. Pre-retirement death benefits are calculated and paid to the beneficiary based on the member's age, service credit, employment status and eligibility for retirement.

Contributions. Covered members of the TRS contributed 5% of earnable compensation to the TRS as required by statute until September 30, 2011. From October 1, 2011, to September 30, 2012, covered members of the TRS were required by statute to contribute 7.25% of earnable compensation. Effective October 1, 2012, covered members of the TRS are required by statute to contribute 7.50% of earnable compensation. Certified law enforcement, correctional officers, and firefighters of the TRS contributed 6% of earnable compensation as required by statute until September 30, 2011. From October 1, 2011, to September 30, 2012, certified law enforcement, correctional officers, and firefighters of the TRS were required by statute to contribute 8.25% of earnable compensation. Effective October 1, 2012, certified law enforcement, correctional officers, and firefighters of the TRS are required by statute to con-tribute 8.50% of earnable compensation.

Tier 2 covered members of the TRS contribute 6% of earnable compensation to the TRS as required by statute. Tier 2 certified law enforcement, correctional officers, and firefighters of the TRS are required by statute to contribute 7% of earnable compensation.

UAB's contractually required contribution rate for the year ended September 30, 2019 was 12.41% of annual pay for Tier1members and 11.35% of annual pay for Tier2 members. UAB's contribution rate for the year ended September 30, 2018 was 12.24% of annual pay for Tier1 members and 11.01% of annual pay for Tier 2 members. These required contribution rates are a percent of annual payroll, actuarially determined as an amount that, when combined with member contributions, is expected to finance the costs of benefits earned by members during the year, with an additional amount to finance any unfunded accrued liability. The total contribution requirement for fiscal years 2019, 2018 and 2017 is as follows:

	2019	2018	2017
Employer Contributions	\$ 97,824,000	\$ 94,481,000	\$ 91,311,000
Employee Contributions	 57,345,000	 56,754,000	 56,000,000
TOTAL CONTRIBUTIONS	\$ 155,169,000	\$ 151,235,000	\$ 147,311,000

Pension Liabilities, Pension Expense, and Deferred Outflows of Resources and Deferred Inflows of Resources Related to Pensions. At September 30, 2019 and September 30, 2018, the financial statements of UAB reflected a liability of \$1.17 billion and \$1.16 billion, respectively, for its proportionate share of the collective net pension liability, as prescribed by GASB 68. At September 30, 2019, the collective net pension liability was measured as of September 30, 2018 and the total pension liability used to calculate the net pension liability was determined by an actuarial valuation as of September 30, 2017. At September 30, 2018, the collective net pension liability was measured as of September 30, 2017 and the total pension liability used to calculate the net pension liability was determined by an actuarial valuation as of September 30, 2016.

UAB's proportion of the collective net pension liability was based on the employers' shares of contributions to the pension plan relative to the total employer contributions of all participating TRS employers. As of September 30, 2018, UAB's proportion was 11.75%, which was a decrease of 0.06% from its proportion measured as of September 30, 2017. At September 30, 2017, UAB's proportion was 11.81%, which was a decrease of 0.05% from its proportion measured as of September 30, 2016.

For the years ended September 30, 2019 and September 30, 2018, UAB recognized pension expense of \$76.3 million and \$86.2 million, respectively. At September 30, 2019 and 2018, UAB reported deferred outflows of resources and deferred inflows of resources related to pensions from the following sources:

2019	 erred Outflows f Resources	Def	erred Inflows of Resources
Differences between expected and actual experience	\$ 25,212,000	\$	35,589,000
Changes of assumptions	64,940,000		_
Net difference between projected and actual earnings on pension plan	_		88,187,000
Changes in proportion and differences between Employer contributions and			
proportionate share of contributions	_		18,915,000
Employer contributions subsequent to the measurement date	94,900,000		_
TOTAL	\$ 185,052,000	\$	142,691,000

2018	Deferred Outflows of Resources	Deferred Inflows of Resources
Differences between expected and actual experience	\$ -	\$ 49,787,000
Changes of assumptions	69,307,000	_
Net difference between projected and actual earnings on pension plan	_	69,426,000
Changes in proportion and differences between Employer contributions and proportionate share of contributions	_	27,849,000
Employer contributions subsequent to the measurement date  TOTAL	91,228,000 <b>\$ 160,535,000</b>	\$ 147,062,000

\$94.9 million reported as deferred outflows of resources related to pensions resulting from UAB contributions subsequent to the measurement date will be recognized as a reduction of the net pension liability in the year ending September 30, 2020. Other amounts reported as deferred outflows of resources and deferred inflows of resources related to pensions will be recognized in pension expense as follows:

Years ending	g Septeml	ber 30:
2020	\$	(265)
2021		(27,925)
2022		(24,287)
2023		(1,821)
2024		1,759
Thereafter		_

**Actuarial assumptions.** The total pension liability was determined by an actuarial valuation as of September 30, 2017 using the following actuarial assumptions, applied to all periods included in the measurement:

Inflation	2.75%
Investment rate of return*	7.70%
Projected salary increases	3.25-5.00%

\*Net of pension plan investment expense

The actuarial assumptions used in the actuarial valuation as of September 30, 2017, were based on the results of an investigation of the economic and demographic experience for the TRS based upon participant data as of September 30, 2015. The Board of Control accepted and approved these changes in September 2016 which became effective the beginning of fiscal year 2016. Mortality rates for TRS were based on the RP-2000 White Collar Mortality Table projected to 2020 using scale BB and adjusted 115% for males and 112% for females age 78 and older.

The long-term expected rate of return on pension plan investments was determined using a log-normal distribution analysis in which best estimate ranges of expected future real rates of return (expected returns, net of pension plan investment expense and inflation) are developed for each major asset class. These ranges are combined to produce the long-term expected rate of return by weighting the expected future real rates of return by the target asset allocation percentage and by adding expected inflation. The target asset allocation and best estimates of geometric real rates of return for each major asset class are as follows:

	Target Allocation	Long-Term Expected Rate of Return*
Fixed Income	17.00%	4.40%
U.S. Large Stocks	32.00%	8.00%
U.S. Mid Stocks	9.00%	10.00%
U.S. Small Stocks	4.00%	11.00%
International Developed Market Stocks	12.00%	9.50%
International Emerging Market Stocks	3.00%	11.00%
Alternatives	10.00%	10.10%
Real Estate	10.00%	7.50%
Cash	3.00%	1.50%
TOTAL	100.00%	

\*Includes assumed rate of inflation of 2.50%.

**Discount rate.** The discount rate used to measure the total pension liability was 7.70%. The projection of cash flows used to determine the discount rate assumed that plan member contributions will be made at the current contribution rate and that the employer contributions will be made at rates equal to the difference between actuarially determined contribution rates and the member rate. Based on those assumptions, components of the pension plan's fiduciary net position were projected to be available to make all projected future benefit payments of current plan members.

Therefore, the long-term expected rate of return on pension plan investments was applied to all periods of projected benefit payments to determine the total pension liability.

Sensitivity of UAB's proportionate share of the net pension liability to changes in the discount rate. The following table reflects UAB's proportionate share of the net pension liability, as prescribed by GASB 68, calculated using the discount rate of 7.70%, as well as what UAB's proportionate share of the net pension liability would be if it were calculated using a discount rate that is 1-percentage point lower (6.70%) or 1-percentage- point higher (8.70%) than the current rate:

	 1% Decrease (6.70%)	Current Rate (7.70%)	1% Increase (8.70%)
UAB's proportionate share of collective net pension liability	\$ 1,626,293,000	\$ 1,168,305,000	\$ 780,918,000

Pension plan fiduciary net position. Detailed information about the pension plan's fiduciary net position is available in the separately issued RSA Comprehensive Annual Report for the fiscal year ended September 30, 2018. The supporting actuarial information is included in the GASB Statement No. 67 Report for the TRS prepared as of September 30, 2018. The auditor's report dated August 16, 2019, on the total pension liability, total deferred outflows of resources, total deferred inflows of resources, total pension expense for the sum of all participating entities as of September 30, 2018, along with supporting schedules is also available. The additional financial and actuarial information is available at is available at www.rsa-al.gov.

### **Other Retirement Plans**

Certain employees also participate in an optional 403(b) plan (403(b) Plan), which is a defined contribution plan. In defined contribution plans, benefits depend solely on amounts contributed plus investment earnings. All full-time regular monthly employees are eligible to participate from the date of employment. UAB contributes a matching amount of up to 5% of total salaries for participating employees. UAB's contribution is funded as it accrues and, along with that of the employee, is immediately and fully vested. The contributions for fiscal years 2019 and 2018, excluding employee amounts not eligible for matching, were approximately \$60.1 million and \$55.4 million, which included approximately \$30.1 million and \$27.7 million each from UAB and its employees, respectively.

The University, the Hospital, LLC and UABRF total salaries and wages for fiscal years 2019 and 2018 were approximately \$1.25 billion and \$1.21 billion, respectively. Total salaries and wages during fiscal years 2019 and 2018 for covered employees participating in TRS were approximately \$806.4 million and \$786.1 million, respectively. Total salaries and wages during fiscal years 2019 and 2018 for covered employees participating in the 403(b) Plan were approximately \$649.0 million and \$591.9 million, respectively.

Triton sponsors a 401(k) plan covering substantially all employees who have completed at least six months of service. Information regarding this benefit is presented in Triton's annual report.

The LLC sponsors a voluntary 403(b) retirement plan for eligible employees. The 403(b) plan is a voluntary, defined-contribution, tax-deferred as well as Roth after tax plan governed by Internal Revenue Code 403(b). TIAA is the administrator for the voluntary retirement program. Employees are vested after 3 years of employment. Eligibility for matching is for all full-time and part-time regular, twelve-hour shift, and weekend staff employees.

### **Compensated Absences**

Certain UAB employees accumulate vacation and sick leave at varying rates depending upon their years of continuous service and their payroll classification, subject to maximum limitations. Upon termination of employment, employees are paid unused accrued vacation at their regular rate of pay up to a designated maximum number of days.

In accordance with GASB Statement No. 16, Accounting for Compensated Absences, the financial statements include accruals of approximately \$71 million and \$69 million as of September 30, 2019 and 2018, respectively, for accrued vacation pay and salary-related payments associated with vacation pay. There is no such accrual recognized for sick leave benefits because there is no terminal cash benefit available to employees for accumulated sick leave.

## (10) Post-Employment Benefits

UAB offers other postemployment health care benefits (OPEB) to all employees who officially retire from UAB. Health care benefits are offered through the Alabama Retired Education Employees Health Care Trust Plan (PEEHIP) with TRS or certain retired employees may elect to continue to participate in UAB's group health plan until they are eligible for Medicare by paying the full cost of the plan premium. Retired employees age 65 or older who are eligible for Medicare must enroll in the Medicare Coordinated Plan under which Medicare is the primary insurer and UAB's health care plan becomes the secondary insurer. Despite the availability of the UAB plan, most retirees elect to participate in the PEEHIP with TRS, in which case the retirees pay a portion of the PEEHIP premium, with UAB paying an allocation towards the cost of retiree coverage.

Certain retirees may also elect to continue their basic term life insurance coverage and accidental death and dismemberment insurance up to certain maximum amounts. The retirees pay the full amount of the premiums in such cases. Retirees are not eligible for tuition assistance benefits themselves. However, their unmarried dependent children may qualify in some cases.

### **PEEHIP**

**Plan description.** The Alabama Retired Education Employees' Health Care Trust (Trust) is a cost-sharing multiple-employer defined benefit postemployment healthcare plan that administers healthcare benefits to the retirees of participating state and local educational institutions. The Trust was established under the Alabama Retiree Health Care Funding Act of 2007 which authorized

and directed the Public Education Employees' Health Insurance Board (Board) to create an irrevocable trust to fund postemployment healthcare benefits to retirees participating in PEEHIP. Active and retiree health insurance benefits are paid through the Public Education Employees' Health Insurance Plan. In accordance with GASB, the Trust is considered a component unit of the State of Alabama (State) and is included in the State's Comprehensive Annual Financial Report.

The PEEHIP was established in 1983 pursuant to the provisions of the Code of Alabama 1975, Title 16, Chapter 25A (Act 83-455) to provide a uniform plan of health insurance for active and retired employees of state and local educational institutions which provide instruction at any combination of grades K-14 (collectively, employees), and to provide a method for funding the benefits related to the plan. The four-year universities participate in the plan with respect to their retired employees, and are eligible and may elect to participate in the plan with respect to their active employees. Responsibility for the establishment of the health insurance plan and its general administration and operations is vested in the Board. The Board is a corporate body for purposes of management of the health insurance plan. The Code of Alabama 1975, Section 16-25A-4 provides the Board with the authority to amend the benefit provisions in order to provide reasonable assurance of stability in future years for the plan. All assets of the PEEHIP are held in trust for the payment of health insurance benefits. The Teachers' Retirement System of Alabama (TRS) has been appointed as the administrator of the PEEHIP and, consequently, serves as the administrator of the Trust.

**Benefits provided.** PEEHIP offers a basic hospital medical plan to active members and non-Medicare eligible retirees. Benefits include inpatient hospitalization for a maximum of 365 days without a dollar limit, inpatient rehabilitation, outpatient care, physician services, and prescription drugs.

Active employees and non-Medicare eligible retirees who do not have Medicare eligible dependents can enroll in a health maintenance organization (HMO) in lieu of the basic hospital medical plan. The HMO includes hospital medical benefits, dental benefits, vision benefits, and an extensive formulary. However, participants in the HMO are required to receive care from a participating physician in the HMO plan.

The PEEHIP offers four optional plans (Hospital Indemnity, Cancer, Dental, and Vision) that may be selected in addition to or in lieu of the basic hospital medical plan or HMO. The Hospital Indemnity Plan provides a per-day benefit for hospital confinement, maternity, intensive care, cancer, and convalescent care. The Cancer Plan covers cancer disease only and benefits are provided regardless of other insurance. Coverage includes a per-day benefit for each hospital confinement related to cancer. The Dental Plan covers diagnostic and preventative services, as well as basic and major dental services. Diagnostic and preventative

services include oral examinations, teeth cleaning, x-rays, and emergency office visits. Basic and major services include fillings, general aesthetics, oral surgery not covered under a Group Medical Program, periodontics, endodontics, dentures, bridgework, and crowns. Dental services are subject to a maximum of \$1,250 per year for individual coverage and \$1,000 per person per year for family coverage. The Vision Plan covers annual eye examinations, eye glasses, and contact lens prescriptions.

PEEHIP members may opt to elect the PEEHIP Supplemental Plan as their hospital medical coverage in lieu of the PEEHIP Hospital Medical Plan. The PEEHIP Supplemental Plan provides secondary benefits to the member's primary plan provided by another employer. Only active and non-Medicare retiree members and dependents are eligible for the PEEHIP Supplemental Plan. There is no premium required for this plan, and the plan covers most out-of-pocket expenses not covered by the primary plan. The plan cannot be used as a supplement to Medicare, the PEEHIP Hospital Medical Plan, or the State or Local Governmental Plans administered by the State Employees' Insurance Board (SEIB).

Effective January 1, 2017, Medicare eligible members and Medicare eligible dependents who are covered on a retiree contract were enrolled in the United Healthcare Group Medicare Advantage plan for PEEHIP retirees. The MAPDP plan is fully insured by United Healthcare and members are able to have all of their Medicare Part A, Part B, and Part D (prescription drug coverage) in one convenient plan. With the United Healthcare plan for PEEHIP, retirees can continue to see their same providers with no interruption and see any doctor who accepts Medicare on a national basis. Retirees have the same benefits in and out-of-network and there is no additional retiree cost share if a retiree uses an out-of-network provider and no balance billing from the provider.

**Contributions.** The Code of Alabama 1975, Section 16-25A-8 and the Code of Alabama 1975, Section, 16-25A-8.1 provide the Board with the authority to set the contribution requirements for plan members and the authority to set the employer contribution requirements for each required class, respectively. Additionally, the Board is required to certify to the Governor and the Legislature, the amount, as a monthly premium per active employee, necessary to fund the coverage of active and retired member benefits for the following fiscal year. The Legislature then sets the premium rate in the annual appropriation bill.

For employees who retired after September 30, 2005, but before January 1, 2012, the employer contribution of the health insurance premium set forth by the Board for each retiree class is reduced by 2% for each year of service less than 25 and increased by 2% percent for each year of service over 25 subject to adjustment by the Board for changes in Medicare premium costs required to be paid by a retiree. In no case does the employer contribution of the health insurance premium exceed 100% of the total health insurance premium cost for the retiree.

For employees who retired after December 31, 2011, the employer contribution to the health insurance premium set forth by the Board for each retiree class is reduced by 4% for each year of service less than 25 and increased by 2% for each year over 25, subject to adjustment by the Board for changes in Medicare premium costs required to be paid by a retiree. In no case does the employer contribution of the health insurance premium exceed 100% of the total health insurance premium cost for the retiree. For employees who retired after December 31, 2011, who are not covered by Medicare, regardless of years of service, the employer contribution to the health insurance premium set forth by the Board for each retiree class is reduced by a percentage equal to 1% multiplied by the difference between the Medicare entitlement age and the age of the employee at the time of retirement as determined by the Board. This reduction in the employer contribution ceases upon notification to the Board of the attainment of Medicare coverage.

OPEB Liabilities, OPEB Expense, and Deferred Outflows of Resources and Deferred Inflows of Resources Related to OPEB. At September 30, 2019 and 2018, the financial statements of UAB reflected a liability of \$659.9 million and \$644.0 million, respectively for its proportionate share of collective net OPEB liability, as prescribed by GASB 75. The collective net OPEB liability was measured as of September 30, 2018 and the total OPEB liability used to calculate the net OPEB liability was determined by an actuarial valuation as of September 30, 2017. UAB's proportion of collective net OPEB liability was based on a projection of UAB's long-term share of contributions to the OPEB plan relative to the projected contributions of all participating employers, actuarially determined. At September 30, 2018, UAB's proportion was 8.03%, which was a decrease of 0.64% from its proportion measured as of September 30, 2017. At September 30, 2017, the UAB's proportion was 8.67%, which was an increase of 1.51% from its proportion measured as of September 30, 2016.

For the years ended September 30, 2019 and 2018, UAB recognized OPEB expense of \$52.9 million and \$58.3 million, respectively with no special funding situations. At September 30, 2019 and 2018, UAB reported deferred outflows of resources and deferred inflows of resources related to the PEEHIP plan from the following sources:

2019	Deferred Outflows of Resources		_	Deferred Inflows of Resources	
Differences between expected and actual experience	\$	12,424,148	\$	_	
Changes of assumptions		_		32,143,869	
Net difference between projected and actual earnings on OPEB plan investments		_		3,535,812	
Changes in proportion and differences between Employer contributions and proportionate share of contributions		82,105,791		44,278,802	
Employer contributions subsequent to the measurement date		19,976,210		_	
Total	\$	114,506,149	\$	79,958,483	

2018	Deferred Outflows of Resources	Deferred Inflows of Resources
Differences between expected and actual experience	\$ -	\$ -
Changes of assumptions	_	66,866,314
Net difference between projected and actual earnings on OPEB plan investments	_	3,428,753
Changes in proportion and differences between Employer contributions and proportionate share of contributions	101,516,146	_
Employer contributions subsequent to the measurement date	19,713,541	_
Total	\$ 121,229,687	\$ 70,295,067

\$20.0 million reported as deferred outflows of resources related to OPEB resulting from UAB's contributions subsequent to the measurement date will be recognized as a reduction of the net OPEB liability in the year ending September 30, 2020. Other amounts reported as deferred outflows of resources and deferred inflows of resources related to OPEB will be recognized in OPEB expense as follows:

Years ending September 30:							
2020	\$	3,806,827					
2021	\$	3,806,827					
2022	\$	3,806,827					
2023	\$	4,600,617					
2024	\$	(940,168)					
Thereafter	\$	(509,474)					

**Actuarial assumptions.** The total OPEB liability for the PEEHIP was determined by an actuarial valuation as of September 30, 2017, using the following actuarial assumptions, applied to all periods included in the measurement:

Inflation	2.75%	
Projected Salary Increases <sup>1</sup>	3.25% - 5.00%	
Long-Term Investment Rate of Return <sup>2</sup>	7.25%	
Municipal Bond Index Rate at the Measurement	4.18%	
Municipal Bond Index Rate at the Prior	3.57%	
Projected Year for Fiduciary Net Position (FNP) to be	2029	
Singe Equivalent Interest Rate the Measurement	4.44%	
Singe Equivalent Interest Rate the Prior	4.63%	
Healthcare Cost Trend Rate		
Pre-Medicare Eligible	7.00%	
Medicare Eligible (beginning in 2019)	5.00%	
Ultimate Trend Rate		
Pre-Medicare Eligible (in 2026)	4.75%	
Medicare Eligible (in 2024)	4.75%	

<sup>1</sup>Includes 3.00% wage inflation.

Mortality rates for the period after service retirement for both PEEHIP and UAB plan are according to the RP-2000 White Collar Mortality Table projected to 2020 using scale BB and adjusted 115% for all ages for males and 112% for ages 78 and over for females. The rates of disabled mortality were based on the RP-2000 Disabled Mortality Table projected to 2020 using scale BB and adjusted 105% for males and 120% for females.

There were no ad hoc postemployment benefit changes, including ad hoc cost of living adjustments, during PEEHIP's fiscal year 2018.

The decremental assumptions used in the valuation were selected based on the actuarial experience study prepared as of September 30, 2015, submitted to and adopted by the Teachers' Retirement System of Alabama Board on September 13, 2016.

The remaining actuarial assumptions (e.g., initial per capita costs, health care cost trends, rate of plan participation, rates of plan election, etc.) used in the September 30, 2017 PEEHIP valuation were based on a review of recent plan experience done concurrently with the September 30, 2017 valuation.

The long-term expected return on plan assets is to be reviewed as part of regular experience studies prepared every five years, in conjunction with similar analysis for the Teachers' Retirement System of Alabama. Several factors should be considered in evaluating the long-term rate of return assumption, including long-term historical data, estimates inherent in current market data, and a log-normal distribution analysis in which best-estimate ranges of expected future real rates of return (expected return, net of investment expense and inflation), as developed for each

major asset class. These ranges should be combined to produce the long-term expected rate of return by weighting the expected future real rates of return by the target asset allocation percentage and then adding expected inflation. The assumption is intended to be a long-term assumption and is not expected to change absent a significant change in the asset allocation, a change in the inflation assumption, or a fundamental change in the market that alters expected returns in future years.

The long-term expected rate of return on the OPEB plan investments is determined based on the allocation of assets by asset class and by the mean and variance of real returns.

The target asset allocation and best estimates of expected geometric real rates of return for each major asset class is summarized below:

	Target Allocation	Long-Term Expected Real Rate of Return*
Fixed Income	30.00 %	4.40 %
U.S. Large Stocks	38.00 %	8.00 %
U.S. Mid Stocks	8.00 %	10.00 %
U.S. Small Stocks	4.00 %	11.00 %
International Developed	15.00 %	9.50 %
Cash	5.00 %	1.50 %
	100.00 %	

<sup>\*</sup> Geometric mean, includes 2.5% inflation

Discount Rate. The discount rate (also known as the Single Equivalent Interest Rate (SEIR), as described by GASB 74) used to measure the PEEHIP total OPEB liability at September 30, 2018 was 4.44%. The discount rate used to measure the total OPEB liability at the prior measurement date was 4.63%. Premiums paid to the Public Education Employees' Health Insurance Board for active employees shall include an amount to partially fund the cost of coverage for retired employees. The projection of cash flows used to determine the discount rate assumed that plan contributions will be made at the current contribution rates. Each year, the State specifies the monthly employer rate that participating school systems must contribute for each active employee. Approximately, 20.307% of the employer contributions were used to assist in funding retiree benefit payments in 2018 and it is assumed that the amount will increase by 2.75% per year and continue into the future. The discount rate determination will use a municipal bond rate to the extent the trust is projected to run out of money before all benefits are paid. The rate used for this purpose is the monthly average of the Bond Buyers General Obligation 20year Municipal Bond Index Rate. Therefore, the projected future benefit payments for all current plan members were projected through 2116. The long term rate of return is used until the assets are expected to be depleted in 2029, after which the municipal bond rate is used.

<sup>&</sup>lt;sup>2</sup>Compounded annually, net of investment expense, and includes inflation.

Sensitivity of the UAB's proportionate share of the net OPEB liability to changes in the healthcare cost trend rates. The following table reflects UAB's proportionate share of the net OPEB liability of the Trust, as prescribed by GASB 75, calculated using the current healthcare trend rate, as well as what the net OPEB liability would be if calculated using one percentage point lower or one percentage point higher than the current rate. A one percent point decrease would change the current healthcare trend rate from 7.00% to 6.00%, the pre-Medicare from 5% to 4%, the Medicare eligible from 4.75% to 3.75%. A one percent point increase would change the current healthcare trend rate from 7.00% to 8.00%, the pre-Medicare from 5% to 6%, the Medicare eligible from 4.75% to 5.75%.

	1% Decrease	Current Healthcare Trend Rate	1% Increase
UAB's proportionate share of the collective net OPEB liability	\$ 542,463,733	\$ 659,913,266	\$ 809,442,914

The following table reflects UAB's proportionate share of the net OPEB liability of the Trust, as prescribed by GASB 75, calculated using the discount rate of 4.44%, as well as what the net OPEB liability would be if calculated using one percentage point lower or one percentage point higher than the current rate:

	1% Decrease (3.44%)	Current Discount Rate (4.44%)	1% Increase (5.44%)
UAB's proportionate share of the collective net OPEB liability	\$ 788,316,306	\$ 659,913,266	\$ 556,337,758

**OPEB plan fiduciary net position.** Detailed information about the OPEB plan's fiduciary net position is located in the Trust's financial statements for the fiscal year ended September 30, 2018. The supporting actuarial information is included in the GASB Statement No. 74 Report for PEEHIP prepared as of September 30, 2018. Additional financial and actuarial information is available at www.rsa-al.gov.

### **UAB Plan**

**Plan description.** The UAB plan is considered a single-employer plan which is administered by University of Alabama at Birmingham (UAB). The UAB Plan offers its members hospital benefits, major medical benefits, a prescription drug program and a basic term life insurance up to an established maximum policy limit. The health care benefits cover medical and hospitalization costs for retirees and their dependents. The portion of the UAB plan related to health care may be amended by the approval of the President of UAB upon recommendation from the Benefits Committee. The portion of the UAB plan related to the life insurance may be amended by the System.

**Benefits provided.** UAB employees can participate in the UAB plan as a retiree if the following condition are met; retiree has 25 years of creditable service, regardless of age

(Tier I only), or retiree has 10 years of service and is 60 years old (62 years old for Tier II), or retiree has 10 years of service and is determined disabled the Social Security Administration or the Teachers' Retirement System of Alabama's Medical Board. These retired UAB employees may elect to continue to participate in UAB plan until they are eligible for Medicare by paying the full cost of the plan premium. Retired employees age 65 or older who are eligible for Medicare must enroll in the Medicare Coordinated Plan under which Medicare is the primary insurer and UAB plan becomes the secondary insurer. Despite the availability of the UAB plan, most retirees elect to participate in the PEEHIP with TRS. The UAB Plan consists of hospital benefits, major medical benefits, a prescription drug program and a basic term life insurance up to an established maximum policy limit.

Employees included in the actuarial valuation include active employees, retirees and disabled employees enrolled in the medical plan and retirees not enrolled in the medical plan with retiree life insurance. The following table summarizes the membership of the UAB Plan as of September 30, 2018, the Valuation Date.

Membership:	2019
Inactive Employees or Beneficiaries Currently Receiving Benefits	302
Inactive Members Entitled To But Not Yet Receiving Benefits	_
Active Employees	12,427
Total Membership	12,729

**Contributions.** UAB retired employees make contributions to the plan by making premium payments associated with their selected health plan option. Eligible disabled retirees are responsible for only the employee portion of those premiums and UAB is responsible for the employer portion. All other UAB retirees are responsible for the full premium cost of the plan and in no case does the employer contribute to the plan.

OPEB Liabilities, OPEB Expense, and Deferred Outflows of Resources and Deferred Inflows of Resources Related to OPEB. At September 30, 2019 and 2018, UAB reported a liability of \$17.7 million and \$20.3 million, respectively for the total OPEB liability (TOL). The TOL is based upon an actuarial valuation as of the valuation date, September 30, 2018. An expected TOL is determined as of September 30, 2017, the prior measurement date, using standard roll back techniques. The roll back calculation begins with the TOL, as of the Measurement Date, September 30, 2017, adds the expected benefit payments for the year, deducts interest at the Discount Rate for the year, and then subtracts the annual Normal Cost (also called the Service Cost).

For the years ended September 30, 2019 and 2018, UAB recognized OPEB expense of \$576,312 and \$102,851, respectively with no special funding situations. At September 30, 2019, UAB reported deferred outflows of resources and deferred inflows of resources related to the UAB plan from the following sources:

2019	De	eferred Outflows of Resources	_	eferred Inflows of Resources
Differences between expected and actual experience	\$	_	\$	698,451
Changes of assumptions		_		1,426,060
Employer contributions subsequent to the measurement period		1,877,839		-
Total	\$	1,877,839	\$	2,124,511

2018	 erred Outflows f Resources	 erred Inflows Resources
Differences between expected and actual experience	\$ _	\$ _
Changes of assumptions	_	853,339
Employer contributions subsequent to the measurement period	2,502,675	_
Total	\$ 2,502,675	\$ 853,339

Other amounts reported as deferred outflows of resources and deferred inflows of resources related to OPEB will be recognized in OPEB expense as follows:

Year ended Se	ptember 30:	
2019	\$	(283,351)
2020	\$	(283,351)
2021	\$	(283,351)
2022	\$	(283,351)
2023	\$	(283,351)
Thereafter	\$	(707,756)

**Actuarial assumptions.** The total OPEB liability for the UAB plan was determined by an actuarial valuation as of September 30, 2017, using the following actuarial assumptions, applied to all periods included in the measurement:

Inflation	2.75%
Real Wage Growth	0.25%
Projected Salary Increases <sup>1</sup>	3.25% - 5.00%
Wage inflation.	3.00%
Municipal Bond Index Rate at the Measurement Date	4.18%
Municipal Bond Index Rate at the Prior Measurement Date	3.57%
Healthcare Cost Trend Rate	
Pre-Medicare Medical and Prescription Drug (decreasing to an ultimate rate of 4.75% by 2026)	7.00 %
Medicare Medical and Prescription Drug (beginning in 2019 decreasing to an ultimate rate of 4.75 % by 2024)	4.75%

<sup>1</sup>Includes 3.00% wage inflation.

Mortality rates for the period after service retirement for the UAB plan are according to the RP-2000 White Collar Mortality Table projected to 2020 using scale BB and adjusted 115% for all ages for males and 112% for ages 78 and over for females. The rates of disabled mortality were based on the RP-2000 Disabled Mortality Table projected to 2020 using scale BB and adjusted 105% for males and 120% for females.

There were no ad hoc postemployment benefit changes, including ad hoc cost of living adjustments to the UAB plan, during fiscal year 2019.

The decremental assumptions used in the valuation were selected based on the actuarial experience study prepared as of September 30, 2015, and are reasonable expectations of anticipated experience under the Plan.

The remaining actuarial assumptions (e.g., initial per capita costs, health care cost trends, rate of plan participation, rates of plan election, etc.) used in the September 30, 2017 UAB plan valuation were based on a review of recent plan experience done concurrently with the September 30, 2017 valuation.

The UAB plan does not hold any plan assets, as such, there are no long-term expected rate of return or target allocation presented.

**Discount Rate.** The discount rate, as defined by Paragraph 155 of GASB 75 to be a 20-year tax- exempt municipal bond (rating AA/Aa or higher) rate (Municipal Bond Index Rate). The Municipal Bond Index Rate used for this purpose is the September average of the Bond Buyer General Obligation 20-year Municipal Bond Index published weekly by The Bond Buyer (www.bondbuyer.com). On the Prior Measurement Date, the Municipal Bond Index Rate was 3.57%. There was a change in the Municipal Bond Index Rate from the Prior Measurement Date to the Measurement Date. The Municipal Bond Index Rate as of the Measurement Date was 4.18%.

Sensitivity of the UAB Plan's net OPEB liability to changes in the healthcare cost trend rates. The following table presents the total OPEB Liability of the UAB Plan, calculated using the current healthcare trend rate, as well as what the total OPEB Liability would be if calculated using one percentage point lower or one percentage point higher than the current rate. A one percent point decrease would change the current healthcare trend rate from 7.00% to 6.00% and pre-Medicare from 4.75% to 3.75%. A one percent point increase would change the current healthcare trend rate from 7.00% to 8.00% and the pre-Medicare from 4.75% to 5.75%.

	19	% Decrease	Current lealthcare rend Rate	1	% Increase
UAB's total OPEB liability	\$	16,689,006	\$ 17,698,575	\$	18,824,560

The following table presents the total OPEB Liability of the UAB Plan, calculated using the discount rate of 4.18%, as well as what the total OPEB liability would be if calculated using one percentage point lower or one percentage point higher than the current rate:

		1%	Decrease (3.18%)	Di	Current scount Rate (4.18%)	19	% Increase (5.18%)
ı	UAB's total OPEB liability	\$	18,988,831	\$	17,698,575	\$	16,558,440

**Changes in the Total OPEB Liability.** Since the UAB Plan does not meet the definition within paragraph 4 of GASB Statement No 75, UAB is disclosing a schedule of changes in the total OPEB liability below:

	2019
Total OPEB Liability as of September 30, 2018	\$ 20,320,823
Changes for the year:	
Service Cost as end of year*	168,312
Interest on TOL and Cash Flows	691,351
Changes in benefit terms	_
Difference between expected and actual experience	(787,087)
Changes of assumptions or other inputs	(767,436)
Benefit payments	(1,927,388)
Net changes	\$ (2,622,248)
Total OPEB Liability as of September 30, 2019	\$ 17,698,575

<sup>\*</sup>The service cost include interest for the year.

# (11) Federal Direct Student Loan Program

The Federal Direct Student Loan Program (FDSLP) was established under the Higher Education Act of 1965, as amended in the Student Loan Reform Act of 1993. The FDSLP enables an eligible student or parent to obtain a loan to pay for the student's cost of attendance directly through the university rather than through private lenders. UAB began participation in the FDSLP on July 1, 1994. As a university qualified to originate loans, UAB is responsible for handling the complete loan process, including funds management, as well as promissory note functions. UAB is not responsible for collection of these loans. During the years ended September 30, 2019 and 2018, respectively, disbursed approximately \$167.1 million and UAB \$167.3 million under the FDSLP, respectively.

### (12) Grants and Contracts

At September 30, 2019 and 2018, respectively, UAB had been awarded approximately \$546.3 million and \$512.3 million in grants and contracts which had not been expended. These awards, which represent commitments of sponsors to provide funds for specific research, training, and service projects, have not been reflected in the financial statements.

# (13) Operating Expenses by Function

Total operating expenses by functional classification for the years ended September 30, 2019 and 2018 are as follows for UAB:

	<b>2019</b> (by fu	perating Expe	nse	s		
	llaries, Wages, and Benefits	Supplies and Services		epreciation and Amortization	Scholarships and Fellowships	Total
Instruction	\$ 251,833,619	\$ 35,393,500	\$		\$ _	\$ 287,227,119
Research	181,672,641	121,470,937		-	_	303,143,578
Public service	114,342,866	50,114,594		_	_	164,457,460
Academic support	159,575,762	21,001,224		_	_	180,576,986
Student services	28,353,005	14,101,853		_	_	42,454,858
Institutional support	95,936,734	60,752,918		_	_	156,689,652
Operations and maintenance of plant	37,905,573	32,841,931		_	_	70,747,504
Scholarships and fellowships	_	_		_	29,041,268	29,041,268
Hospital	808,705,699	904,354,651		_	_	1,713,060,350
Auxiliary	70,735,039	606,222,882		-	_	676,957,921
Depreciation	_	_		148,344,143	_	148,344,143
Total Operating Expenses	\$ 1,749,060,938	\$ 1,846,254,490	\$	148,344,143	\$ 29,041,268	\$ 3,772,700,839

	<b>2018</b> (by fu	perating Expe	nse	s			
	llaries, Wages, and Benefits	Supplies and Services		epreciation and Amortization	S	cholarships and Fellowships	Total
Instruction	\$ 250,164,211	\$ 34,646,118	\$	_	\$	_	\$ 284,810,329
Research	173,462,671	115,171,617		_		_	288,634,288
Public service	113,420,025	50,991,271		_		_	164,411,296
Academic support	152,857,956	21,446,293		_		_	174,304,249
Student services	28,148,560	14,544,409		_		_	42,692,969
Institutional support	82,186,048	59,165,635		_		_	141,351,683
Operations and maintenance of plant	34,208,815	32,705,420		_		_	66,914,235
Scholarships and fellowships	_	_		_		27,779,628	27,779,628
Hospital	774,548,034	827,709,076		-		-	1,602,257,110
Auxiliary	65,994,368	578,031,120		-		_	644,025,488
Depreciation	_	-		146,686,513		_	146,686,513
Total Operating Expenses	\$ 1,674,990,688	\$ 1,734,410,959	\$	146,686,513	\$	27,779,628	\$ 3,583,867,788

# (14) Contingencies and Commitments

UAB has sovereign immunity and is, therefore, in the opinion of UAB counsel, immune to ordinary tort actions including those based on medical malpractice or general injury to patients. Consequently, while UAB is sometimes named as defendant in malpractice actions and other actions for injuries arising in the Hospital, it has consistently been dismissed from those lawsuits on the basis of the sovereign immunity doctrine. That doctrine also protects UAB from vicarious liability arising from the negligence of its employees. To the extent that UAB employees are sued in their individual capacity for actions related to their official duties within the line and scope of their employment, UAB has defended those actions and paid for any resulting costs through its self-insured trust fund. While UAB is not aware of any impending threat to this doctrine, UAB is a named insured under the terms of the PLTF and excess insurance purchased from commercial companies (Note 8). There are some exceptions to the sovereign immunity doctrine, most notably federal court cases arising under the federal constitution or federal statutes.

UAB is engaged in various legal actions in the ordinary course of business. Management does not believe the ultimate outcome of these actions will have a material adverse effect on the financial statements. However, the settlement of legal actions is subject to inherent uncertainties and it is possible that such outcomes could differ materially from management's current expectations.

Amounts received or receivable from grantor agencies are subject to audit and adjustments by such agencies, principally the United States Government. Any disallowed claims, including amounts already collected, may constitute a liability of UAB. The amount, if any, of expenditures that may be disallowed by the grantor cannot be determined at this time, although UAB expects any such amounts to be immaterial.

UAB has contracted for the construction and renovation of several facilities. At September 30, 2019 and 2018, the estimated remaining cost to complete the construction and renovation of these facilities was approximately \$246 million and \$282 million, respectively, which is expected to be financed from private gifts, grants, bond proceeds, and UAB reserves.

# (15) Segment Reporting

As discussed in Note 1, UAB's two significant identifiable activities that have bonds outstanding where revenue is pledged in support of the bonds are the University and the Hospital. Condensed financial statement information related to the University and Hospital as of and for the years ended September 30, 2019 and 2018 is as follows:

UNIVERSITY		2019		2018
CONDENSED STATEMENTS OF NET POSITION				
Current assets	\$	803,788,221	\$	729,161,329
	Ψ		Ψ	
Capital assets, net		1,123,608,474		1,064,526,904
Other assets	_	951,213,153		807,443,751
TOTAL ASSETS	\$	2,878,609,848	\$	2,601,131,984
DEFERRED OUTFLOW OF RESOURCES	\$	203,548,877	\$	188,944,572
TOTAL ASSETS AND DEFERRED OUTFLOWS OF RESOURCES	\$	3.082.158.725	\$	2.790.076.556
Current liabilities		323,028,646		308,190,717
Long-term debt		624,939,646		460,629,168
Other noncurrent liabilities		1,180,783,793		1,168,595,713
TOTAL LIABILITIES	\$	2,128,752,085	\$	1,937,415,598
DEFERRED INFLOW OF RESOURCES	\$	143,674,851	\$	140,753,365
Net investment in capital assets		620,309,247		606,482,225
Restricted nonexpendable		401,505,297		385,517,036
Restricted expendable		330,611,740		305,697,808
Unrestricted		(542,694,495)		(585,789,476)
TOTAL NET POSITION	\$	809,731,789	\$	711,907,593
TOTAL LIABILITIES, DEFERRED INFLOWS AND NET POSITION	\$	3.082.158.725		2.790.076.556
CONDENSED STATEMENTS OF REVENUES EVERNICES AND QUANCES IN				
CONDENSED STATEMENTS OF REVENUES, EXPENSES AND CHANGES IN				
Tuition and fees, net	\$	239,912,344	\$	253,707,923
Grant and contract revenue		494,047,342		461,633,394
Sales and services, educational		67,616,490		68,464,868
Other operating revenues		116,635,954		103,338,320
Salaries, wages, and benefits		(891,465,112)		(856,904,362)
Supplies and services		(367,622,835)		(360,697,738)
Depreciation		(75,251,119)		(74,865,905)
Scholarships and fellowships	_	(29,040,392)	_	(27,779,628)
OPERATING LOSS	_	(445,167,328)	_	(433,103,128)
State appropriations		253,102,906		239,944,876
Investment income		13,591,529		51,583,890
Interest expense		(13,088,125)		(12,789,385)
Gifts		46,152,386		33,913,813
Other nonoperating revenues		40,282,427	_	33,261,051
LOSS BEFORE OTHER CHANGES IN NET POSITION		(105,126,205)		(87,188,883)
Capital gifts and grants		789,044		2,282,241
Endowment gifts		29,098,263		18,401,517
Intergovernmental transfers		173,063,095	_	160,097,420
INCREASE IN NET POSITION		97,824,197	_	93,592,295
Net position, beginning of year		711,907,593		928,095,581
Adoption of 75		_		(309,780,283)
Net Position, beginning of year as restated as of October 1, 2017		711,907,593	_	618,315,298
NET POSITION, END OF YEAR	\$	809,731,790	\$	711,907,593
CONDENSED STATEMENTS OF CASH FLOWS				
Net cash provided by (used in):				
Operating activities	\$	(389,066,206)	\$	(368,620,596)
Noncapital financing activities		540,437,693		495,726,637
Investing activities		(51,845,275)		59,561,004
Capital and related financing activities		21,952,161		(186,017,051)
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS		121,478,373		649,994
Cash and cash equivalents, beginning of year		97,466,495		96,816,501
CASH AND CASH EQUIVALENTS, END OF YEAR	\$	218.944.868	\$	97.466.495

HOSPITAL		2019		2018
CONDENSED STATEMENTS OF NET POSITION	_		_	
Current assets	\$	984,037,176	\$	825,383,460
Capital assets, net		594,578,200	•	579,688,386
Other assets		662,765,113		655,167,341
TOTAL ASSETS	\$	2,241,380,489	\$	2,060,239,187
DEFERRED OUTFLOW OF RESOURCES	\$	110,192,665	\$	108,582,095
TOTAL ASSETS AND DEFERRED OUTFLOWS OF RESOURCES	\$	2,351,573,154	\$	2,168,821,282
Current liabilities		127,767,027		116,909,996
Long-term debt		502,151,049		441,661,316
Other noncurrent liabilities		689,120,222		682,363,248
TOTAL LIABILITIES	\$	1,319,038,298	\$	1,240,934,560
DEFERRED INFLOW OF RESOURCES	\$	81,140,021	\$	77,511,348
Net investment in capital assets		134,347,019		134,941,156
Restricted nonexpendable		128,099		1,121,797
Restricted expendable		35,878,430		36,186,903
Unrestricted		781,041,287		678,125,518
TOTAL NET POSITION	\$	951,394,835	\$	850,375,374
TOTAL LIABILITIES, DEFERRED INFLOWS AND NET POSITION	\$	2,351,573,154	\$	2,168,821,282
CONDENSED STATEMENTS OF REVENUES, EXPENSES AND CHANGES IN				
Operating revenues	\$	2,008,333,371	\$	1,864,776,264
Operating expenses		(1,713,161,226)	•	(1,602,357,111)
Depreciation expense		(72,137,317)		(70,588,213)
OPERATING INCOME		223,034,828	_	191,830,940
State appropriations		34,588,829		33,406,248
Investment income		15,224,317		38,191,857
Interest expense		(16,666,917)		(16,175,076)
Gifts		111,817		95,670
Other nonoperating revenues		(1,706,373)		(2,500,741)
INCOME BEFORE OTHER CHANGES IN NET POSITION		254,586,501		244,848,898
Capital gifts and grants		275		3,085
Intergovernmental transfers		(153,567,313)		(144,260,386)
INCREASE IN NET POSITION		101,019,463		100,591,597
Net position, beginning of year		850,375,374		978,376,939
Adoption of 75		_		(228,593,162)
Net Position, beginning of year as restated as of October 1, 2017		850,375,374		749,783,777
NET POSITION, END OF YEAR	\$	951,394,837	\$	850,375,374
CONDENSED STATEMENTS OF CASH FLOWS				
Net cash provided by (used in):				
Operating activities		279,439,132		252,068,699
Noncapital financing activities		(119,860,364)		(110,758,469)
Investing activities		(18,118,961)		(57,905,657)
Capital and related financing activities		(83,941,304)		(89,607,785)
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS		57,518,503		(6,203,212)
Cash and cash equivalents, beginning of year		31,003,295		37,206,507
CASH AND CASH EQUIVALENTS, END OF YEAR	\$	88,521,798	\$	31,003,295

## (16) Health Care Services

### **Net Patient Service Revenue**

The Hospital has agreements with governmental and other third-party payors that provide for reimbursement to the Hospital at amounts different from its established rates. Contractual adjustments under third-party reimbursement programs represent the difference between the Hospital's billings at established rates for services and amounts reimbursed by third-party payors. A summary of the basis of reimbursement with major third-party payors follows:

**Medicare.** Substantially all acute-care services rendered to Medicare program beneficiaries are paid at prospectively determined rates. These rates vary according to the patient classification systems that are based on clinical, diagnostic, and other factors. Additionally, University Hospital is reimbursed for both its direct and indirect medical education costs (as defined), principally based on per-resident prospective payment amounts and certain adjustments to prospective rate-per-discharge operating reimbursement payments. The Hospital generally is reimbursed for certain retroactively settled items at tentative rates, with final settlement determined after submission of annual cost reports by the Hospital and audits by the Medicare fiscal intermediary, the Hospital's cost reports have been audited and settled for all fiscal years through 2012. Revenue from the Medicare program accounted for approximately 21% of the Hospital's net patient service revenue for the years ended September 30, 2019 and 2018.

Section 302 of the Tax Relief and Health Care Act of 2006 authorized a permanent program involving the use of third-party recovery audit contractors (RACs) to identify Medicare overpayments and underpayments made to providers. As of September 30, 2019, the Hospital reported claims in various stages of review based on the requests received by the RACs during the fiscal year. Payment recoveries resulting from RAC reviews are appealable through administrative and judicial processes, and the Hospital intends to pursue the reversal of adverse determinations, where appropriate the Hospital cannot predict with certainty the impact of the Medicare RAC program on our future results of operations or cash flows.

Blue Cross. Inpatient services rendered to Blue Cross subscribers are paid at a prospectively determined per diem rate. Outpatient services are reimbursed at a prospectively determined rate or under a cost reimbursement methodology. The method of reimbursement is determined by the procedures that are performed. For outpatient services reimbursed under the cost reimbursement methodology, a final settlement is determined after submission of annual cost reports by the Hospital and audits thereof by Blue Cross. The Hospital's Blue Cross cost reports have been audited and settled for all fiscal years through 2016. Effective December 1, 2016 Blue Cross outpatient services began being reimbursed under the Ambulatory Payment Group methodology. This is a prospective payment methodology with no retroactive settlement. Revenue from the Blue Cross program accounted for approximately 34% of the Hospital's net patient service revenue for the years ended September 30, 2019 and 2018.

**Medicaid.** Inpatient services rendered to Medicaid program beneficiaries are reimbursed at all-inclusive prospectively determined per diem rates. Outpatient services are reimbursed based on an established fee schedule. the Hospital is designated as a Disproportionate Share Hospital (DSH) and receives payments under the Medicaid DSH program. In addition, as a participant in the Alabama Medicaid Plan, the Hospital also receives supplemental payments based on formulas established by the Alabama Medicaid Agency. The net benefit associated with the Hospital's participation in these programs, totaling approximately \$65.1 million and \$56.8 million in 2019 and 2018, respectively, is included in net patient service revenue in the accompanying statement of revenues, expenses and changes in net position. There can be no assurance that the Hospital will continue to qualify for future participation in these programs or that the programs will not ultimately be discontinued or materially modified.

Revenue from the Medicaid program accounted for approximately 16% of the Hospital's net patient service revenue for the year ended September 30, 2019 and 14% for the year ended September 30, 2018.

**Other.** The Hospital has also entered into payment agreements with certain commercial insurance carriers, health maintenance organizations, and preferred provider organizations. The basis for payments to the Hospital under these agreements includes discounts from established charges and prospectively determined daily and case rates.

The composition of Hospital operating revenue follows:

	2019	2018
Gross Patient Service Revenue	\$ 7,839,365,711	\$ 6,995,013,022
Less Provision for Contractual and Other Adjustments	(5,969,587,958)	(5,294,475,882)
Less Provision for Bad Debts	(157,700,738)	(152,151,403)
Net Patient Service Revenue	\$ 1,712,077,015	\$ 1,548,385,737
Capitation Revenue	73,206,414	75,816,425
Other Operating Revenue	223,035,722	240,553,387
Total Hospital Sales Revenue	\$ 2,008,319,151	\$ 1,864,755,549

### **Charity Care**

The Hospital maintains records to identify and monitor the level of charity care it provides. These records include the amount of charges foregone for services and supplies furnished under its charity care policy, the estimated costs of those services, and supplies and equivalent service statistics.

The estimated cost of charity care provided during the years ended September 30, 2019 and 2018 was approximately \$32.3 million and \$34.8 million, respectively, calculated based on the ratio of total direct and indirect costs to establish charges applied to the charges foregone under the charity care policy.

	2019	2018
Approximate charges foregone, based on established rates	\$ 123,735,691	\$ 143,380,483
Percentage of charity charges to total charges	1.6%	2.0%

### **Credit Risk**

The Hospital grants credit without collateral to its patients, most of whom are local residents and are insured under third-party payor agreements. The mix of receivables from patients and third-party payors at September 30, 2019 and 2018 follows:

	2019	2018
Other	45%	48%
Blue Cross	35%	33%
Medicare	13%	12%
Medicaid	7%	7%
	100%	100%

### **Related Parties**

The Hospital and the other divisions of UAB provide a variety of support services to each other. The cost of these services is allocated to the end user on bases which vary according to the service being furnished. These services are paid for by transfers of funds which reduce operating expenses of the unit providing the service and are included in the operating costs of the unit receiving the service. Administrative and purchased services provided by UAB and allocated to and reimbursed by the Hospital during the years ended September 30, 2019 and 2018 were approximately \$38.7 million and \$36.8 million, respectively. In addition, during the years ended September 30, 2019 and 2018, the Hospital transferred approximately \$153.6 million and \$144.3 million, respectively, to UAB to support UAB's academic and medical programs.

As noted in footnote 7, in June 2019, University Hospital borrowed \$77.0 million of UAB Medicine Finance Authority 2019A and 2019B Revenue Bond proceeds from UAB Health System. \$31.4 million of the loan amount was distributed to the Hospital during the year ended September 30, 2019 for capital improvement project spending during the year and the remaining \$45.6 million is held in trust for future projects. The Hospital recorded a note payable for the \$77.0 million loan amount and the undistributed amounts are recorded as Due from UAB Health System and classified as Due from affiliate on the statement of net position.

During 2008, University Hospital entered into an operating agreement with HSF whereby HSF would lease two floors of the Women and Infants Center ("WIC"). HSF reimbursed University Hospital for construction costs of this space as they were incurred on a square-footage basis. Total reimbursements are being amortized as rent revenue on a straight-line basis over a period equal to the 90 year total lease term, commencing on February 22, 2010, the date the building was placed into service. The Hospital had received reimbursements from HSF totaling approximately \$14.7 million in 2019 and 2018, of which approximately \$12.9 million and \$13.1 million respectively, is included in the accompanying statement of net position as unearned revenue-other for the years ended September 30, 2019 and 2018, respectively.

The Board and the HSF's board have entered into an agreement under which UAB and HSF have established a common management group, the UAB Health System (Health System), to provide management for their existing and future health care delivery operations.

In connection with its agreement with the Health System, the Hospital partially funded the operations of the Health System and its corporate office, charging approximately \$13.2 million and \$13.3 million to other operating expense in fiscal year 2019 and 2018, respectively. The Hospital also received equity transfers of approximately \$3.7 million and made equity transfers of \$9.9 million to the Health System during fiscal 2019 and 2018, respectively. In addition, the Health System periodically makes payments on behalf of the Hospital for which it is reimbursed. The Hospital had a net payable to the Health System of approximately \$6.7 million and \$7.2 million at September 30, 2019 and 2018, respectively.

In March 2014, the Hospital assumed operations of the outpatient clinics in The Kirklin Clinic and entered into an agreement with HSF to lease the land and the building known as The Kirklin Clinic. The initial term of the lease, which is cancellable by either party upon proper written notice and without penalty, is five years, with automatic one-year renewals thereafter.

VF's primary purpose is to provide a group medical practice for physicians who are faculty members in the UAB School of Medicine Huntsville program. It is governed by a 17-member board of directors, consisting of three nonvoting members and 14 voting members, of whom seven are affiliated with UAB.

The Hospital received premium revenue (capitation fees) of approximately \$73 million and \$76 million from Triton during the years ended September 30, 2019 and 2018, respectively.

The Hospital purchased \$406 million and \$354 million in management, administrative, and staffing services from the LLC during the years ended September 30, 2019 and 2018, respectively. Payment for contract labor as reported on the Statements of Cash Flows includes amounts paid to employees of the LLC and HSF.

## (17) Recently Issued Pronouncements

The GASB issued Statement No. 83, Certain Asset Retirement Obligations, in November 2016. This Statement addresses accounting and financial reporting for certain asset retirement obligations (AROs). This statement is effective for reporting periods beginning after June 15, 2018. UAB evaluated its assets subject to this guidance and determined that the impact from its adoption of GASB 83 was not material to the financial statements.

The GASB issued Statement No. 84, Fiduciary Activities, in January 2017. The objective of this Statement is to improve guidance regarding the identification of fiduciary

activities for accounting and financial reporting purposes and how those activities should be reported. This statement is effective for reporting periods beginning after December 15, 2018. UAB is evaluating whether there will be any material impact from its adoption of GASB 84.

The GASB issued Statement No. 87, Leases, in June 2017. The objective of this Statement is to better meet the information needs of financial statement users by improving accounting and financial reporting for leases by governments. This statement is effective for reporting periods beginning after December 15, 2019. UAB is evaluating whether there will be any material impact from its adoption of GASB 87.

The GASB issued Statement No. 88, Certain Disclosures Related to Debt, Including Direct Borrowings and Direct Placements, in April 2018. The objective of this Statement is to improve the information that is disclosed in notes to government financial statements related to debt, including direct borrowings and direct placements. It also clarifies which liabilities governments should include when disclosing information related to debt. This statement is effective for reporting periods beginning after June 15, 2018. Refer to Note 7 for enhanced disclosures related to UAB's long-term debt.

The GASB issued Statement No. 89, Accounting for Interest Cost Incurred before the End of a Construction Period, in June 2018. The objectives of this Statement are (1) to enhance the relevance and comparability of information about capital assets and the cost of borrowing for a reporting period and (2) to simplify accounting for interest cost incurred before the end of a construction period. This statement is effective for reporting periods beginning after December 15, 2019. UAB is evaluating whether there will be any material impact from its adoption of GASB 89.

The GASB issued Statement No. 90, Majority Equity Interest - An Amendment of GASB Statements No. 14 and No. 61, in August 2018. The primary objectives of this Statement are to improve the consistency and comparability of reporting a government's majority equity interest in a legally separate organization and to improve the relevance of financial statement information for certain component units. This statement is effective for reporting periods beginning after December 15, 2018. UAB is evaluating whether there will be any material impact from its adoption of GASB 90.

The GASB issued Statement No. 91, Conduit Debt Obligations, in May 2019. The objectives of this Statement are to provide a single method of reporting conduit debt obligations by issuers and eliminate diversity in practice associated with (1) commitments extended by issuers, (2) arrangements associated with conduit debt obligations, and (3) related note disclosures. This statement is effective for reporting periods beginning after December 15, 2020. UAB is evaluating whether there will be any material impact from its adoption of GASB 91.

# The University of Alabama at Birmingham Required Supplementary Information (Unaudited)

The following required supplementary information relates to UAB's participation in the Teachers' Retirement System of Alabama.

### Schedule of UAB's Proportionate Share of the Net Pension Liability Teachers' Retirement Plan of Alabama

_	2019 2018		2018	2017		2016		2015		
Employer's proportion of the net pension liability		11.750518%		11.814264%		11.863961%		11.916376%		12.188512%
Employer's proportionate share of the collective net	\$	1,168,305,000	\$	1,161,162,000	\$	1,284,396,000	\$	1,247,128,000	\$	1,107,275,000
Employer's covered payroll during the measurement	\$	916,059,000	\$	901,338,000	\$	876,899,000	\$	864,300,000	\$	880,666,000
Employer's proportionate share of the collective net pension liability as a percentage of its covered payroll		127.54%		128.83%		146.47%		144.29%		125.73%
Plan fiduciary net position as a percentage of the total collective pension liability		72.29%		71.50%		67.93%		67.51%		71.01%

### Schedule of UAB's Contributions Teachers' Retirement Plan of Alabama

	2019			2018		2017		2016		2015
Contractually required contribution	\$	94,900,000	\$	91,228,000	\$	88,660,000	\$	86,334,000	\$	84,999,000
Contributions in relation to the contractually required contribution	\$	94,900,000	\$	91,228,000	\$	88,660,000	\$	86,334,000	\$	84,999,000
Contribution deficiency (excess)		_		_		_		_		_
Employer's covered payroll	\$	940,203,000	\$	916,059,000	\$	901,338,000	\$	876,899,000	\$	864,300,000
Contributions as a percentage of covered payroll		10.09%		9.96%		9.84%		9.85%		9.83%

### Notes to Schedules

Employer's covered payroll: The payroll on which contributions to a pension plan are based.

### Measurement period:

For fiscal year 2019, the measurement period is October 1, 2017 – September 30, 2018 For fiscal year 2018, the measurement period is October 1, 2016 – September 30, 2017 For fiscal year 2017, the measurement period is October 1, 2015 – September 30, 2016 For fiscal year 2016, the measurement period is October 1, 2014 – September 30, 2015 For fiscal year 2015, the measurement period is October 1, 2013 – September 30, 2014

# The University of Alabama at Birmingham Required Supplementary Information (Unaudited)

The following required supplementary information related to UAB's participation in the Alabama Retired Education Employees' Health Care Trust (PEEHIP).

Schedule of UAB's Proportionate Share of the Net OPEB Liability Alabama Retired Education Employees' Health Care Trust (PEEHIP)

	2019			2018		
Employers' proportion of the net OPEB liability		8.029386%		8.670675%		
Employer's proportionate share of the net OPEB liability	\$	659,913,266	\$	644,008,211		
Employer's covered-employee payroll during the measurement period	\$	922,919,000	\$	908,353,000		
Employer's covered-employee payroll OPEB liability (asset) as a percentage of its covered-payroll		71.50%		70.90%		
Plan fiduciary net position as a percentage of the total OPEB liability		14.81%		15.37%		

### Schedule of UAB's Contributions to the Alabama Retired Education Employees' Health Care Trust (PEEHIP)

	2019			2018
Contractually required contribution	\$	19,976,210	\$	19,713,541
Contributions in relation to the contractually required contribution	\$	19,976,210	\$	19,713,541
Contribution deficiency (excess)		-		-
Employer's covered-employee payroll	\$	911,573,992	\$	922,919,000
Contributions as a percentage of covered-employee payroll		2.19%		2.14%

### **Notes to Schedules**

Employer's covered payroll: The payroll on which contributions to an OPEB plan are based.

### Measurement period:

For fiscal year 2019, the measurement period is October 1, 2017 – September 30, 2018 For fiscal year 2018, the measurement period is October 1, 2016 – September 30, 2017

# The University of Alabama at Birmingham Required Supplementary Information (Unaudited)

The following required supplementary information is related to the UAB Health Care Plan.

### Schedule of Change in UAB Health Care Plan's Total OPEB Liability

	2019			2018		
Total OPEB Liability	\$	20,320,823	\$	26,032,496		
Service Cost as end of year*		168,312		6,230,996		
Interest on TOL and Cash Flows		691,351		690,596		
Changes in benefit terms		_		(6,710,449)		
Difference between expected and actual experience		(787,087)		_		
Changes of assumptions or other inputs		(767,436)		(961,631)		
Benefit payments		(1,927,388)		(4,961,185)		
Net changes in Total OPEB Liability	\$	(2,622,248)	\$	(5,711,673)		
Total OPEB Liability - Beginning	\$	20,320,823	\$	26,032,496		
Total OPEB Liability - Ending	\$	17,698,575	\$	20,320,823		
Covered-employee payroll	\$	922,919,000	\$	908,353,000		
Total OPEB Liability as a percentage of covered-employee payroll		1.92%		2.24%		

<sup>\*</sup>The service cost include interest for the year.

### **Notes to Schedules**

Employer's covered payroll: The payroll on which contributions to an OPEB plan are based.

### Measurement period:

For fiscal year 2019, the measurement period is October 1, 2017 – September 30, 2018 For fiscal year 2018, the measurement period is October 1, 2016 – September 30, 2017

### The University of Alabama at Birmingham Administration

### As of September 30, 2019

Ray L Watts, M.D. President



Pamela Benoit

Senior Vice President for Academic Affairs and Provost

G. Allen Bolton, Jr.

Senior Vice President for Finance and Administration

Tom Brannan

Vice President for Advancement

Christopher S. Brown

Vice President for Research

Curtis A. Carver, Jr.

Vice President for Information Technology and Chief Information Officer

Paulette Patterson Dilworth

Vice President for Diversity, Equity and Inclusion

Will Ferniany

CEO, UAB Health System

John R. Jones

Vice President for Student Affairs

Selwyn M. Vickers, M.D.

Senior Vice President for Medicine and Dean, School of Medicine

**Shannon Blanton** 

Dean, UAB Honors College

Andrew J. Butler

Dean, School of Health Professions

Autumn T. Cyprès

Dean, School of Education

Paul C. Erwin

Dean, School of Public Health

Doreen C. Harper

Dean, School of Nursing

Eric P. Jack

Dean, Collat School of Business

Lori L. McMahon

Dean, Graduate School

John M. Meador, Jr.

Dean, UAB Libraries

Kelly K. Nichols, O.D.

Dean, School of Optometry

Robert E. Palazzo

Dean, College of Arts and Sciences

Russell Taichman, D.M.D., DMSc.

Dean, School of Dentistry

Timothy M. Wick

Interim Dean, School of Engineering

### The Board of Trustees of The University of Alabama

As of September 30, 2019

### The Honorable Kay Ivey

Governor of Alabama President ex officio

### Ronald W. Gray

President pro tempore Huntsville

### Karen Phifer Brooks

Tuscaloosa

### John H. England, Jr.

Tuscaloosa

### Joseph C. Espy III

Montgomery

### **Barbara Humphrey**

Birmingham

### Vanessa Leonard

Rockford

### W. Davis Malone III

Dothan

### Evelyn VanSant Mauldin

Florence

### Harris V. Morrissette

Mobile

### Scott M. Phelps

Tuscaloosa

### William "Britt" Sexton

Decatur

### W. Stancil Starnes

Birmingham

### Marietta M. Urquhart

Mobile

### Kenneth L. Vandervoort, M.D.

Anniston

### James W. Wilson III

Montgomery

### Trustees Emeriti

Paul W. Bryant, Jr.
Angus R. Cooper II
Oliver H. Delchamps, Jr.
Joseph L. Fine
Sandral Hullett
Andria Hurst
John D. Johns
Peter L. Lowe
John J. McMahon,
Jr. John T. Oliver, Jr.
Joe H. Ritch
Cleophus Thomas, Jr.
John Russell Thomas

### Finis E. St. John IV

Chancellor